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Abhigna Polavarapu 
Computational Studies to Understand the Role of Allostery in Copper 
Regulation in Mycobacterium tuberculosis and in the Design of HPV Vaccines 
Allostery is defined as the change in the structure, function or activity of a specific 
site on a protein, due to the binding of a substrate or effecter on a different site of 
the same protein. This phenomenon has been observed and studied in two 
different protein systems of therapeutic importance. CsoR protein in 
Mycobacterium tuberculosis adopts classical allostery to regulate the concentration 
of Cu(I) inside the cell. Cu(I) is speculated to bind in an unusual trigonal planar 
geometry with two cysteines and one histidine. When CsoR is bound to copper an 
overall structural change (allostery) is envisioned and its affinity to DNA is lost. 
In the current computational exploration we focus on the binding mode of Cu(I) 
and identify different protonation states of copper bound cysteines. MD 
simulations were performed on the apo and copper bound form with a starting 
structure from QM/MM calculations to predict the allosteric structural transition. 
The dynamic properties of the capsid of the human papillomavirus (HPV) type 16 
were also examined using classical molecular dynamics simulations. The allostery 
identified in the components of the HPV is non-classical because the mean 
structure of the epitope carrying loops remains unchanged as the result of 
vii 
 
allosteric effect, but the structural fluctuations are altered significantly, which in 
turn changes the biochemical reactivity profile of the epitopes. Exploiting this 
novel insight, a new vaccine design strategy is proposed, where a relatively small 
virus fragment is deposited on a silica nanoparticle in such a way that the 
fluctuations of the h4 helix are suppressed. The structural and dynamic properties 
of the epitope carrying loops on this hybrid nanoparticle match the characteristics 
of epitopes found on the full virus like particle precisely, suggesting that these 
nanoparticles may serve as potent, cost-effective and safe alternatives to 
traditionally developed vaccines. 
        Mu-Hyun Baik, Ph.D. 
 
 
        David Giedroc, Ph.D.  
 
 
        Charles Dann III, Ph.D. 
 
 
        Peter Ortoleva, Ph.D.  
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INTRODUCTION 
The interaction between biochemical macromolecules and small molecules 
that serve as messengers or trigger of cellular responses play a pivotal role in 
biological sensing and signaling, which in turn are critical for the survival of any 
organism.1 Proteins are one of the main pillars of these constructs and unlike 
other biologically important macromolecules, such as DNA, RNA or glycosides, 
they display a rich regulatory mechanism based on allostery - the coupling of 
molecular changes of one site to detectable chemical changes at a remote site of 
the protein.1-4 The most obvious manifestation of this principle is documented in 
the lock-and-key mechanism, where the interaction of a small molecule with a 
specific binding site of a regulatory protein can lead to the activation of the 
protein that sets in motion a chain of biochemical reactions. For example, the 
cooperative binding of oxygen to hemoglobin is under allosteric control, wherein 
the uptake of one oxygen molecule by hemoglobin increases the oxygen binding 
affinities of remaining unoccupied binding sites by influencing the quaternary 
structure of the protein.5-9 Over the years, hemoglobin served as an important 
model system for investigating the basic principle of allostery and cooperativity 
in macromolecules.10-13 Hemoglobin is a tetrameric metalloprotein, and has four 
binding sites in each monomeric unit that consists of a heme moiety, a porphyrin 
group carrying a Fe(II) center.13,14 Due to the presence of these four binding sites, 
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the oxygen binding gives rise to multiple equilibria.13-15 Curiously, the rate of 
oxygen binding that can be visualized for example as a function of partial 
pressure, as shown in Figure 1.1a, is sigmoidal.5,16 The equilibrium constants for 
these four oxygen binding events are dependent on each other i.e., filling the first 
oxygen binding site in hemoglobin increases the affinity of the remaining sites 
for oxygen and vice versa. This influence of one oxygen molecule binding on the 
binding of another oxygen is known as homotropic cooperativity. Overall, this 
cooperative equilibrium binding makes the binding curve sigmoidal rather than 
hyperbolic, which is characteristic of single-site oxygen binding proteins, such as 
myoglobin.5,13,16 Cooperativity in hemoglobin results from a conformational 
"switch" from a weak-binding state to a strong-binding state, which is the 
manifestation of allostery.8,9,17 
 
Figure Error! No text of specified style in document..1. (a) Oxygen binding curve 
of hemoglobin and myoglobin (b) Hill plot describing the transition between low 
affinity, transition and high affinity oxygen binding states of hemoglobin 
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The O2 binding equilibrium for myoglobin can be given by the following 
expression: 𝑀𝑏 +  𝑂2  ↔ 𝑀𝑏 − 𝑂2 and the equilibrium constant, 𝐾𝑒𝑞 =  
[𝑀𝑏−𝑂2]
[𝑀𝑏][𝑂2]
. 
Oxygen dissociation from myoglobin follows Michaelis-Menten kinetics and can 
be expressed as fractional saturation, ‘θ’ and [O2] in partial pressure, pO2 where: 
 𝜃 =  
[𝑀𝑏−𝑂2]
[𝑀𝑏]+[𝑀𝑏−𝑂2]
 1.1 
Substituting Keq and 1/Keq = [O2]1/2 in equation 1.1, yields equation 1.2 that 
describes a hyperbolic curve (Figure 1.1a): 
 𝜃 =  
𝑝𝑂2
𝑃50+𝑝𝑂2
 1.2 
As hemoglobin is a tetramer, the equilibrium involves four binding steps which 
can be expressed as 𝐻𝑏 + 4 𝑂2  ↔  𝐻𝑏(𝑂2)4 and in more general terms 𝐻𝑏 +
𝑛𝑂2  ↔  𝐻𝑏(𝑂2)𝑛 and does not follow Michaelis-Menten kinetics. Hence, the 
fractional saturation is described by Hill equation and the binding curve is 
sigmoidal rather than hyperbolic: 
 𝜃 =  
(𝑝𝑂2)
𝑛
(𝑃50)𝑛+(𝑝𝑂2)𝑛
 1.3 
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Quantitatively, the binding curve of hemoglobin and the allosteric nature of 
cooperativity is explained by equation 1.4 and this equation yields Hill plot 
(Figure 1.1b): 
 log
𝜃
1−𝜃
= 𝑛 log(𝑝𝑂2) − 𝑛 log(𝑃50) 1.4 
where ‘θ’ is the fraction of oxygen-binding sites that are occupied, pO2 is the 
partial pressure of oxygen, and P50 is the oxygen partial pressure for half-
saturation. Hill plots predict the transition between n binding states in 
cooperativity and give a direct numerical measure of the degree of cooperativity 
from its maximum slope, n x H, which is known as the Hill coefficient. A Hill 
coefficient of 1 indicates that the binding of oxygen is non-cooperative as seen in 
myoglobin, a value greater than 1 indicates positive cooperativity. For example, a 
maximum value of n x H is 3.5 (Figure 1.1b) for hemoglobin observed for the 
transition between low affinity and high affinity states, suggesting cooperativity 
between the four oxygen binding sites. This model explains allostery in 
hemoglobin as the interconversion between two states: the T (tense) and the R 
(relaxed) conformations of the molecule.8,9,18 The R state has higher affinity for 
oxygen. Under conditions where pO2 is high (such as in the lungs), the R-state is 
favored; in conditions where pO2 is low (as in exercising muscle), the T-state is 
favored.8,9,18 In agreement with the above model, the X-ray crystal structures of 
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oxygen bound and unbound structures of hemoglobin revealed the existence of 
two quaternary conformations - low-affinity deoxy T-state and the high-affinity 
oxy R-state.17 The transition within the two states has been determined based on 
stereochemical events triggered by O2 binding to Fe(II), which moves the iron 
atom by 0.6 Å into the plane of the porphyrin ring.10-12 This structural change 
initiates a series of geometrical responses in the F-helix and neighboring helices, 
due to the pull on the proximal histidine exerted by the movement of iron atom 
into the plane of the porphyrin ring, illustrated in Figure 1.2.10-12 These structural 
variations are transmitted to the subunit interfaces and the salt bridges between 
the subunits are broken to attain a relaxed ‘R’ state.10-12 Upon conversion from the 
deoxy (T) structure to the oxy (R) structure, the α1β2 dimer rotates relative to the 
other by ~15° and opens the Fe(II) binding sites to accommodate oxygen in other 
subunits.10-12,17 Similarly, even today allostery in proteins is often explained via 
structural changes - Structure-function paradigm, open and closed state of a 
binding site to accommodate and release substrate at a distant site, surface 
remodeling to allow protein-protein association and inter-domain movements 
with respect to each other that impact the quaternary structure of the protein. 
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Figure 1.2. (a) Structural change at the heme center of deoxy-hemoglobin ‘T’ state 
(blue) on binding to oxygen that initiates the allosteric transition to oxy-
hemoglobin ‘R’ state (red) (b) Cartoon showing the quaternary structure change 
from ‘T’ to ‘R’ state 
The structure-function relationship supports the existence of distinct key 
structures for different functional states of protein. Two conceptual models exist 
for understanding allostery and explaining the relationship between structure-
coupled transitions and discrete functional states of a protein. These models have 
benefited tremendously from precise molecular structure determinations of 
tetrameric hemoglobin and they are: The Koshland-Nemethy-Filmer (KNF)9 and 
the Monod-Wyman-Changeux (MWC) models.8 The KNF model describes the 
structural transition between the T- and R-states as an induced-fit mechanism, 
where binding of a ligand leads to a subsequent structural change at a remote 
functional site. This theory suggests that the subunits in hemoglobin switch 
independently from the binding to an oxygen molecule, but cooperatively 
facilitate further transitions to the high-affinity R-state. In contrast, the main 
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concept of the MWC model is the existence of different interconvertible states in 
equilibrium, e.g. all subunits of hemoglobin must exist in either the T- or R-state. 
Binding of a ligand leads to a shift in the thermal equilibrium towards one state. 
The transition within the two states has been determined based on 
stereochemical events triggered by O2 binding to Fe(II), which moves the iron 
atom by 0.6 Å into the plane of the porphyrin ring.10-12 This structural change 
initiates a series of geometrical responses in the F-helix and neighboring helices, 
due to the pull on the proximal histidine exerted by the movement of iron atom 
into the plane of the porphyrin ring, illustrated in Figure 1.2.10-12 Support for the 
MWC model of allostery comes from nuclear magnetic resonance (NMR) studies 
that demonstrate the coexistence of different conformations of phosphorylation 
regulated nitrogen regulatory protein C (NtrC).19-21 NMR spectroscopy was used 
to demonstrate a strong correlation between the phosphorylation-driven 
activation of the signaling protein NtrC and microsecond timescale backbone 
dynamics in an area remote from the phosphorylation site as shown in Figure 
1.3.19 Solution structures and the motions of the regulatory domain of NtrC were 
determined in three functional states: unphosphorylated (inactive), 
phosphorylated (active) and a partially active mutant.19 The NMR-detected 
dynamics in the unphosphorylated state were detected exactly at the area of 
conformational change upon activation, indicative of an equilibrium of states 
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(Figure 1.3).19 Chemical shift analysis of NtrC states with different activity 
revealed that the dynamics detected by NMR relaxation experiments represent 
an exchange between inactive and active states in unphosphorylated NtrC. The 
relative amount of shift is a direct measure of the equilibrium constant between 
the two states. Phosphorylation shifts the equilibrium towards the active state. 
Additional studies have indicated that the area involved in dynamic exchange is 
responsible for downstream signal transduction, the activation of ATPase 
activity in the central domain of NtrC and consequently activation of 
transcription.22  
 
Figure 1.3. (a) Superimposition of inactive (orange/yellow) and active (blue/cyan) 
of NtrC regulatory (switch) domain. (b) NMR backbone relaxation techniques 
were applied to detect microsecond timescale motion in region that undergoes 
conformational changes due to ligand binding. Dynamic regions were identified 
by the NMR exchange term Rex (shown as a continuous color scale)19 
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NtrC protein, is the first single domain allosteric protein and the presence 
of allosteric regulation in this protein challenged the traditional MWC and KNF 
models, which only considered oligomeric proteins as potentially allosteric. The 
NMR relaxation studies on NtrC protein also provide experimental evidence for 
dynamic origins of allostery (Figure 1.3).19 For calmodulin - a calcium binding 
signaling protein, a similar conformational exchange process was also detected 
using NMR relaxation experiments.23-25 Hence, ligand binding favors a pre-
existing structure and the allosteric process can be viewed as a shift in the 
thermal equilibrium in these systems. The different co-existing conformations 
can be attributed to local minima on an energy landscape25-28 a model originally 
developed for protein folding, that are divided by energy barriers. In this theory, 
the allostery changes the energy landscape by either lowering the end state 
minima or lowering the energy barriers, thereby allowing transitions to other 
conformations.29-32 
DYNAMIC ALLOSTERY 
Over the last few decades, advances in experimental and computational 
tools led to a more quantitative understanding of the role that structural 
dynamics play in protein function in biochemical processes.3,4,29,33-37 One 
consequence of this deeper appreciation was that the classical static perspective 
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of allosteric interactions has been extended and there is growing awareness in 
the community now that the modulation of chemical behavior does not 
necessarily have to be linked to structural changes in the protein quaternary 
structure.8,9,18 In this sense, the perspective on allostery can be extended to 
include entropically dominated state changes, in addition to more classical views 
that include state variations that are mostly determined by enthalpic changes - 
which are mostly linked to detectable structural variations.3,4  
To cast this view in the framework of population shift models that have 
enjoyed some popularity,27,38-40 protein fluctuations give rise to changes in the 
partition of the populated conformational states between which the protein 
alternates and these protein motions can play a significant role in allosteric 
control mechanisms.33 The rates of these structural fluctuations depend on the 
ligand binding affinity and ligand binding can stabilize certain fluctuations that 
have functional significance.41 Different kinds of structural fluctuations exist 
within a protein, each covering a different time scale that ranges from ~10−14 to 
~105 seconds. These molecular motions include vibrational modes (~10−14s to 
~10−11 sec) and stochastic conformational transitions (~10−11 to ~105 sec).42 
Transitions between conformational states in typical biochemical reactions like 
association and dissociation of ligands or large scale changes like protein folding 
and unfolding are divided by barriers greater than ~4kBT.42 The high frequency 
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modes correspond to localized stretching of N–H or C–H bonds. High frequency 
vibrational modes (time scales shorter than ~10−13 sec) correspond to energies 
greater than kBT at physiological temperatures of 300K. Therefore, they are in 
principle not thermally excited. Frequencies that are thermally excited in the 
higher frequency region correspond to the vibrations of side chains, as illustrated 
in Figure 1.4.42 The low frequency vibrational modes in operation at a time scale 
of ~10−11 sec are over-damped collective modes, which are correlated over whole 
domains contribute significantly to the entropy of the protein.42 
 
Figure 1.4. (a) High frequency modes (ring, side chain rotations and bond 
stretches) (b) Low frequency global modes (domain movements) 
Though these protein motions play a crucial role in fostering the allosteric 
conformational change, the concept of allostery without a conformational change 
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was introduced - dynamic allostery,33 in which changes in protein dynamics 
alone produce allostery. By separating the motions into vibrational (normal 
mode) and conformational effects, the feasibility of an extreme case of no 
enthalpic term in the allosteric free energy was proposed: where even with the 
total absence of a conformational change, ligand-induced changes in protein 
dynamics could produce free energies sufficient for an allosteric communication 
between distinct binding sites.33 These energy contributions originate from the 
changes in frequencies and amplitudes of thermal fluctuations in response to 
ligand binding and can involve dynamic behavior ranging from highly 
correlated low-frequency normal mode vibrations to random local anharmonic 
motions of individual atoms or groups. Dynamic allostery of this form is 
predominantly an entropic effect.33,36,43,44 For example, this effect is manifested in 
the negative cooperative binding of cAMP to the dimeric catabolite activator 
protein (CAP).36,45-47 The binding of the first cAMP to one subunit of a CAP dimer 
does not alter the conformation of the other subunit as evidenced in NMR 
chemical shift data.45 However, the system dynamics were modulated by the 
sequential binding process: the first cAMP partially enhanced and the second 
cAMP completely quenched protein motions.36,45 Consequently, the second 
cAMP binding has significant contribution to conformational entropy penalty, 
leading to the observed negative cooperative binding of cAMP to CAP.36,45 To 
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understand the propagation of dynamic behavior along the cooperative reaction 
coordinate, the backbone motions of CAPN as a function of the cAMP ligation 
state, over a wide range of functionally relevant timescales were measured using 
NMR relaxation techniques.36,45 Upon binding of the first cAMP to CAPN, the 
backbone residue resonances of both subunits undergo extensive peak 
broadening which indicates substantial conformational exchange and also 
suggesting that the cAMP1–CAPN complex populates an ensemble of alternate 
conformations that interconvert on the μs–ms timescale. These slow motions are 
activated by the first cAMP binding but this chemical change cannot induce 
long-range structural effects in the other subunit. Residues of the unliganded 
subunit in the cAMP1–CAPN complex that are located as far as 35 Å from the 
bound cAMP (for example, Tyr23, Leu29 and Ile30) showed enhanced dynamics 
and the prominent conformational dynamics on the μs–ms timescale exhibited 
by almost all residues in cAMP1–CAPN are completely quenched upon binding to 
the second cAMP molecule.36,45,48 Particularly, the slow and fast motions of 
residues located at distant regions are affected in the absence of a visible 
connectivity pathway.48,49 This finding strengthens the mechanical view of 
allosteric cooperativity, wherein binding effects are assumed to propagate 
through a series of conformational distortions (or mechanical coupling of protein 
motions). In this system, the ligand-induced redistribution of the protein's 
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dynamic fluctuations affects the regions associated with cooperativity, thereby 
providing a means of propagating the allosteric signal to the distal site even in 
the absence of structural changes.  
Hence, in this broadened view of allostery - proteins are treated as a 
dynamic ensemble of conformational states where the ligand binding re-
distributes the molecular ensemble leading to altered conformations at remote 
substrate binding sites. The dynamic view of allostery illustrates the possibility 
of inducing allostery in classically non-allosteric proteins by either mutating 
certain residues or by introducing disorder in certain regions of protein. These 
perturbations can redistribute the protein dynamic ensembles and facilitate a 
population shift that can alter the function of the protein.38,41 Consistent with this 
model, all non-fibrous proteins can be considered allosteric and studies focused 
on identification of dynamically coupled conserved sites in these proteins can aid 
in modulating the hidden allosteric property.35,50 In an effort to understand such 
networks between dynamically coupled sites, multiple V  A mutations were 
made in the small globular protein eglin c.50,51 NMR spin relaxation, residual 
dipolar coupling, and scalar coupling studies, illustrate that the structural 
architecture of this non-allosteric protein forms a dynamic network and that local 
perturbations are transmitted as dynamic and structural changes to distal sites as 
far as 16 Å away.50,51 Two basic types of propagation mechanism were observed 
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in eglin c:  contiguous pathways of enhanced (attenuated) dynamics with no 
change in structure; and dispersed (noncontiguous) changes in methyl rotation 
rates that appear to result from subtle deformation of backbone structure.50,51 In 
this thesis, particular emphasis was placed on understanding this inherent 
dynamic behavior of two distinct protein systems using theoretical methods 
wherein: a conformational change is observed in one protein while the allostery 
in the other system propagates through coupling of protein motions at distant 
sites. 
ALLOSTERIC SYSTEMS STUDIED IN THIS THESIS 
In this thesis, the goal is to understand the role and mechanism of 
allostery in functional motions and structural changes in two different protein 
systems. Computational methods are used to illustrate the mechanism of 
allostery and exploit the principles of allostery in the design of new drugs and 
vaccines. We describe two systems, a regulatory metalloprotein in bacteria that 
exhibits conformational change when bound to a metal and a human papilloma 
virus (HPV) virus-like particle system in which a conformational change is not 
observed instead, the protein dynamics contribute to the allosteric control. In 
Chapter 3, allosteric regulation in metal transcriptional regulator proteins on 
binding to Cu(I) was investigated. The metal transcriptional regulator protein on 
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binding to a metal ion alters its affinity towards DNA either by binding or 
unbinding to DNA.52-56 The coordination geometry of the metal in the protein 
plays a key role to drive changes in tertiary and/or quaternary structure and/or 
dynamics of the metal transcriptional regulator protein. In this research, the 
coordination geometry of the Cu(I) ion was studied and the correlation between 
the specific geometry enforced by the protein to bind to Cu(I) and allostery in the 
protein was thoroughly investigated using high level quantum calculations as 
well as molecular dynamics simulations. In the following section, an overview of 
the allosteric regulation in different metal transcriptional regulator proteins in 
bacteria is provided. 
METAL TRANSCRIPTIONAL REGULATORS AND ALLOSTERY 
Transcriptional regulators are specialized allosteric proteins that sense 
cytosolic concentrations of metabolic compounds and other small molecular 
effectors in order to achieve an appropriate response to changing growth 
conditions.57-59 These proteins operate through the interaction with the 
operator/promoter region of DNA just upstream of the specific operon that is 
being regulated.59,60 The ligand or the compound to be regulated binds to the 
protein–DNA complex, to a site distinct from the DNA binding site and a 
structural or dynamic change in conformation occurs, that modulates the affinity 
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or structure of the regulatory protein–DNA complex.61 Metalloregulatory 
proteins are a sub-class of transcriptional regulators that have evolved to 
regulate the expression of cellular metal uptake and detoxification systems.52-56,62 
A number of metal transcriptional regulator families exists and the metal 
selectivity and specificity of individual proteins can vary significantly even 
within a single family.63 
Metal regulatory proteins also known as metal sensor proteins, are 
involved in metal resistance and their role is to increase the expression of genes 
involved in metal detoxification, storage and efflux.53 Metal sensor proteins can 
regulate the transcription of genes in different ways; one way is by de-repression 
of regulated genes where the direct binding of a specific ion to a repressor 
allosterically inhibits DNA binding as is seen in ArsR, CsoR and CopY families,64-
66 or by allosteric activation of transcription initiation by RNA polymerase 
through the remodeling of the promoter structure as is observed in MerR 
family.67 Some metal regulator proteins turn off the expression of uptake systems 
in response to metal excess, where direct binding of metal ion(s) allosterically 
activates DNA binding; in this case the metal ion acts as co-repressor of the 
regulated operon.68 Consistent with this, the Fur, DtxR and NikR structural 
scaffolds have evolved to sense only the first row transition elements that are 
required for biological function; in contrast, the ArsR64 and MerR families67 
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contain representative members that have evolved to sense a far wider range of 
metal ions, including both first row transition elements as well as heavy metal 
ion xenobiotics, and organic As/Sb/Hg metalloid compounds.56 
Recent structural insights from a wide range of bacterial metal sensor 
proteins collectively emphasize several common features that characterize these 
allosteric switches on binding to specific metal ions.55,56,63,68 One important aspect 
is that the covalent bond between a metal and its ligand influences the tertiary 
and/or quaternary structure and/or dynamics but a thorough understanding of 
the effect of metal coordination geometry on structural and dynamic changes in 
the protein is not fully established. The degree of metal specificity enforced by 
these transcriptional regulators suggests that the biological metal selectivity is 
dictated primarily by the coordination chemistry of the metal ion being 
regulated.55 
Chapter 3 focuses on the computational studies that were performed on a 
Cu(I) sensing transcriptional regulator protein in Mycobacterium tuberculosis that 
belongs to the CsoR family (Mtb-CsoR).65 The main objective of this study is to 
critically evaluate the role that protein dynamics play in mediating the overall 
structural change leading to allostery in these systems as well as to determine 
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precisely how allostery is linked to coordination geometry of metal ion in these 
bacterial metal sensor proteins. 
Broadly stated, the studies described in Chapter 3 have been motivated 
and driven by the following question: What is the mechanism of allosteric 
communication between the metal binding amino acids of CsoR that affords 
Cu(I) mediated loss of affinity towards DNA? Throughout this chapter an effort 
is made to map functional information on specific CsoR residues to account for 
the evolutionary conservation of residues other than the Cu(I) binding residues 
that are suggested to be important in driving the allosteric switch. Using 
computational modeling techniques and the insights derived from the previously 
performed experimental studies,65,69-73 the results presented identify specific 
residues that are important for the communication mechanism and lay the 
groundwork for future efforts to fully elucidate the allosteric mechanism. This 
chapter also presents what is known about CsoR structure and function and 
motivates the driving questions behind the studies presented in this thesis. 
In addition, computational techniques and methodologies that are 
developed and applied to study Mtb-CsoR like system, but have more general 
applicability in the study of other proteins with allosteric control mechanisms or 
multiple ligand binding sites are also described in Chapter 2. Finally, the results 
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presented for Mtb-CsoR are used to make connections with other proteins that 
belong to the CsoR family to develop a more general understanding of these 
systems. 
ALLOSTERY IN HPV VACCINE DESIGN 
In Chapter 4, the dynamics of Human papilloma virus (HPV) virus-like 
particle (VLP) were studied and a new vaccine design strategy was proposed by 
exploiting the dynamic allosteric coupling between two strongly correlated 
immunogenic sites in HPV VLP. In general, most currently available vaccines are 
based on a ‘natural’ form of the pathogen, which is rendered either non- or 
weakly pathogenic by killing, inactivating or attenuating the pathogen, or by 
inclusion in the vaccine of selected antigenic components of the pathogen 
(subunit vaccines).74,75 In essence, the vaccine is designed to be as similar as 
possible to the full or naturally occurring form of the pathogen.76 Epitope-based 
vaccines provide a new strategy for therapeutic application of pathogen-specific 
immunity while decreasing the risks associated with the natural vaccines that 
contain the viral genetic material.77-80 In this thesis, a VLP based vaccine design 
approach was presented where the viral capsid protein structures of HPV mimic 
the organization and conformation of authentic native viruses but lack the viral 
genome, potentially yielding safer and cheaper vaccine candidates. A handful of 
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VLP-based vaccines are currently commercialized worldwide: GlaxoSmithKline's 
Engerix (hepatitis B virus)81 and Cervarix (HPC),82-85 and Merck and Co., Inc.'s 
Recombivax HB (hepatitis B virus)86 and Gardasil (human papillomavirus)87,88 are 
some examples. The HPV type 16 VLP surface, has outwardly projecting loops 
containing epitopes that elicit the production of type-specific antibodies and 
immune response.89-91 Several factors should be considered in the design of a new 
vaccine and the most critical factor is the orientation and presentation of the 
epitopes to the host immune system. Previous experimental work on the HPV 
VLP’s elaborated the implications of deleting certain regions other than the 
epitopes from the VLP capsid pentamer suggesting a long distance control over 
epitope conformation within the VLP.92,93 Recent computational studies on HPV 
VLP propose fluctuation-immunogenicity hypothesis wherein the 
immunogenicity is anti-correlated with epitope loop fluctuation intensity94 
suggesting that the immunogenicity/antibody-binding is correlated with the size 
of VLP. In this research, considering the insights from previous experimental and 
computational work, we tried to predict the relation between the assembly size 
of the VLP and epitope dynamics which is anticipated to be linked with the 
extent of immune response. Molecular dynamics simulations and associated 
analysis on these systems traced us to the concept of dynamic allostery which is 
in interplay between the h4 helices that stabilize the higher assemblies of capsid 
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proteins and epitopes of the VLP. Based on this concept, a vaccine design 
strategy has been proposed in this research, where the dynamics of the h4 helix 
are controlled by providing a nanoparticle support and the subsequent changes 
in the epitope fluctuations are studied. In Chapter 4, we describe how the 
principles of allostery are applied in the design of hybrid nanoparticle based 
vaccines and suggest a computational model of a new generation vaccine. 
Each of the subsequent chapters of this thesis focuses on different aspects 
of allostery and understanding as well as exploiting this phenomenon to design 
new generation drugs and vaccines. Chapter 2 of this thesis, demonstrates the 
application of MD simulations and discusses about the specific approaches 
required to understand allosteric mechanisms. The force field development 
protocol and new force fields that were devised to simulate the two protein 
systems are also discussed in Chapter 2. These force fields are especially required 
to simulate the proteins in solution with their corresponding ligands and also 
enable us to analyze the change in protein conformation and dynamics in the 
presence and absence of the ligand. The MD simulation and computational 
analyses presented in Chapters 3 and 4 identify a network of specific residue 
contacts or correlations between specific epitope domains that connect the 
perturbation site of these proteins to the active site. 
23 
 
REFERENCES 
(1) Kuriyan, J.; Eisenberg, D., Nature 2007, 450, 983-990. 
(2) Goodey, N. M.; Benkovic, S. J., Nat. Chem. Biol. 2008, 4, 474-482. 
(3) Tsai, C. J.; Del Sol, A.; Nussinov, R., Mol. BioSyst. 2009, 5, 207-216. 
(4) Tsai, C.-J.; Del Sol, A.; Nussinov, R., J. Mol. Biol. 2008, 378, 1-11. 
(5) Hill, A. V., Biochem. J. 1913, 7, 471. 
(6) Adair, G. S., J. Biol. Chem. 1925, 63, 529-545. 
(7) Wyman, J.; Allen, D. W., J. Polym. Sci. 1951, 7, 499-518. 
(8) Monod, J.; Wyman, J.; Changeux, J.-P., J. Mol. Biol. 1965, 12, 88-118. 
(9) Koshland Jr, D.; Nemethy, G.; Filmer, D., Biochemistry 1966, 5, 365-385. 
(10) Perutz, M. F., Q. Rev. Biophys. 1989, 22, 139-237. 
(11) Perutz, M. F., Nature 1970, 228, 726-734. 
(12) Perutz, M. F.; Wilkinson, A.; Paoli, M.; Dodson, G., Annu. Rev. Biophys. 
Biomol. Struct. 1998, 27, 1-34. 
(13) Pauling, L., Proc. Natl. Acad. Sci. U. S. A. 1935, 21, 186. 
(14) Wyman, J., Adv. Protein Chem 1964, 19, 91. 
(15) Edelstein, S. J., Annu. Rev. Biochem. 1975, 44, 209-232. 
(16) Bohr, C.; Hasselbalch, K.; Krogh, A., Skand. Arch. Physiol. 1904, 16, 402-412. 
(17) Perutz, M.; Bolton, W.; Diamond, R.; Muirhead, H.; Watson, H., Nature 1964, 
203, 687-690. 
24 
 
(18) Monod, J.; Changeux, J.-P.; Jacob, F., J. Mol. Biol. 1963, 6, 306-329. 
(19) Volkman, B. F.; Lipson, D.; Wemmer, D. E.; Kern, D., Science 2001, 291, 2429-
2433. 
(20) Liu, M. S.; Todd, B.; Yao, S.; Feng, Z. P.; Norton, R. S.; Sadus, R. J., Proteins: 
Struct., Funct., Bioinf. 2008, 73, 218-227. 
(21) Tripathi, S.; Portman, J. J., J. Phys. Chem. B 2013, 117, 13182-13193. 
(22) Otten, R.; Villali, J.; Kern, D.; Mulder, F. A., J. Am. Chem. Soc. 2010, 132, 
17004-17014. 
(23) Tjandra, N.; Kuboniwa, H.; Ren, H.; Bax, A., Eur. J. Biochem. 1995, 230, 1014-
1024. 
(24) Malmendal, A.; Evenäs, J.; Forsén, S.; Akke, M., J. Mol. Biol. 1999, 293, 883-
899. 
(25) Miyashita, O.; Wolynes, P. G.; Onuchic, J. N., J. Phys. Chem. B 2005, 109, 1959-
1969. 
(26) Frauenfelder, H.; McMahon, B. H.; Austin, R. H.; Chu, K.; Groves, J. T., Proc. 
Natl. Acad. Sci. U. S. A. 2001, 98, 2370-2374. 
(27) Okazaki, K.-i.; Takada, S., Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 11182-
11187. 
(28) Onuchic, J. N.; Luthey-Schulten, Z.; Wolynes, P. G., Annu. Rev. Phys. Chem. 
1997, 48, 545-600. 
25 
 
(29) Zhuravlev, P. I.; Papoian, G. A., Q. Rev. Biophys. 2010, 43, 295-332. 
(30) Tsai, C.-J.; Ma, B.; Nussinov, R., Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 9970-
9972. 
(31) Levy, Y.; Cho, S. S.; Onuchic, J. N.; Wolynes, P. G., J. Mol. Biol. 2005, 346, 
1121-1145. 
(32) Chung, H. S.; McHale, K.; Louis, J. M.; Eaton, W. A., Science 2012, 335, 981-
984. 
(33) Cooper, A.; Dryden, D., Eur. Biophys. J 1984, 11, 103-109. 
(34) Chennubhotla, C.; Yang, Z.; Bahar, I., Mol. BioSyst. 2008, 4, 287-292. 
(35) Gunasekaran, K.; Ma, B.; Nussinov, R., Proteins: Struct., Funct., Bioinf. 2004, 
57, 433-443. 
(36) Popovych, N.; Sun, S.; Ebright, R. H.; Kalodimos, C. G., Nat. Struct. Mol. Biol. 
2006, 13, 831-838. 
(37) Swain, J. F.; Gierasch, L. M., Curr. Opin. Struct. Biol. 2006, 16, 102-108. 
(38) Kar, G.; Keskin, O.; Gursoy, A.; Nussinov, R., Curr. Opin. Pharmacol. 2010, 10, 
715-722. 
(39) Ma, B.; Shatsky, M.; Wolfson, H. J.; Nussinov, R., Protein Sci. 2002, 11, 184-
197. 
(40) Ruschak, A. M.; Kay, L. E., Proc. Natl. Acad. Sci. U. S. A. 2012, 109, E3454-
E3462. 
26 
 
(41) Kumar, S.; Ma, B.; Tsai, C. J.; Sinha, N.; Nussinov, R., Protein Sci. 2000, 9, 10-
19. 
(42) Kurzyński, M., Phys. A (Amsterdam, Neth. 2000, 285, 29-47. 
(43) Kern, D.; Zuiderweg, E. R., Curr. Opin. Struct. Biol. 2003, 13, 748-757. 
(44) Wand, A. J., Nat. Struct. Mol. Biol. 2001, 8, 926-931. 
(45) Popovych, N.; Tzeng, S.-R.; Tonelli, M.; Ebright, R. H.; Kalodimos, C. G., 
Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 6927-6932. 
(46) Toncrova, H.; McLeish, T. C., Biophys. J. 2010, 98, 2317-2326. 
(47) Yang, J.; Garrod, S. M.; Deal, M. S.; Anand, G. S.; Woods Jr, V. L.; Taylor, S., 
J. Mol. Biol. 2005, 346, 191-201. 
(48) Hawkins, R. J.; McLeish, T. C., Biophys. J. 2006, 91, 2055-2062. 
(49) Bahar, I.; Chennubhotla, C.; Tobi, D., Curr. Opin. Struct. Biol. 2007, 17, 633-
640. 
(50) Clarkson, M. W.; Gilmore, S. A.; Edgell, M. H.; Lee, A. L., Biochemistry 2006, 
45, 7693-7699. 
(51) Clarkson, M. W.; Lee, A. L., Biochemistry 2004, 43, 12448-12458. 
(52) Grossoehme, N. E.; Giedroc, D. P., In Spectroscopic Methods of Analysis, 
Springer: 2012; pp 165-192. 
(53) Giedroc, D. P.; Arunkumar, A. I., Dalton Trans. 2007, 3107-3120. 
27 
 
(54) Waldron, K. J.; Rutherford, J. C.; Ford, D.; Robinson, N. J., Nature 2009, 460, 
823-830. 
(55) Waldron, K. J.; Robinson, N. J., Nat. Rev. Microbiol. 2009, 7, 25-35. 
(56) Reyes-Caballero, H.; Campanello, G. C.; Giedroc, D. P., Biophys. Chem. 2011, 
156, 103-114. 
(57) Browning, D. F.; Busby, S. J. W., Nat. Rev. Microbiol. 2004, 2, 57-65. 
(58) Hantke, K., Curr. Opin. Microbiol. 2001, 4, 172-177. 
(59) Lefstin, J. A.; Yamamoto, K. R., Nature 1998, 392, 885-888. 
(60) Ogata, K.; Sato, K.; Tahirov, T., Curr. Opin. Struct. Biol. 2003, 13, 40-48. 
(61) Ptashne, M.; Gann, A., Nature 1997, 386, 569-577. 
(62) Chen, P. R.; He, C., Curr. Opin. Chem. Biol. 2008, 12, 214-221. 
(63) Pennella, M. A.; Giedroc, D. P., BioMetals 2005, 18, 413-428. 
(64) Busenlehner, L. S.; Pennella, M. A.; Giedroc, D. P., FEMS Microbiol. Rev. 2003, 
27, 131-143. 
(65) Liu, T.; Ramesh, A.; Ma, Z.; Ward, S. K.; Zhang, L. M.; George, G. N.; Talaat, 
A. M.; Sacchettini, J. C.; Giedroc, D. P., Nat. Chem. Biol. 2007, 3, 60-68. 
(66) Fu, Y.; Tsui, H. C. T.; Bruce, K. E.; Sham, L. T.; Higgins, K. A.; Lisher, J. P.; 
Kazmierczak, K. M.; Maroney, M. J.; Dann, C. E.; Winkler, M. E.; Giedroc, D. P., 
Nat. Chem. Biol. 2013, 9, 177-183. 
28 
 
(67) Brown, N. L.; Stoyanov, J. V.; Kidd, S. P.; Hobman, J. L., FEMS Microbiol. Rev. 
2003, 27, 145-163. 
(68) Ma, Z.; Jacobsen, F. E.; Giedroc, D. P., Chem. Rev. (Washington, DC, U. S.) 
2009, 109, 4644-4681. 
(69) Ma, Z.; Cowart, D. M.; Scott, R. A.; Giedroc, D. P., Biochemistry 2009, 48, 3325-
3334. 
(70) Sakamoto, K.; Agari, Y.; Agari, K.; Kuramitsu, S.; Shinkai, A., Microbiology 
2010, 156, 1993-2005. 
(71) Dwarakanath, S.; Chaplin, A. K.; Hough, M. A.; Rigali, S.; Vijgenboom, E.; 
Worrall, J. A., J. Biol. Chem. 2012, 287, 17833-17847. 
(72) Higgins, K. A.; Giedroc, D. P., Chem. Lett. 2013. 
(73) Coyne III, H. J.; Giedroc, D. P., Biomol. NMR Assignments 2013, 7, 279-283. 
(74) Theiler, M.; Smith, H. H., J. Exp. Med. 1937, 65, 787-800. 
(75) Plotkin, S. L.; Plotkin, S. A., Vaccines 2004, 5, 1-16. 
(76) Plotkin, S. A., Clin. Infect. Dis. 2008, 47, 401-409. 
(77) Correia, B. E.; Bates, J. T.; Loomis, R. J.; Baneyx, G.; Carrico, C.; Jardine, J. G.; 
Rupert, P.; Correnti, C.; Kalyuzhniy, O.; Vittal, V., Nature 2014. 
(78) Correia, B. E.; Ban, Y.-E. A.; Holmes, M. A.; Xu, H.; Ellingson, K.; Kraft, Z.; 
Carrico, C.; Boni, E.; Sather, D. N.; Zenobia, C., Structure 2010, 18, 1116-1126. 
29 
 
(79) Sette, A.; Livingston, B.; McKinney, D.; Appella, E.; Fikes, J.; Sidney, J.; 
Newman, M.; Chesnut, R., Biologicals 2001, 29, 271-276. 
(80) Sette, A.; Fikes, J., Curr. Opin. Immunol. 2003, 15, 461-470. 
(81) Keating, G. M.; Noble, S., Drugs 2003, 63, 1021-1051. 
(82) Crosbie, E. J.; Kitchener, H. C., Expert Opin. Biol. Ther. 2007, 7, 391-396. 
(83) Le Tallec, D.; Doucet, D.; Elouahabi, A.; Harvengt, P.; Deschuyteneer, M.; 
Deschamps, M., Hum. Vaccines 2009, 5, 467-474. 
(84) Monie, A.; Hung, C. F.; Roden, R.; Wu, T. C., Biologics 2008, 2, 97-105. 
(85) Szarewski, A., Expert Opin. Biol. Ther. 2010, 10, 477-487. 
(86) Venters, C.; Graham, W.; Cassidy, W., Expert. Rev. Vaccines 2004, 3, 119. 
(87) Brown, D. R.; Garland, S.; Ferris, D. G.; Joura, E.; Steben, M.; James, M.; 
Radley, D.; Vuocolo, S.; Garner, E. I. O.; Haupt, R. M.; Bryan, J. T., Hum. Vaccines 
2011, 7, 230-238. 
(88) Smith, J. F.; Brownlow, M.; Brown, M.; Kowalski, R.; Esser, M. T.; Ruiz, W.; 
Barr, E.; Brown, D. R.; Bryan, J. T., Hum. Vaccines 2007, 3, 109-115. 
(89) Chen, X. S.; Garcea, R. L.; Goldberg, I.; Casini, G.; Harrison, S. C., Mol. Cell 
2000, 5, 557-567. 
(90) Nardelli-Haefliger, D.; Roden, R.; Benyacoub, J.; Sahli, R.; Kraehenbuhl, J.-P.; 
Schiller, J. T.; Lachat, P.; Potts, A.; De Grandi, P., Infect. Immun. 1997, 65, 3328-
3336. 
30 
 
(91) Day, P. M.; Gambhira, R.; Roden, R. B.; Lowy, D. R.; Schiller, J. T., J. Virol. 
2008, 82, 4638-4646. 
(92) Ryding, J.; Dahlberg, L.; Wallen-Ohman, M.; Dillner, J., J. Gen. Virol. 2007, 88, 
792-802. 
(93) White, W. I.; Wilson, S. D.; Palmer-Hill, F. J.; Woods, R. M.; Ghim, S. J.; 
Hewitt, L. A.; Goldman, D. M.; Burke, S. J.; Jenson, A. B.; Koenig, S.; Suzich, J. A., 
J. Virol. 1999, 73, 4882-4889. 
(94) Joshi, H.; Cheluvaraja, S.; Somogyi, E.; Brown, D. R.; Ortoleva, P., Vaccine 
2011, 29, 9423-9430. 
 
  
31 
 
COMPUTATIONAL MODELING OF ALLOSTERIC PROTEINS 
Allosteric transitions, in which binding of an effector molecule to one site 
of a protein is coupled to a conformational change at a distant site or the change 
in the dynamics of specific domains correlate to the fluctuation of other domains, 
are examined using computational methods in this thesis. Although the concept 
of allostery was proposed more than 40 years ago,1,2 developing a mechanistic 
understanding of different classes of allostery continues to be an active and 
dynamic area of research. The X-ray crystal structures of ligand bound and 
unbound states have provided insight into the structural transitions underlying 
allostery in small number of allosteric proteins.3-6 However, the static nature of 
these structures present several important challenges for structural biology that 
can be approached using computational methods. To study allostery, atomistic 
level details are required to decipher how the ligand binding or the altered 
dynamics information is passed between two distant sites through a protein. This 
transfer of information involves both side chain groups and the polypeptide 
backbone scaffold. The inherent complexity of the allosteric phenomenon requires 
multiple approaches to obtain the necessary detail for a complete mechanistic 
understanding of allosteric transitions. 
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NMR spectroscopy is a particularly useful tool for investigating protein 
motions because it is sensitive to molecular motion over a wide variety of 
timescales.7-9 Solution NMR experiments can be performed under physiological 
conditions of solvent, pH, and temperature, thereby making a more direct 
correlation to the in vivo function however, detailed mechanistic information on 
allostery is not easily obtained from the aforementioned NMR experiments.10 This 
mechanistic detail is essential for a fundamental understanding of the allosteric 
behavior and, is crucial for aiding in the design of allosteric drugs and vaccines 
that interact with the target, altering the allostery and in turn impede the function 
of the protein. The atomistic detail on amino acid motions derived from molecular 
dynamics (MD) simulations is a powerful complement to solution NMR and 
crystallographic studies to shed further light on allosteric mechanisms. Various 
methods employed to study the protein motions of are shown in Figure 1. 
In this chapter, the computational methodologies applied in studying the 
allostery are discussed with the focus on the derivation of all-atom molecular 
mechanics force fields for modeling metal sensor proteins and silica nanoparticle 
tethered HPV VLP systems. 
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MOLECULAR DYNAMICS SIMULATIONS OF ALLOSTERIC PROTEINS 
Molecular dynamics simulations emerged as a very useful tool to study 
time dependent processes/motions in molecular systems.11-13 In bio-systems each 
of these dynamic motions have a characteristic time-scale, amplitude and energy 
range. Macromolecules in general, and proteins in particular, display a broad 
range of characteristic motions that are either very fast and very localized, such as 
atomic fluctuation or slow motions that occur on the scale of the whole molecule, 
such as the folding transition.14,15 Many of these motions have an important role in 
the biochemical function of the protein and lead to the allosteric transitions.14,15 
Furthermore, various small- or medium-scale protein motions are coupled to one 
another that lead to large-scale dynamic transitions.14,16,17 The time scales of several 
of these motions are listed in Table Error! No text of specified style in document..1.18 
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Figure Error! No text of specified style in document..1. List of different methods 
available to study protein dynamic modes based on their time scale18 
Table Error! No text of specified style in document..1. Classification of protein 
dynamic modes based on their time scale 
Local Motions: 
Atomic fluctuation and Side chain motion 
Medium Scale Motions: 
Loop motion, Terminal-arm motion and Rigid-body 
motion (helices) 
Large Scale Motions: 
Domain motion and Subunit motion 
Global Motions: 
Helix-coil transition, Folding/unfolding and Subunit 
association 
fs - ps (10-15 - 10-12 s) 
 
ns - μs (10-9 - 10-6 s) 
 
μs - ms (10-6 - 10-3 s) 
 
ms - h (10-3 - 104 s) 
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Allosteric transitions can often result in conformational changes of 
significant magnitude that take place in the μs–ms time scale, a time regime that 
cannot currently be sampled by means of standard MD techniques.19-21 However, 
the binding of the allosteric effector molecule increases the population of active 
conformations by modulating certain intermediate protein motions at different 
time scales and accelerating the allosteric transition. Standard MD simulations can 
be used to analyze the thermal motion of atomic sites in the ps–ns time scale. In 
this time scale, several protein motions take place, including side chain motion of 
hindered and unhindered surface residues, methyl group rotations, loop motion, 
collective motion of a few residues, helix–coil transitions, and folding of small 
peptides as listed in Table Error! No text of specified style in document..1. Modification 
of these protein motions caused by effector binding can be captured by correlation 
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analysis of motions observed along MD trajectories and combined with 
observations obtained by experimental NMR or crystallographic data.17,20,21 For the 
purposes of this work, focus is placed on the characterization of fast (picosecond - 
10 nanosecond) time scale motions that may collectively lead to the allosteric 
transition. 
MD BASED ANALYSIS 
The collective motions within proteins that lead to allosteric transitions can 
be derived from atomic interactions from a crystal structure, from the comparison 
of two molecular conformations or from the analysis of several conformations of 
the protein in its active and inactive states, as can be generated by the MD 
simulations. The analysis of these collective motions of the allosteric proteins can 
be used to investigate the conformational energy landscape, to improve the 
sampling space and in the refinement of X-ray and NMR data.22,23 Computational 
analysis of collective behavior must be based on knowledge of the structural 
fluctuations that occur as a result of thermal motion in the protein and can be 
obtained using different approaches as discussed in the following sections.24-28 
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PRINCIPAL COMPONENT ANALYSIS  
MD simulations generate an overwhelming amount of information 
contained in the trajectory of atomic coordinates. In order to extract the concerted 
fluctuations with large amplitudes from the trajectory, a principal component 
analysis (PCA) can be carried out on a large number of configurations chosen from 
the MD trajectory.29-31 PCA involves diagonalization of the covariance matrix of 
atomic fluctuations to yield collective variables that are sorted based on their 
contribution to the total mean-square fluctuation.32-36 For studies that focus on 
relating large-scale motions to function, however, the computational task can be 
reduced by selecting only backbone or Cα atoms for the PCA. This analysis is often 
termed as essential dynamics analysis (EDA).37,39 
NORMAL MODE ANALYSIS 
Normal mode analysis (NMA) is one another major simulation techniques 
used to probe the large-scale, shape-changing motions in biological molecules.40-42 
Although it has a connection to the experimental techniques of infrared and 
Raman spectroscopy, its recent application has been to predict functional motions 
in proteins or other biological molecules.43,44 Functional motions are those that 
relate to function and are often the consequence of binding other molecules. In 
NMA studies, it is always assumed that the normal modes with the largest 
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fluctuation (lowest frequency modes) are the ones that are functionally relevant, 
because, like function, they exist by evolutionary design.45,46 The ultimate 
validation of the functionally relevant mode must come from comparisons with 
experimental data and indeed studies that compare predictions of NMA with 
transitions derived from multiple X-ray conformers do suggest that the low-
frequency normal modes are often functionally relevant.42,47 A Hessian matrix is 
created, which is the matrix of second derivatives of the potential energy function 
with respect to the mass-weighted Cartesian coordinates. This stage determines 
the eigenvalues and eigenvectors. Because of the large size of this 3N×3N matrix, 
where N is the number of atoms in the molecule, this stage presents memory 
problems for large molecules. The process results in a set of 3N eigenvalues and a 
set of 3N eigenvectors each with 3N components. The eigenvalues are sorted in 
ascending order and the eigenvectors are sorted accordingly. The first six 
eigenvalues should have values close to zero because these correspond to the three 
translational and three rotational degrees of freedom for the whole molecule. The 
seventh eigenvector is the lowest frequency mode, and it is often predicted to be a 
functionally relevant mode.48,49 
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MOLECULAR DYNAMICS SIMULATIONS AND MOLECULAR 
MECHANICS FORCE FIELDS 
Molecular dynamics (MD) is a powerful scientific method to study the 
properties, conformations, internal atomic motions and bio-molecular fluctuations 
of molecules as a function of time in atomistic level of detail.50-54 In molecular 
mechanics methods the smallest unit is the atom, and all the atoms are considered 
to be spherical with particular radii (derived from experiments or theory) and have 
a net charge.50-52 The interactions between these spherical atom-like particles are 
defined by classical potentials and these interactions are pre-assigned to obtain 
spatial distribution and energy of atom-like particles.51,52 A simple molecular 
mechanics potential energy equation is given by Eq. (1). 
Energy = Bond Stretching Energy + Angle bending Energy + Torsional Energy + 
Non-Bonded Interaction Energy  2.1 
Equation 2.1, substituted with the required parameters describe the 
behavior of different kinds of atoms and bonds, is called a force field. Many 
different kinds of force fields have been developed over the years which are 
associated with various MD packages. Some include additional energy terms that 
describe other kinds of deformations. In this study both GROMOS55-57 and 
CHARMM58 force fields are used and new force fields were parameterized to 
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model the system of interest. The mathematical form of the energy terms varies 
from force-field to force-field. Hence the more common and general energy terms 
are described in this chapter. 
BOND STRETCHING 
The function for defining bond stretching is given in Eq. (2.2). 
 𝐸 =  ∑ 𝑘𝑏(𝑟 − 𝑟𝑜)
2
𝑏𝑜𝑛𝑑𝑠  2.2 
The bond stretching energy equation is based on Hooke's law. The "kb" force 
constant controls the stiffness of the bond, while "ro" defines the equilibrium bond 
length. Unique "kb" and "ro" parameters are assigned to each pair of bonded atoms 
based on the type of bond and bond length. This equation calculates the energy 
associated with vibration about the equilibrium bond length. 
ANGLE BENDING 
The function for determining the angle bending is given in Eq. (3). 
 𝐸 =  ∑ 𝑘𝜃(𝜃 − 𝜃𝑜)
2
𝑎𝑛𝑔𝑙𝑒𝑠  2.3 
The angle bending energy equation is also based on Hooke's law. The "kθ" is the 
force constant that controls the stiffness of the angle spring, while "θo" defines its 
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equilibrium angle. Equation 3 estimates the energy associated with vibration 
about the equilibrium angle. 
TORSIONAL ENERGY 
Proper Dihedral: The rotation of ‘R’-groups around a bond is defined by a 
periodic equation, as the rotation is periodic every no. In order to avoid negative 
terms this equation uses a cosine function as shown in Eq. (2.4). 
 𝐸 =  ∑ 𝐴[1 + 𝑐𝑜𝑠(𝑛𝜏 − 𝜑)]𝑡𝑜𝑟𝑠𝑖𝑜𝑛  2.4 
The "A" parameter controls the amplitude of the curve, the “n” parameter controls 
its periodicity, and “φ“shifts the entire curve along the rotation angle axis (τ).”n" 
reflects the type symmetry in the dihedral angle. For example, a CH3-CH3 bond, 
repeats its energy every 120°. The cis conformation of a dihedral angle is assumed 
to be the zero torsional angle by convention. 
Improper Dihedral: An improper dihedral is required to preserve the 
planarity in planar groups (like aromatic rings). This dihedral type can also be 
used to prevent interconversion of stereocenters. The main difference between 
dihedral and improper angles is that, traditionally, the order of atoms making up 
a dihedral angle follows the lineup of covalent bonds. Whereas, in an improper 
angle the sequence of atoms often permutes the succession of chemical bonds, so 
  
42 
 
that the axis of an improper rotation does not necessarily coincide with a chemical 
bond. A virtual torsion (or improper dihedral) angle describes a torsion in terms 
of geometry, but not in terms of chemical bond and the functional form used is 
represented in Eq. (2.5). The most important modification when moving to 
coordination complexes is that the plane of the ligands need to be exactly defined. 
For example, in square planar complexes it is necessary to define an average plane 
through the ligands. Alternatives to the regular out-of-plane function for square 
planar complexes have included deviation of the metal from the coordination 
plane,59 functions of the angle of each ligand with the normal to the coordination 
plane,60 or dummy atoms placed at the axial positions.61,62 
 𝐸 =  ∑ 𝑘𝛿(𝛿 − 𝛿𝑜)
2
𝑖𝑚𝑝𝑟𝑜𝑝𝑒𝑟  2.5 
In addition to these terms, the CHARMM force field has one additional term; that 
is the Urey-Bradley term,51 which is an interaction based on the distance between 
atoms separated by two bonds(1,3 interaction). 
NON-BONDED ENERGY 
The non-bonded energy represents the pair-wise sum of the energies of all 
possible interacting non-bonded atoms “i” and “j”. Non-bonded potential includes 
van-der-Waals and electrostatic potentials. The van-der-Waals potentials take into 
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account repulsion between atoms at small separations and weak attraction at 
larger distances. The common form of this potential for a pair of atoms “i” and “j” 
is given by a Lennard-Jones function E LJ is represented in Eq. (2.6). 
 ELJ =  ∑ ∑
−Aij
rij
6ji +
Bij
rij
12  2.6 
Van der Waals attraction occurs at short distances between atoms, and 
rapidly dies off as the interacting atoms move apart by a few Angstroms. 
Repulsion occurs when the distance between interacting atoms becomes slightly 
less than the sum of their contact radii. The "A" and "B" parameters control the 
depth and position (interatomic distance) of the potential energy well for a given 
pair of non-bonded interacting atoms. The repulsion at small separations between 
atoms is associated with the Pauli Exclusion Principle, while weak attraction at 
larger distances is due to London dispersion interactions. 
The electrostatic contribution is modeled using a coulombic potential which 
is represented in Eq. (2.7). 
 𝐸𝑐𝑜𝑙𝑜𝑢𝑚𝑏 =  ∑ ∑
𝑞𝑖𝑞𝑗
𝑅𝑖𝑗
𝑗𝑖   2.7 
The electrostatic energy is a function of the charge on the non-bonded atoms, their 
interatomic distance, and a molecular dielectric expression that accounts for the 
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attenuation of electrostatic interaction by the environment (e.g. solvent or the 
molecule itself). Often, the molecular dielectric is set to a constant value between 
1.0 and 5.0. A linearly varying distance-dependent dielectric (i.e. 1/R) is sometimes 
used to account for the increase in environmental bulk as the separation distance 
between interacting atoms increases. Partial atomic charges can be calculated for 
small molecules using an ab-initio or semi-empirical quantum techniques. The final 
potential energy function for the force field description is given in Eq. (2.8). 
𝐸 = ∑ 𝑘𝑏(𝑟 − 𝑟𝑜)
2
𝑏𝑜𝑛𝑑𝑠 + ∑ 𝑘𝜃(𝜃 − 𝜃𝑜)
2
𝑎𝑛𝑔𝑙𝑒𝑠 + ∑ 𝐴[1 +𝑡𝑜𝑟𝑠𝑖𝑜𝑛
𝑐𝑜𝑠(𝑛𝜏 − 𝜑)] + ∑ 𝑘𝛿(𝛿 − 𝛿𝑜)
2
𝑖𝑚𝑝𝑟𝑜𝑝𝑒𝑟 + ∑ ∑
−Aij
rij
6ji +
Bij
rij
12 + ∑ ∑
𝑞𝑖𝑞𝑗
𝑅𝑖𝑗
𝑗𝑖  2.8 
FORCE FIELD PARAMETERIZATION AND OPTIMIZATION 
In the previous section, the potential energy function that determines the 
force field, and the required parameters were described. This chapter focuses on 
determining the parameter values for previously undefined or poorly defined 
systems. The choice of force field, the potential energy functions and their 
parameterization, is solely determined by the system of study. The two 
possibilities which are considered during parameterizing a new compound are 
general force fields63 which cover wide areas of chemistry such as the CGenFF64-66, 
UFF67 etc. or force fields developed for a specific type of compound. The latter 
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types lack transferability and general applicability, but are supposed to be 
accurate, as they are built to suit the specific system.68 For most applications the 
essential task, and the first step to consider, is to accurately reproduce structures, 
and these are also the basis for an exact computation of the corresponding 
spectroscopic and thermodynamic properties of inorganic and bioinorganic 
compounds.69-72 
During the process of parameterization of new force field the most 
important factor to consider is the goal of the force field and accuracy that is 
needed for structures. For some applications, a reasonable structure is all that is 
needed. If so, it is even possible that an existing force field with generalized 
parameters can fulfill the goal.67 Type of the functional form needed is very 
dependent upon the goal and also upon the type of complex to be modeled. 
Reasonable structures of metal complexes can be achieved with relatively simple 
functional forms, but sterically induced distortions in coordinatively unfilled 
complexes (e.g. distortions from planarity) require an accurate and flexible 
definition of metal-centered angles. Especially, when the system of interest 
involves metal coordinating with a protein, the coordination of the ligands may be 
unusual. These types of complexes require extra terms in the potential energy 
function to enforce unusual geometry at the metal center. For example, improper 
dihedrals and out of plane bending terms are introduced to maintain the planarity 
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of the metal complex as well as the orientation of the rings while coordinating with 
the metal. 
Assigning an initial set of values for unknown parameters is very important 
and this step controls the tediousness of this process. Most of the MD simulation 
programs are provided with modules that will identify atoms with missing 
parameters and provide an initial first guess of values.73-75 These programs use a 
pattern recognition algorithm to guess the approximate parameter, and these 
parameters should be checked with chemical intuition. But generating an initial 
set of parameters from these programs is always a better estimate than to start with 
random numbers. Since the new parameters are usually estimated by one’s 
intuition and then optimized, a second consideration in developing force fields is 
the selection of reference or target data that is used to improve the new parameters. 
It must always be remembered that force fields are empirical, and can never be 
better than the data used to create the force field. The parameters needed to extend 
the force field for a new system should fit into the different terms of the force field 
that is chosen,68 as these parameters are generally optimized using different 
target/source data. The internal parameters such as equilibrium bond lengths, 
equilibrium angle values, and dihedral multiplicity are often adjusted to 
reproduce gas-phase geometric data obtained from quantum mechanical 
calculations, electron diffraction, crystallographic data or microwave 
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experiments.51 The force constants, such as the bond length and angle force 
constants are usually deduced using vibrational spectra or calculations, which 
contain individual frequencies and their assignments.76 The approaches for 
deriving electrostatic parameters mostly include reproduction of target data from 
QM calculations.77,78 One method of obtaining partial atomic charges is to correlate 
the calculated electrostatic potential (ESP) of the molecule calculated with QM 
methods.77,78 A popular variation of this method is called the RESP method,79 
where the charges on atoms that are minimally exposed to solvent are restrained. 
The goal of both methods is to produce the partial atomic charges that reproduce 
the electrostatic potential created by the molecule.80 Automatic parameterization 
procedures have been attempted in this work; however, a significant amount of 
manual interference is generally required. A third consideration during 
parameterization is the procedure used to optimize the force field. When a force 
field is selected for use, the information that one wishes to extract must be 
considered.81 For example, if one is interested in examining the atomic details of 
water interactions with protein residues, the proper force field to use would be an 
all-atom force field designed specifically for biomolecules that allows for explicit 
representation of water molecules (as opposed to an extended atom force field 
where hydrogens are not explicitly represented but treated as part of the atom to 
which they are bound). 
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A flow chart outlining the parameterization and automation procedure is 
shown in Figure Error! No text of specified style in document..2. Though the chart looks 
linear and simple several cycles of optimization have to be performed to validate 
the new force fields. For example, the functional form is frequently updated 
during the process, by adding, removing, or changing specific terms. The quality 
and accuracy obtained from the simulations with a newly parameterized force 
field is obviously based on the methods and target data which are used in the 
optimization of the derived parameters.68 Any new compounds to be used with 
the new force field must be tested in order to ensure that they are treated correctly 
and the required accuracy is obtained.68 Generally, the extent of transferability is 
considered to be minimal, and new parameters must be generated each time a new 
class of molecules is being used with the force field.68 In this case, the GROMOS 
force fields55 were used and extended to model the Cu(I) coordination in the 
copper sensing proteins and CHARMM27 force fields58 were adopted to model the 
silica surface tethered to the virus-like particle. Since silica force fields82 are 
developed using CHARMM package, applying CHARMM force fields to model 
this system is the suitable choice. 
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Figure Error! No text of specified style in document..2. Process flow used in the 
derivation of new parameters for developing the new MM force field 
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TRANSITION METALS IN BIOCHEMISTRY 
Transition metal ions like manganese, iron, cobalt, copper, zinc and to a 
lesser degree nickel, molybdenum, tungsten, and vanadium are known to be vital 
for many biochemical processes in all living organisms.1-3 The unique properties 
of transition metals (d-block metals), including access to several oxidation states 
and varied coordination geometries have been exploited by nature to perform a 
wide variety of functions. Metal ions are essential cofactors for functional 
expression of many proteins and for performing various biochemical functions.4 
In cells, several trace elements are needed to activate and stabilize enzymes, such 
as superoxide dismutase, metalloproteases, protein kinases, and transcriptional 
factors containing zinc finger proteins.4 Metal ions also play key roles as catalytic 
cofactors in reversible oxidation-reduction reactions, hydrolytic reactions, and 
structural rearrangements of small organic signaling molecules by coordinating to 
the active site of the respective enzymes. Most of the proteins involved in the 
electron transfer chemistry consist of metals at the active site e.g. Iron sulfur cluster 
proteins.4 Despite of their importance in cellular homeostasis, they can be toxic to 
the cell at higher concentrations.5 As a result, all the cells have evolved 
mechanisms to ensure a balance between each of these transition metal ions. The 
homeostasis of these essential metal ions is maintained by extensive network of 
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regulatory proteins that control the uptake, intracellular availability and 
efflux/storage.2,3 
METAL HOMEOSTASIS 
Metal homeostasis is defined as the process in which an optimal 
concentration of metal ions and their bioavailability is maintained in the cell, or in 
intracellular components of the cell.2,3 The shortage of a metal ion may initiate 
several cellular events that may increase the uptake and lower the cellular 
requirement for this particular metal ion by down-regulating the proteins or 
biochemical processes that necessitate the metal. On the other hand, when there is 
excess metal ion concentration, cells are required to efflux, store or detoxify metal 
ions to mitigate the effect of metal toxicity.2 In bacteria, all of these processes are 
highly coordinated largely at the level of transcriptional regulation by a panel of 
metal sensor proteins/metal regulator proteins. 
In Gram-negative bacteria, metal ions have to pass through the outer 
membrane into the periplasmic space and then through the plasma membrane 
before they reach the cytoplasm where they are complexed with proteins.3 
Trimeric ß-barrel proteins, porins in the outer membrane allow for non-selective 
diffusion of metal ions; in other cases, specific high affinity outer membrane 
receptors mediating the transport of specific metal chelates are present.3,6 The 
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cytosol effectively collects all metal ions by employing specific metal uptake 
transporters located in the plasma membrane.6 The uptake systems are driven 
either by the hydrolysis of ATP, for example, ATP-binding cassette (ABC) 
transporters and P-type ATPases, or via coupling to an energetically favorable 
process, such as co-transport of protons or other small molecules across the lipid 
bilayer.7 In gram-positive bacteria, an extra layer of lipopolysaccharide or complex 
carbohydrates is present and this may potentially affect the rate and mechanism 
of metal uptake.7 
In the cytoplasm and periplasmic space in Gram-negative bacteria, copper 
ions require specific transporting and trafficking mechanisms to target it to correct 
proteins1 and this is usually mediated by proteins called metallochaperones.1,8 The 
metal transfer from these metallochaperones to a target protein is accomplished 
by formation of an intermediate protein-protein complex like the mechanism 
described Cu trafficking via a ligand exchange reaction.9,10 Cys-rich 
metallothioneins involved in Zn and Cu detoxification, or ferritin-like 
bacterioferritins and Dps-type proteins for iron storage, can function to sequester 
excess metal ions in the cytosol.8,11-16 Overall, the intracellular concentration of the 
metal ions is tightly regulated to maintain normal metabolism of the cell. 
Pathogenic bacteria which colonize in human body require the same 
micronutrients (metals and other inorganic ions) that are essential for the host cells 
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to maintain their cellular metabolism. As a result, a competition exists between the 
host cells and the colonizing pathogenic bacteria leading to metal stress in the 
immediate environment of the bacteria in the host cell. Hence, both prokaryotes 
and eukaryotes developed specific metal acquiring protein systems which import, 
store and export metal ions by distinguishing each metal based on its charge, size, 
stable oxidation state, coordination geometry etc.17-19 Each metal has specific role 
in the cell and an individual metal ion is capable of performing only one or a few 
of these functions. One such biologically active metal is copper which is required 
by many enzymes such as oxidases and antioxidant enzymes like superoxide 
dismutases.20 The reversible oxidation reaction of copper from Cu(I) to Cu(II) 
makes copper an essential cofactor for some critical enzymes involved in O2 
binding and reduction like the multicopper oxidases.21,22 Uncomplexed Cu(I) in the 
cytosol can also catalyze the formation of peroxides and reactive oxygen species 
which can create an oxidative stress in the cells.23-25 Many neurodegenerative 
diseases like Alzheimer's and Parkinson's are associated with Cu(II) dependent 
nucleation of amyloid peptides and catalyzing the reduction of di-oxygen to 
peroxides after reduction of Cu(II) to Cu(I).26-37 Hence the copper concentration 
inside the cells should be regulated in a way the bioavailability of Cu(I) should be 
minimal and kept very low by complexing with cysteine rich proteins such as 
metallothioneins and copper chaperones.1,14-17,19,38-40 Studies on copper homeostasis 
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mechanism in pathogenic organisms have shown that copper export, in addition 
acquisition is important for virulence and these organisms are very sensitive to 
excess concentrations.38,41-44 Pathogenic bacteria regulate the copper concentration 
by employing a network of proteins which can sense excess copper by binding to 
them with high specificity and activating the transcription of gene which translates 
metal exporter proteins like the ATPases. 37,40-43 Hence, for many bacterial 
organisms maintaining cellular metal ion homeostasis is an essential requirement 
for survival. 
ROLE OF COPPER IN BIOLOGY 
Copper is an essential transition metal ion in various biochemical processes 
and is required by many proteins and enzymes involved in electron-transfer cycle 
and in the catalytic oxidation of substrates.22,45-47 The ability of Cu to undergo 
reversible oxidation and reduction is very detrimental as free cellular Cu ions can 
undergo Fenton-like reaction, catalyzing the production of activated oxygen 
radicals, reactive hydroxyl radicals, which can readily react with proteins, lipids 
and nucleic acids.23,25,38,48,49 In support of this, recent studies show that copper stress 
can activate the genes related to oxidative stress defense, suggesting a connection 
between Cu homeostasis and oxidative stress,50,51 although the underlying 
mechanism remains unclear. A more recent report suggests that in E. coli and B. 
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subtilis, Cu(I) may directly damage the solvent exposed iron-sulfur clusters in 
proteins and significantly interrupt their functions in the absence of molecular 
oxygen; iron release caused by such damage may induce mis-regulation of Fe 
homeostasis and, in aerobic conditions, Fe mediated oxidative stress.25,52 On the 
other hand, free Cu(II) ion is capable of directly oxidizing amino acid side chains 
as well as inducing amyloid formation, and thus is associated with many amyloid-
related diseases in mammals.53,54 Therefore, the bioavailable copper levels must be 
strictly controlled inside the cell and is proposed to be buffered at a concentration 
in the 10-18 M range.6 As such, it is widely accepted that in bacterial and yeast cells, 
there is no free or bio-available copper in the cell.40 Control of Cu homeostasis in 
bacteria is particularly important since most bacteria seem to lack a cytosolic Cu 
requirement.55,56 Thus, virtually any Cu(I) in the cytoplasm in a non-
photosynthetic bacterium is toxic. This high reactivity of copper is the reason why 
bacteria try to avoid Cu toxicity through buffering Cu in the cytoplasm very 
tightly.1,55,56 Once the buffering capacity of the Cu is exceeded in cytosol, 
transcriptional regulatory proteins termed Cu sensors bind to the Cu ions, and 
through allosteric regulation mechanism they up regulate the expression of genes 
that encode metal efflux systems such as Cu-exporting P1-type ATPases and Cu 
metallochaperones.1,8,14,15,21,38,39,50,55 P1-type ATPases efflux the excess copper while 
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metallochaperones sequester extra Cu ions simultaneously, attaining 
homeostasis.14,15,26,57  
CU(I) SENSING PROTEIN FAMILIES IN BACTERIA 
As discussed in the previous section, to combat the elevated levels of Cu, 
bacterial pathogens implement sophisticated mechanisms for Cu sensing and 
detoxification.1,3,15,21,38,58 The Cu regulatory mechanisms are generally encoded into 
an operon with the following basic framework: a Cu transcription factor 
(commonly a repressor), a Cu-binding protein (chaperone) that delivers Cu to the 
repressor, and a P-type ATPase (an exporter).1-3,8 This operon is de-repressed in the 
presence of Cu, leading to expression of one or more Cu efflux pumps. In different 
bacterial pathogens, the above basic framework is modified to respond to their 
unique niche.16,56,58 Several transcriptional metal regulatory protein families have 
thus far been structurally and /or functionally characterized to some detail and the 
major Cu sensing families among these are reviewed in the next subsections. 
ArsR/SmtB and MerR proteins are the two most extensively studied families of 
metalloregulatory proteins, and the proteins involved in sensing Cu specifically 
will be discussed here.59-65 The CopY family, the other known family of Cu-sensors 
in prokaryotes, will also be briefly described.2,57,66 From this discussion, an 
understanding of metal specificity and mechanisms involved in metal-dependent 
63 
 
allosteric regulation of DNA binding allows us to place our studies on the CsoR 
family proteins in context. It should be noted that the molecular and atomic level 
details by which an individual metalloregulatory protein selectively responds to 
one or more metal ions remain elusive, due to the limited number of high 
resolution structures of each functionally relevant conformational state within the 
regulatory network. 
MerR FAMILY 
CueR belongs to the MerR‐family of metal‐responsive transcriptional 
regulators67-70 is a Cu(I) sensing protein, other members of which include zinc‐
sensing ZntR,71-74 mercury‐sensing MerR,65,75,76 cadmium‐sensing CadR,77 lead‐
sensing PbrR,78,79 and cobalt‐sensing CoaR.80 All MerR family metal sensors 
possess very similar N-terminal winged helical domains comprised of a helix-
turn-helix-β-hairpin structure, followed by a long dimerization helix, but quite 
divergent C-terminal effector binding domains.65,76 The structural diversity in the 
C-terminal region makes it possible for individual MerR family proteins to sense 
not only various metal ions as mentioned above but also oxidative stress by SoxR 
via an [2Fe-2S] cluster,81-85 and small molecule drugs in the case of BmrR and 
MtaN.86-89 This family of metal sensor proteins are shown to be bound to the 
promoters of their target genes in the presence and absence of their effector 
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metals.65,76 In the presence of elevated levels of metal ions, they allosterically 
activate transcription by realigning unusually spaced consensus RNA polymerase 
recognition sequences, while in the absence of metal ions these proteins may lead 
to the repression.65,76 The operator‐promoter regions upstream of copA and cueO 
reveal unusual spacing (19‐bp, rather than 17‐bp) between −10 and −35 RNA 
polymerase consensus binding sequences, characteristic of genes regulated by 
MerR‐family transcriptional activators.65,69,70,76 Expression of both cueO and copA is 
substantially induced in response to elevated copper levels by the action of the 
CueR transcriptional regulator which has zeptamolar sensitivity to free Cu(I), less 
than one atom per cell.68,69 Mutants lacking cueR show reduced copper‐tolerance 
and lack copper‐induced expression of copA and cueO.66,90,91 The crystal structure 
of a CueR homodimer reveals a buried metal‐receptor site at the dimer interface 
that contributes to selectivity toward the monovalent metals by restricting binding 
to a linear two‐coordinate geometry involving two cysteines, Cys112 and Cys120.68 
CopY FAMILY 
The copYZAB operon in E. hirae is regulated by the copper‐responsive 
repressor CopY.92-95 The current model indicates that at low copper concentrations 
CopY is present as a Zn(II) containing homodimer and binds to the copYZAB 
operator‐promoter region repressing transcription.96,97 In the presence of copper, 
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the copper‐chaperone donates Cu(I) to CopY, displacing Zn(II), alleviating DNA‐
binding and allowing transcription of copYZAB to proceed.95,96 The carboxyl‐
terminal region of CopY possesses a CXCXXXXCXC metal‐binding motif. Each 
Zn(II) ion is coordinated to all four cysteines in the repressing form of CopY, and 
is replaced by two Cu(I) ions in the induced, non DNA‐binding form.97-100 
Spectroscopic studies suggest that each CopY protomer within the dimer is 
capable of binding two equivalents of Cu(I) per monomer to form a highly 
luminescent binuclear S4-Cu2 cluster exactly analogous to Cu(I) formed by the 
ArsR/SmtB family regulator BxmR.2,92,96,98 CopY‐like regulatory proteins are not 
widely distributed amongst bacteria but have been associated with the copper‐
resistance determinants of Enterococcus faecium,101 Lactococcus lactis IL140351 
Streptococcus mutans,102 and Streptococcus gordonii.103 The amino‐terminal half of 
CopY has structural similarity to the BlaI and MecI repressors that belong to the 
“winged helix” family of proteins and mediate resistance to β‐lactam antibiotics.99 
Further biophysical and structural characterization of the C-terminal Cu(I) 
binding domain in the intact homodimeric repressor, however, will be required to 
fully understand how Cu(I) is capable of mediating an allosteric or regulatory 
response upon DNA binding, while Zn(II) binding is not initiating the allosteric 
response. 
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CsoR FAMILY 
The first copper sensing CsoR family was discovered in Mycobacterium 
tuberculosis (Mtb-CsoR).104 Under elevated Cu levels the expression of Mtb-CsoR 
was found to be strongly induced, with the binding of Cu(I) triggering the 
derepression of the rv0967-rv0970 operon in which rv0969 encodes for a P1-type 
ATPase involved in Cu transport and rv0967 for Mtb-CsoR.104 It has subsequently 
been found that members of the CsoR family are wide spread in bacterial genomes. 
Examples of CsoR proteins that transcriptionally regulate copZA Cu resistance 
operons have been identified and characterized to varying degrees in Bacillus 
subtilis,105 Listeria monocytogenes,39 Thermus thermophillus,106 Streptomyces lividans,107 
Geobacillus thermodenitrificans,108 and Staphylococcus aureus.109  
CsoR binds to a region of the cso operon containing dyad symmetry and 
DNA‐binding is weakened upon Cu(I)‐binding, thus alleviating repression in 
elevated metal.104 The structure of Cu(I)‐CsoR reveals a homodimer with two Cu(I) 
ions, each Cu(I) bound in a trigonal coordination complex involving two cysteines 
and a histidine in a subunit bridging site.104 Although initial studies described 
CsoR as a homodimer,104 it is now known that most CsoR proteins exist in dimer 
of dimers architecture and bind to Cu(I) with a stoichiometry of one ion per 
protomer.106-108 
67 
 
The majority of identified CsoR‐related sequences appear to possess all 
three Cu(I)‐binding ligands, consistent with Cu(I)‐sensing.39,104,105,107-109 However, 
some of the more distantly related sequences lack all three ligands raising 
possibility that they might be involved in sensing metals other than Cu(I) or other 
substrates such as organic molecules.106 Furthermore, a recent report has identified 
a CsoR member that is not thought to be involved in Cu homeostasis, but instead 
appears to function in response to sulfur stress.110  
COPPER(I) AND DNA BINDING SITES IN CsoR PROTEINS 
Unlike other Cu(I) sensors such as E. coli CueR and E. hirae CopY which are 
largely confined to the Proteobacteria and Firmicutes, respectively, genes 
encoding CsoR proteins are widely distributed through most other major bacterial 
species.104 The 2.6 Å crystallographic structure of Cu(I)-bound CsoR reveals a 
homodimeric structure with a core antiparallel four-helix bundle (α1, α1’, α2, α2’) 
and the short C-terminal α3 helix stacked against the base of the molecule, 
proximate to α2’ helix of the opposite protomer.104 The Cu(I) ion is coordinated to 
an inter-subunit metal binding site formed by two conserved cysteines (Cys36 and 
Cys65’) and one conserved histidine (His61’).104,107 Crystal structures have been 
solved for Cu(I)-bound CsoR from Mycobacterium tuberculosis,104 Geobacillus 
thermodenitrificans108 and Apo CsoR from Streptomyces lividans107 and Thermus 
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thermophilus.106 Mtb–CsoR was suggested to form a homodimer, while Sl–CsoR, 
Gt-CsoR and Tt–CsoR were shown to possess dimer of dimers architecture.106-108 
The core four-helix bundle structure of the CsoR proteins from the above 
mentioned three families is very similar except that the Mtb-CsoR has a C-terminal 
tail spanning ~30 amino acids.104 This C-terminal tail is present in certain 
pathogenic Mycobacterium species and was not revealed in the crystal structure 
of Mtb-CsoR possibly due to its higher flexibility.104 The function of the tail in Mtb-
CsoR remains unclear but the role of the tail was proposed to be responsible for 
maintaining dimer-tetramer equilibrium in the solution.104 All three regulators 
bind two Cu(I) ions per dimer. Each copper ion is coordinated by one residue of 
the first protomer and two residues of the second protomer in a dimer. C-H-C 
motifs coordinate Cu(I) in Mtb–CsoR (Cys36-His61′-Cys65′) and Sl–CsoR (Cys75-
His100′-Cys104′), while copper ion binding involves a C-H-H motif in Tt–CsoR 
(Cys41, His70′ and His66′).104,106,108  
Due to the lack of a classical DNA binding motif such as winged helix-turn-
helix domain commonly found in other metalloregulatory proteins, how apo-
CsoR binds to the associated DNA operator remains unclear, as well as the 
mechanism by which Cu(I) binding induces allosteric negative regulation of 
operator DNA binding. Though these transcriptional regulators do not contain 
any known DNA-binding motif the characteristic antiparallel four-helix bundles 
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have been suggested to act as a DNA-binding fold.57,104 Recent experiments 
directed towards the prediction of the DNA binding motifs in CsoR proteins,111 
suggest that the prominent patch of positive electrostatic surface potential on the 
1- 2 face and close to the Cu(I) binding site (R15 (R24 in Bsu-CsoR) and R52 (next 
to K60 in Bsu-CsoR) in Mtb-CsoR) forms a part of the DNA binding site.111 
Previous studies on Mtb-CsoR have shown that the substitution of both Arg15 and 
Arg52 with alanine resulted in the loss of DNA binding104 and the multiple 
sequence alignments of CsoR in different bacteria suggest that Arg15 is conserved 
in CsoR orthologs.104 The mass spectrometry studies on Bsu-CsoR show that K3 
and K96 are the most reactive lysines in the apoprotein, with the reactivity of K96, 
K97, and K100 most strongly attenuated in the CsoR–DNA complex.111 The two 
Lys residues, K18 at the N-terminus of the α1 helix and K96 just C-terminal to the 
α3 helix, are shown to be protected from amidation in the Cu(I)-loaded tetramer 
versus apo-CsoR.111 Attenuation of reactivity of K18 relative to apo state (R10 in 
Mtb-CsoR and R13 in Tt-CsoR structures) may suggest a reorganization of the α1 
and α2 helices on Cu(I) binding.111 Modest protection from amidation of K96 was 
also observed and was suggested to be a result of change in the structure or 
remodeling of the tetramer interface, which is required to drive allosteric 
inhibition of operator DNA binding by Cu(I).111 A most recent work on the DNA 
operator binding of S.lividans CsoR predicts that the α1-helix RLXR motif 
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establishes contact at the GTA dyad regions of the type 2 operator site, and this 
would lead to the positioning of an Arg-rich cluster (RLXR) towards these major 
or minor grooves of the GTA dyads through hydrogen bonding interactions 
between Arg and purines (G/A).112 This work suggests that one Sl-CsoR tetramer 
binds with the RLXR motif pointed towards the major face and the second CsoR 
tetramer binds with the RLXR motif towards the minor face where the functional 
groups of the purines of the GTA dyads are likely to be exposed.112 The above 
proposed interactions indicate that the apo CsoR tetramer binds DNA through one 
face, creating asymmetry on the opposite face of tetramer. On binding to Cu(I) this 
type of flexes leading to asymmetry are restricted and a ‘flat or taut’ conformation 
was shown to exist on binding all four Cu(I) sites.112  
MOTIVATION TO UNDERSTAND ALLOSTERIC COPPER SENSOR 
PROTEINS IN PATHOGENIC BACTERIA 
Mtb is a pathogen that is well-adapted to respond to anti-microbial Cu in 
the host, as shown by its success as a human pathogen. The Mtb genome encodes 
two Cu-responsive regulons, the established Cu responsive operon regulated by 
CsoR104 as well as a second Cu-responsive regulon controlled by RicR.113 The cso 
operon is expressed in mice, implicating an important role during infection, and 
mutation of the cso operon member encoding the Cu transporting ATPase, CtpV, 
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leads to decreased lung damage in guinea pigs and in mice with compromised 
immunity.114 Moreover, loss of an outer membrane channel protein, MctB, which 
is not regulated by CsoR or RicR, leads to increased cellular copper load and 
decreased virulence in guinea pig infections.42 In comparison, MymT, a 
metallothionein, is protective against Cu stress in vitro, but mutation of mymT 
does not result in a detectable decrease in virulence in the mouse infection model.11 
It is unclear why the mymT mutant does not have any discernible phenotype in the 
mouse model, but perhaps using the guinea pig model, where phenotypes were 
observed for ctpV and mctB mutants, may elucidate a role.55,56,114 Mounting 
evidence suggests that the anti-microbial properties of copper are used by host 
immune cells as one tool to defend against microbial pathogens.55,56 In turn, 
pathogenic bacteria like Mtb implement tightly controlled copper homeostatic 
mechanisms to utilize copper yet resist copper toxicity.18,42 Understanding how the 
pathogens sense and cope with Cu deficiency or toxicity at distinct times after 
infection may possibly lead to new drug targets against Mtb for the development 
of novel therapeutic agents to cure tuberculosis. Attacking bacterial Cu resistance 
mechanisms and copper responsive regulator proteins like CsoR in conjunction 
with conventional antibiotics, may prove to be a valuable avenue for the 
development of anti-bacterial therapies. 
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COMPUTATIONAL MODEL OF Mtb-CsoR AND STUDIES ON ALLOSTERY 
IN METAL SENSOR PROTEINS 
As mentioned in the previous section Mtb-CsoR was initially characterized 
as a dimer as shown in Figure 3.1,104 but recent biophysical and structural studies 
on CsoR in other bacteria demonstrate the presence of dimer of dimers 
architecture.104,106-108 Therefore, in this computational evaluation of allostery in 
CsoR both the dimeric and tetrameric states were considered. In the presence of 
copper the CsoR repressor dissociates from the cso operon which can then be 
expressed. The operon contains the gene for what is believed to be a cellular 
copper exporter – CtpV.114 Binding of Cu(I) to the Mtb-CsoR dimer is believed to 
cause a conformational change that has low affinity for DNA, allowing expression 
of the cso operon, thus providing a protective mechanism against toxic levels of 
copper within cells.104 The binding of copper to Mtb-CsoR is exceptionally strong 
(KCu ≥ 10-19M), which is expected for a system that is critical for removal of toxic 
copper from cells. Liu et al., 2007 used a series of techniques to understand the 
structure of the Cu(I)-bound CsoR repressor.104 Protein crystallography of Cu(I)-
bound CsoR indicates that CsoR is an alpha-helical dimer, with each protomer 
composed of three helices (Figure 3.1).104 The copper is bound between the two 
protomers, coordinated by the side chains of amino acids from each subunit 
(Cys36, Cys65΄, and His61΄). Copper K-edge X-ray absorption spectroscopy (XAS) 
73 
 
was used to provide accurate bond-length information of the copper site in Cu(I)-
bound CsoR.104 Analysis of the extended X- ray absorption fine structure (EXAFS) 
oscillations indicated a three-coordinate site with two Cu—S ligands at 2.21 Å and 
one oxygen or nitrogen at 2.06 Å.104 Analysis of the Cu XAS of the Cu(I)-bound 
Mtb-CsoR H61A mutant indicated a two-coordinate site with two sulfurs at 2.14 
Å.104 Cys-Cys-His ligand trigonal binding mode of Cu(I) is unusual and there are 
only few other examples of such trigonal coordination of Cu(I) that include ScAtx1 
metallochaperone115 and a yeast Sco1 protein.116 The functional relevance of the 
atypical binding motif of Cu(I) in allostery is investigated using computational 
methods in this research. Unnatural amino acid substitution experiments 
performed on Mtb-CsoR show that atom substitutions on the Nε2 of Cu(I) 
coordinating His-61 can allosterically uncouple Cu(I) and DNA binding, with no 
effect on Cu(I) binding affinity and coordination structure.117 Tyr-35 and Glu-81 
amino acids were observed to be in close proximity to the Cu(I) binding region in 
the crystal structure and a collective interaction between the Nε of His-61, phenol 
group of Tyr 35 and the carboxylic acid group of Glu-81 was hypothesized to be 
crucial for the allosteric coupling in Mtb-CsoR.117 In this chapter, we describe the 
computational studies that are performed on Mtb-CsoR to answer the following 
questions: What role does copper binding have in the conformational preference 
of CsoR? Does copper-binding preferentially stabilize one conformation over 
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another? What residues are important in promoting these conformational 
changes? In order to predict the Cu(I) coordination geometry and the residue 
contacts which lead to the allosteric regulation, a thorough understanding of the 
electronic structure of Cu(I) and it coordinating ligands is crucial. Hence, we chose 
to use high level quantum mechanics calculations to predict the geometry around 
Cu(I) along with protonation state of coordinating cysteines. In this evaluation, we 
observed that the coordination geometry of Cu(I) is extremely effected by the 
protonation state of the cysteines, there by influencing the secondary coordination 
sphere residue contacts that might lead to the conformational change on Cu(I) 
binding.  
Quantum mechanics methods allow us to model the distribution of 
electrons around atomic nuclei and can explicitly account for the making and 
breaking of covalent bonds during chemical reactions, while being limited to very 
short (fs to ps) timescales. But our goal is to interpret the protein dynamics that 
may cause the conformational change of the protein on binding to Cu(I) and these 
motions happen in the medium range (ns-us) timescales (Table 2.1). Therefore 
hybrid QM/MM methods in conjugation with all atom MD simulations were 
employed to predict the contacts between residues in the first and second 
coordination sphere and the small motions in the protein regions on binding to 
Cu(I) that might contribute to the allosteric transition. 
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Figure Error! No text of specified style in document..1. X-Ray crystal structure of 
Mtb-CsoR, showing the copper coordinating amino acids104 
To elucidate the role of copper binding on conformational states and 
dynamics of CsoR, additional sampling was carried on various forms of CsoR from 
Mycobacterium tuberculosis, Thermus thermophillus and Streptomyces lividans using 
all-atom molecular dynamics (MD) simulations. MD simulations of biological 
molecules have often been utilized to elucidate biological mechanisms.118-121 
Computational studies and MD simulations of some metal transcriptional 
regulators have also been reported in literature.122-129 Bradley, Chivers, & Baker, 
utilized equilibrium molecular dynamics simulation to explore the conformational 
dynamics of the E. coli NikR tetramer.122 Correlation analyses and PCA were used 
to identify residue contacts between Ni(II) and DNA binding domains of NikR. 
One drawback of this study is the absence of Ni(II) coordination data and 
simulations were only performed on the apo-NikR.122 But the residue interactions 
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that might be important in the allosteric transformation were calculated using 
contact and position correlation methods, to find clusters of residues that share 
similar correlation patterns with Ni(II)- and DNA-binding site.122,130 Sindhikara, 
Roitberg, & Merz, in a different study evaluated the Ni(II) and apo form of 
Pyrococcus horkoshii species NikR using both quantum mechanics based methods 
and MD simulations.127 QM based force-field parameters were developed to 
accurately represent the four nickel-centers in the nickel-bound form.127 These 
simulations provide additional insight into the dynamical preference that different 
initial conformations and nickel-binding states have on the protein overcoming 
the limitations of the computational model developed by Bradley et al., in 2008.122 
While the global conformational changes on the computational time-scale are not 
observed, several key flexible regions were highlighted especially the α2-β2 loop 
whose hinge-like motion allows functional global conformational change.127 
Sindhikara et al., 2009 suggest that regions with either high correlation relevance 
or flexibility seem to be correlated with biologically important and evolutionarily 
conserved regions.127 Specific mutations were suggested to these residues for the 
P. horikoshii species and also identified analogous regions in E. coli and H. pylori 
species of NikR that were expected to have similar character.122,127 Guo et al., 2010 
evaluated the structure and conformational dynamics of the MerR metal sensor on 
binding to Hg(II).129 MD simulations were used in the above work,129 to predict the 
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interdomain motions on a timescale of approximately 10 ns involving large-
amplitude (approximately 20 Å) domain opening-and-closing, coupled to 
approximately 40° variations of interdomain torsional angle. This correlated 
domain motion was suggested to be important in propagating the allosteric 
changes from the metal-binding site to the DNA-binding site while maintaining 
DNA contacts required to initiate DNA unwinding.129 
Extensive simulations were also performed on the Staphylococcus aureus 
CzrA that belongs to ArsR/SmtB family of metal sensing transcriptional repressors 
by Merz and coworkers.123,126,128 Unrestrained MD and QM/MM MD simulations 
performed on the apo and zinc-bound form of CzrA reveal the conformational 
change from “closed” to “open” form on binding to zinc.123 Chakravorty et al., 2013 
successfully determined a structural ensemble for the zinc-bound form of CzrA by 
effectively using NOE and RDC data in combination with modern MD and 
QM/MM MD techniques to model metal ion coordination.128 Crucial second-
coordination shell hydrogen bond between the conserved metal-binding ligand 
His97 and His 67’ of the αR helix,131,132 that connects the metal binding region to 
the residues in the DNA-binding region was predicted experimentally in Zn-
bound form of CzrA.132 Computational studies performed by Chakravorty et al., 
2012 suggest that this hydrogen bond is strengthened on the order of ~10 kcal/mol 
on metal ion binding compared to an apo allosteric form of the protein.126 Similar 
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study was performed on Mtb apo-NmtR using constrained MD and energy 
minimization methods to design the Zn(II) binding site in this protein.124 Several 
calculations performed at the DFT level of theory to validate the proposed Ni(II) 
coordination complex in NmtR were also published.124 Steered MD simulations 
were also performed on the NmtR system to predict the Ni(II) coordinating 
ligands and predict the structural change on binding to the metal.124 
In this computational exploration we show that Cu(I) coordination in Mtb-
CsoR can be studied by combining experimentally derived structural information 
(XAS, X-ray crystallography)104 with QM/MM methods to derive the first and 
second coordination sphere geometries and residue interactions. The QM/MM 
derived bonds, angles, dihedrals and charges were used to approximate and 
derive the force constants to create coordinate-covalent bonds between metal and 
protein in MD simulations. The accurate treatment of metal ions will correctly 
account for first and second coordination-shell effects such as metal ion mediated 
hydrogen-bonding interactions and will help capture the polarizing influence of 
metal ion binding on the protein conformation, ultimately leading to a more 
precise ensemble of structures. Correlation analysis and residue contacts were also 
analyzed to predict the changes in the local motions of Mtb-CsoR in Cu(I) bound 
and apo forms. 
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METHODS AND MATERIALS 
QUANTUM MECHANICS 
All calculations were carried out using Density Functional Theory(DFT) as 
implemented in the Jaguar 7.0 suite133 of ab-initio quantum chemistry programs. 
Geometries were optimized using the B3LYP134-136 functional with the 6-31G** basis 
set. Copper was represented by the Los Alamos LACVP basis. The energies were 
reevaluated by additional single point calculations at each optimized geometry 
using Dunnings’s correlation consistent triple-ζ basis set137 cc-pVTZ(-f) with the 
standard double set of polarization functions. In these single-point calculations, 
Cu was described by a modified version of LACVP, designated as LACV3P, where 
the exponents were decontracted to match the effective core potential with the 
triple- ζ quality basis. Vibrational frequency calculation results based on analytical 
second derivatives at the B3LYP/6-31G**/LACVP level of theory were used to 
confirm proper convergence to local minima and to derive the zero-point-energy 
(ZPE) and vibrational entropy corrections at room temperature using un-scaled 
frequencies. Solvation energies were evaluated by a self-consisted reaction field138-
140 (SCRF) approach with a solvent-excluding surface cavity, based on accurate 
numerical solutions of the Poisson–Boltzmann equation. In the results reported 
below, solvation calculations were carried out at the gas phase geometry using the 
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6–31G**/LACVP basis and employing a dielectric constant of ε = 80.37 for water. 
Whereas the accurate computation of absolute solvation energies remains a 
challenge and potentially requires careful inspection of the empirical parameters, 
the differential solvation energy is expected to be less sensitive owing to 
significant error cancellation when the same empirical parameters are used. Thus, 
the differential solvation corrections are most likely more reliable than the 
absolute energies of solvation. The energy components were computed with the 
following protocol. The free energy in solution phase G (sol) has been calculated 
as follows: 
 G(sol) = G(gas) + ΔG(solv) 3.1 
 G(gas) = H(gas) - TS(gas) 3.2 
 H(gas) = E(SCF) + ZPE 3.3 
 ∆E(SCF) = ∑E(SCF)products - ∑E(SCF)reactants 3.4 
 ∆E(SCF) = ∑E(SCF)products - ∑E(SCF)reactants 3.5 
G (gas) is the free energy in gas phase; ΔG (solv) is the free energy of solvation as 
computed using the continuum solvation model; H (gas) is the enthalpy in gas 
phase; T is the temperature (298.15K); S (gas) is the entropy in gas phase; E (SCF) 
is the self-consistent field energy, i.e. “raw” electronic energy as computed from 
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the SCF procedure and ZPE is the zero point energy. Note that by entropy here we 
refer specifically to the vibrational/rotational/translational entropy of the solute(s); 
the entropy of the solvent is incorporated implicitly in the continuum solvation 
model. Equation 3.6 was used to calculate the pKa of deprotonation of cysteines in 
the copper bound form of CsoR. 
 ∆G(sol) = -RTlnKa = 2.303*R*T*pKa = 1.36*pKa (at 298.15 K) 3.6 
QUANTUM MECHANICS/MOLECULAR MECHANICS 
We used QSite141 4.5 for combined QM and MM calculations. The QM and 
MM boundary is treated based on a frozen orbital approximation142. Quantum 
calculations in QSite are carried out using Jaguar 7133 and the molecular mechanics 
calculations are performed by IMPACT143 which is developed by Levy and co-
workers. The OPLS-AA molecular mechanics force field is used for the treatment 
of the MM part while the pure QM part was treated at the DFT-B3LYP134-136 level 
of theory. The basis set used for the entire QM region is LACVP*, which uses 6-
31G* for non-transition metals. This is the default basis set used in the 
parameterization of the frozen orbital cuts. All geometry optimizations are 
performed using LACVP* basis set. The methodology has been extensively tested 
and shown to give reliable results for the relative conformational energies of 
dipeptides and protonation energies of protein side-chains. The errors resulting 
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from the QM/MM interface have been tested to be small ( 0.5 kcal/mol) and are 
within the error ranges of DFT methodology.142 This methodology uses an 
adiabatic approach, in which the MM region is fully optimized after each QM step, 
resulting in very large reductions in computational effort as compared to carrying 
out a QM gradient evaluation at each geometry step.142,144,145 
The fundamental idea of QM/MM methodology is to divide a large system 
into two regions, QM and MM. The reactive chemical event is limited within the 
QM region, while the surrounding region is modeled by MM. If a suitable coupling 
of the QM and MM energy functions can be achieved, this methodology enables 
us to study reactions with the accuracy of the QM model, retaining the structural 
and electrostatic effects of the MM environment with the same computational cost 
of a quantum chemical treatment of the QM region alone. Four QM/MM models 
were built, using the Cu-CsoR crystal structure104 as reference with the QM and 
MM regions shown in Figure 3.2. The Mtb-CsoR computational model starts with 
Glu-4 at the N-terminus and residue Phe-88 at the C-terminal due to the lack of 
coordinates for residues 1-3 and the C-terminal tail in the crystal structure.104 The 
number of atoms that can be included in the QM region is limited to 200.146 An 
iterative approach was adopted to evaluate the two copper centers in CsoR. The 
first set of calculations included a single copper coordination sphere in the QM 
region while the other copper center was treated as the MM region. Positional 
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restraints were used to restrict the movement of Cu(I) in the MM region. In the 
second set of calculations the other copper center was optimized using the QM, 
wherein the previously optimized copper coordination complex was included in 
the MM region, and the geometry is fixed at the QM optimized geometry. 
Simultaneous optimizations were performed until a reasonable agreement has 
been obtained between the two copper centers. In all the models, carboxylic acid 
amino acids are deprotonated (Glu, Asp) and the basic amino acids are protonated 
(Lys). The N-Terminal is modeled as —NH2 and the C-Terminal as —COOH. 
 
Figure 3.2. QM and MM regions as used in the QM/MM calculations of Mtb-CsoR 
protein. The small region marked in violet is the QM which includes copper 
coordination environment, and the large yellow region is the MM region 
MOLECULAR DYNAMICS SIMULATIONS 
MD simulations were carried out using the gromacs147 package with 
constant number, pressure, and temperature (NPT) and periodic boundary 
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conditions. Standard Gromos force-field148 for the apo form was used, and force 
fields for each copper complex that we developed in our laboratory. The linear 
constraint solver149 (LINCS) method was used to constrain bond lengths, allowing 
an integration step of 2 fs. Electrostatic interactions were calculated with the 
Particle-Mesh Ewald algorithm. All simulations were preceded and followed by 
minimizations and sufficient equilibrations. Minimizations were run using the 
steepest descent algorithm with an energy minimization tolerance of 1 kJ mol-1 nm-
1 and maximum force of no greater than 1000 kJ mol-1 nm-1, with Lennard-Jones 
and Coulomb cutoffs set to 1.0 nm. Equilibration was performed on the solvent 
and ions around the protein to stabilize the system from collapsing during the 
unrestrained dynamics simulation. The reason is that the solvent is mostly 
optimized within itself, and not necessarily with the solute. Indeed, the solvent 
should be brought to the desirable temperature and proper orientation around the 
solute (the protein). After a desired temperature is reached, pressure is applied to 
the system until it reaches a certain density. All equilibrations are performed with 
a position restraining force on the heavy atoms of the protein (anything that is not 
hydrogen). The motion of the atoms is not restricted to avoid large energy changes 
in the system. The utility of position restraints is that they allow us to equilibrate 
the solvent (water) around the protein, without the added variable of structural 
changes in the protein. Equilibration is conducted in two phases. The first phase is 
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conducted under an NVT ensemble (constant Number of particles, Volume, and 
Temperature) over a time frame of 100ps. This ensemble is also referred to as 
"isothermal-isochoric" or "canonical". V-rescale temperature coupling method is 
used. NVT equilibration stabilizes the temperature of the system. Equilibration of 
pressure is conducted under an NPT ensemble, wherein the number of particles, 
pressure, and temperature are all constant over a time frame of 100ps. The 
ensemble is also called the "isothermal-isobaric" ensemble, and most closely 
resembles experimental conditions. For pressure coupling the Parrinello-
Rahman150 barostat is used. Starting velocities were generated with a Maxwell-
Boltzmann distribution corresponding to 300 K. All structures reported in this 
work were found to be stable within these MD runs. The energy minimized 
structure from the QM/MM calculations was used as the starting structure, by 
freezing the positions of Cu(I) and heavy atoms coordinating amino acids. 
CHELPG charges from the Jaguar output file are used for Cu(I) and its 
coordinating amino acids to maintain a charge of -2 units for the Cu(I)-bound Mtb-
CsoR dimer, each Cu(I) coordination contributing a charge of -1( (2 Cys-S— ) -> -2 
(Cu(I)) -> +1 = -1 per Cu(I) site) . The simulation trajectories obtained over 10 ns for 
copper bound form and 20 ns for apo form were subjected to cluster analyses with 
the Jarvis-Patrick algorithm151-154. 
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RESULTS AND DISCUSSION 
SMALL MODEL QM CALCULATIONS 
DFT has emerged as the QM method of choice for realistic simulations of 
systems as large as 150 atoms using a relatively high level of theory. Even so, this 
limit is still much smaller than the total size of the Cu(I)–CsoR complex. Therefore, 
smaller models were constructed using the immediate coordination environment 
of copper for the high-level calculations. A representative minimalist model is 
shown in Figure 3.3a. Only the copper atom and the amino acid side chains 
directly bound to copper were included in these calculations. To reduce the 
computational cost and to avoid irrelevant conformations of N- and C-termini, 
amino acids were terminated at the Cα position, and the amine and carboxyl 
groups are replaced by protons. DFT calculations show that the copper 
coordination geometry is linear, with the two cysteines as coordinating ligands 
(Figure 3.3b). The histidine ring was observed to be in non-coordinating distance 
and shifts away from the Cu(I) center. Not surprisingly, the QM calculations 
predict a linear geometry for Cu(I) which is not in agreement with the EXAFS 
experiments that reveal a trigonal coordination104 as shown in Figure 3.3c. 
Therefore, carrying out exclusive QM calculations will limit our understanding of 
protein enforced constraints on the Cu(I) binding and prediction of the incurred 
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electronic structures. Hence, QM/MM methods (discussed in the next section) 
were utilized to calculate the electronic structure of copper binding geometry with 
higher level of theory and the protein effect with classical theory. 
 
Figure 3.3. (a) Small model representative of Cu coordination used in QM 
calculations (b) Optimized QM geometry of Cu complex (c) EXAFS data depicted 
on the Cu complex 
COORDINATION GEOMETRY OF COPPER(I) IN Mtb-CsoR 
To investigate the copper coordination geometry and study the effect of 
protonation of cysteines on binding to Cu(I), four QM/MM models were built, 
starting from the crystal structure of copper bound Mtb-CsoR.104 In all the models, 
the protonation state of the polar amino acids was adjusted to mimic the biological 
pH of 7. Different protonation states of the amino acids are assigned using the 
ProtAssign program at pH of 7. The computational model does not include the 30 
amino acid tail in the C-terminal and 3 amino acids in the N-terminal.104 As a result 
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of this, the C- and N-termini were protonated (-COOH and –NH2) in all the Mtb-
CsoR models. All the backbone cuts were made 5 Å from the metal active site. The 
boundaries of QM region in this model include Tyr32 and Val33 of chain A, and 
Asn67 and Phe63 of Chain B. The QM region consists of following amino acids 
with the copper binding amino acids depicted in red color- TYR-CYS-VAL, ASN-
HIS-LEU-GLU-THR-CYS-PHE. 
Model A (Cys65-S-, Cys36-S-, His61- Nδ, Cu(I)) 
In Model A both the copper coordinating Cys65 and Cys36 are 
deprotonated. The total charge on the QM region is -2, with the copper 
coordination geometry contributing to -1 charge and glutamate carboxylic acid 
group contributing a charge of -1. The optimized structure of the QM regions is 
shown in Figure 3.4. The geometry around the copper is calculated to be tri-
coordinate, with Cys65—Cu(I)—Cys35 angle ~130° slightly higher than the angles 
(120°) in trigonal planar complexes. Thus the geometry around the Cu(I) in this 
model was inferred to be distorted trigonal. The His61- Nε proton involves in a 
hydrogen bonding interaction with the OH atom of Tyr35. This hydrogen bonding 
has been proposed in the previous experimental work on the Mtb-CsoR system 
and has been shown to be crucial in transmitting the signal involved in the 
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allosteric regulation on binding to copper.104 The hydrogen bonding distance is 
calculated to be ~2.2 Å. 
 
Figure 3.4. QM/MM optimized structure of Model A, Cu (Cyan) coordinating with 
Cys36, Cys61 and His61. H-bond interaction (red dotted line) between His61-Nε 
proton and Ty35-OH is shown 
Model B (Cys65-S-, Cys36-SH, His61- Nδ, Cu(I)) 
In Model B, Cys65 is deprotonated. On protonating Cys36 ( Cys65-S– -> -1, 
Cys36-SH -> 0, Cu(I) -> +1 = 0 per Cu(I) site) the net charge on Cu(I) site was 
calculated to be “zero”. The overall charge of the QM region is -1, with the 
glutamate carboxylic acid that is included in the QM region contributing to the -1 
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charge. The optimized structure of the QM regions is shown in Figure 3.5. The 
coordination geometry around Cu(I) differs from the geometry predicted in Model 
A, and also from the XAS experiments. The deprotonated Cys36 and His61 ligands 
coordinate in a linear fashion, while the protonated Cys65 was observed to be at a 
non-coordinating distance of 4.25 Å from Cu(I). The geometry around Cys36, Cu(I) 
and His61 is close to linear with an angle of 179°. The hydrogen bonding 
interaction between His61- Nε proton and Tyr35-OH is not identified in Model B. 
 
Figure 3.5. QM/MM optimized structure of Model-B, Cu (Cyan) coordinating with 
Cys36-SH, Cys65 and His61. Hydrogen bonding interaction is not observed 
between His61-Nε proton and Ty35-OH 
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Model C (Cys65-SH, Cys36-S-, His61- Nδ, Cu(I)) 
Cys36 is protonated in Model C. The total charge of the QM region is -
1(calculation showed in the Model-B), with the deprotonated glutamate carboxylic 
acid contributing to the -1 charge. The optimized structure of the QM region is 
shown in Figure 3.6. The geometry around Cu(I) is close to trigonal planar, but this 
model does not possess the crucial hydrogen bonding involved in the coupling of 
copper binding to allosteric regulation. 
 
Figure 3.6. QM/MM optimized structure of Model C, Cu (Cyan) coordinating with 
Cys36, Cys65-SH and His61. Hydrogen bonding interaction is not observed 
between His61-Nε proton and Ty35-OH 
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Model D (Cys65-SH, Cys36-SH, His61- Nδ, Cu(I)) 
 In this model both Cys65 and Cys36 are protonated. The total charge of the 
QM region is 0, +1 charge from the copper coordination(2 Cys-SH -> 0, Cu(I) -> +1 
= +1 per Cu(I) site) and -1 charge from the glutamate carboxylic acid group. The 
optimized structure of the QM region is shown in Figure 3.7. The calculated 
geometry around Cu(I) is close to trigonal planar and the hydrogen bond between 
His61- Nε proton and Tyr35-OH is not present in this model. 
 
Figure 3.7. QM/MM optimized structure of Model-D, Cu (Cyan) coordinating with 
Cys36-SH, Cys65-SH and His61. Hydrogen bonding interaction is not observed 
between His61-Nε proton and Ty35-OH 
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 As discussed above, the protonation state of Cys36 and Cys65, has a drastic 
influence on the coordination geometry of Cu(I) as well as the hydrogen bonding 
network and residue-residue interactions of the second coordination shell amino 
acids. QM/MM calculations validate the presence of a “bonded model” and reveal 
that the Cu(I) remains bonded to its amino acid ligands that are shown to involve 
in trigonal coordination.104 The hydrogen bond between the His61, Tyr35 and 
Glu81 (Figure 3.4) is only observed in Model A, where both cysteines were 
deprotonated. This interaction was proposed to have an important role in 
allosteric regulation of Mtb-CsoR.104,117 In order to predict the underlying electronic 
and structural aspects that result in the loss of H-bonding interaction between 
metal coordinating His61 and second coordination shell Tyr35 and Glu81 on 
protonating cystienes, the bond lengths, angles and the energetics of the ligand 
coordination to Cu(I) were evaluated.  
The coordination geometry of Cu(I), QM/MM derived bond lengths and 
angles were (Table 3.1) compared with those obtained from the EXAFS 
experiments on Cu(I)-bound form of Mtb-CsoR.104 When one of the cysteine is 
protonated, His-ND becomes a better ligand to Cu(I) which is indicated by the 
decrease in the bond distance between Cu(I) and His61 in Model B and C (Table 
3.1). Even shortening of Cu(I)‒His bond length is observed on protonating both 
the coordinating cysteines. The bonding model represented by Model A is 
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consistent with the data derived from EXAFS data with variance of 0.009 Å. In 
Model A the geometry around Cu(I) is observed to be distorted trigonal 
coordination which is in close agreement with the predicted trigonal planar 
coordination geometry around Cu(I).104  
Table Error! No text of specified style in document..1. Calculated Bond lengths of 
QM/MM models 
Model Description 
Cu—N 
 (His61) Ǻ 
Cu—S 
(Cys36) Ǻ 
Cu—S 
 (Cys65) Ǻ Calculated Geometry 
A 
Both Cys 
deprotonated 
2.12 2.35 2.28 Distorted trigonal 
B Cys65 deprotonated 1.94 4.25 2.20 Linear 
C 
Cys36 
Deprotonated 
2.08 2.29 2.43 Distorted trigonal 
D Both Cys protonated 2.04 2.48 2.31 Distorted trigonal 
Crystal EXAFS 2.06 2.21 2.21 Trigonal planar 
To evaluate the nature of interaction particularly between His61 and Cu(I), 
Zeigler Rauk energy decomposition analysis was performed. Several small models 
were generated from the structural data derived from the QM/MM structures. 
Two fragments were constructed by performing a cut at the Cu(I)‒Nδ(His61) bond 
in different protonation state combinations of the two cysteines. The various 
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contributions to the electronic bonding energy of Cu(I)‒Nδ(His61) bond are 
tabulated in Table 3.2. In Model A, the electronic interaction between His61 and 
Cys65‒Cu(I)‒Cys36 fragment is calculated to be -0.35 kcal/mol suggesting the 
presence of a weak bond. In the experimental evaluation of binding constant of 
Mtb-CsoR the log KCu of wild type was reported to be 18.0, while in the H61A 
mutant log KCu is predicted to be 14.9 suggesting that His61 does not contribute 
majorly to the binding energy of Cu(I) which is in agreement with our computed 
binding energy.104,117 However, in other binding models when at least one of the 
cysteine is protonated the electronic interaction between the histidine and Cu(I) 
increases and the maximum interaction energy of ~36kcal/mol was observed for 
Model D. According to lewis acid and base theory, cysteine in thiolate form is 
stronger nucleophile compared to a thiol, hence in the deprotonated form the bond 
between cysteine and Cu(I) is stronger and the partial negative charge on thiolate 
stabilizes the positive charge on Cu(I) leading to stronger electrostatic interaction. 
This renders the histidine imidazole interaction weaker when the two 
coordinating cysteines are deprotonated. But, when either of the cysteine is 
protonated, the histidine imidazole is a stronger nucleophile compared to a thiol 
promoting a stronger bonding interaction between histidine and Cu(I) which is 
supported by the increase in the interaction energy in Models B, C and D in Table 
3.2. In addition to the electronic and structural analysis, pKa analysis was also 
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performed to further evaluate the energetics of deprotonation of cysteines at 
physiological pH.  
Table 3.2. Ziegler–Rauk energy decomposition of His61-Cu bond in different 
models, all energies are in kcal mol-1 
Ziegler–Rauk energy decomposition A S-, S- B SH,S- C S-,SH D SH,SH 
∆Epauli 84.11 85.36 83.61 78.25 
∆Eel-st -58.04 -85.81 -68.35 -77.94 
∆Enonorb-int 26.07 -0.50 15.26 0.31 
∆Eorb-int -26.42 -33.41 -30.00 -36.40 
∆Etotal -0.35 -33.85 -14.74 -36.09 
pKa ANALYSIS 
Bonding and structural analysis of Cu(I) coordination geometry in Mtb-
CsoR prove that for the formation of hydrogen bond between Nε-His and Tyr-OH 
and Glu-COO-, both Cys36 and Cys65 should be deprotonated. In addition to the 
above discussed computational studies, theoretical pKa calculations were 
performed to validate the shift in pKa’s that triggers the deprotonation of Cys36 
and Cys65 when bound to Cu(I). Both histidine and cysteine prefer to bind to 
borderline soft metal cations such as Cu(I).155,156 At physiological pH, cysteine side 
chains with typical pKa values between 8 and 9 would be protonated in metal-free 
proteins.157 Binding to a metal cation (acting as a Lewis acid) decreases the pKa of 
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cysteines,156,158 facilitating the deprotonation of sulfhydryl group under 
physiological conditions.  
Small models of Model A, B, C and D were built with different protonation 
states of cysteines and the free energies of proton loss are calculated using the 
Equation 3.6. Subsequently, the pKa of each deprotonation step is calculated and 
are presented in Table 3.3. The first deprotonation of Cys65 sulfhydryl side chain 
has a pKa of 3.6 and that of Cys36 is calculated to be -1.6, indicating that when 
bound to Cu(I) Cys36 is likely to deprotonate first. The second deprotonation of 
Cys65 with Cys36 in deprotonated state is calculated to be 7.7 and for that of Cys36 
when Cys65 is deprotonated is 2.5. From these results, we can interpret that the 
two copper coordinating cysteines are present in the deprotonated form (Model 
A) even considering the error associated with the computed values (+/- 0.5 pH 
units). The pKa of cysteines in Mtb-CsoR shifts by 9 pH units and these relatively 
large shifts in pKa of cysteines were previously reported in Cu(I) binding 
chaperone CopZ in Bacillus subtilis.159 The two pKa’s of cysteines coordinating to 
Cu(I) in CopZ are experimentally predicted to be <4 and ~6.159 The acid–base 
properties of thioredoxin-like proteins, which also contain a CXXC motif, have 
been extensively characterized and very wide range of pKa values are found in 
these proteins, from ~3.5 for the first cysteine of the active site motif of E. coli DsbA 
to ~8.8 for the same cysteine of B. subtilis ResA.160-163 
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Table 3.3.pKa values calculated for all the QM/MM models 
Description pKa 
Cys65-SH 
(first deprotonation) 
3.6 
 
Cys36-SH 
(second deprotonation) 
2.5 
 
Cys36-SH 
(first deprotonation) 
-1.6 
Cys65-SH 
(second deprotonation 
7.7 
From the above presented quantum chemical calculations we were able to 
understand the Cu(I) first coordination sphere geometry and identify the 
proposed hydrogen bond between Cu(I) coordinating His61 and second 
coordination sphere Tyr35 and Glu81.104,117 QM/MM structural studies and pKa 
analysis predicted a valid model for the coordination of Cu(I) by Mtb-CsoR 
protein. The geometry of Cu(I) in Mtb-CsoR is described to be a tricoordinate [2+1] 
binding mode, with two strong bonds between Cu(I) and cysteines and a weak 
interaction between Cu(I) and histidine. Due to a stronger interaction between Nδ 
of His61 and Cu(I) (Models B, C and D) the pull exerted by the movement of 
histidine towards Cu(I), increases the distance between histidine and second 
coordination amino acids Tyr35 and Glu81, eventually leading to loss of hydrogen 
bonds. Therefore, an optimal bonding distance is necessary between Cu(I) and Nδ 
of His61 for the formation of H-bond between Tyr35 and His61. Moreover, the 
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bond distance is a measure of bond strength which was perceived to be influenced 
by the protonation state of the cysteines bound to Cu(I) and this phenomenon 
suggests that changes in the pH may have an underlying effect on the allosteric 
mechanism in Mtb-CsoR protein. Though further experimental studies are 
required to validate the above finding. Overall, quantum calculations were 
successful in providing a clear understanding of electronic structure of Cu(I) 
binding to Mtb-CsoR. The experimental Cu(I) binding studies and X-ray structures 
support our predicted structures and binding energies. Hence, Model A structural 
parameters were taken as a reference to build force fields for the Cu(I) bound form 
of Mtb-CsoR. The details, protocol and validation of the Cu(I) force fields were 
presented in the next section.  
FORCE FIELD DEVELOPMENT 
The copper bound CsoR models were simulated using the specifically 
developed force fields for Cu(I) ion trigonal coordination. The metal–ligand force 
field derivation is highly nontrivial and tedious. A small model was built to 
represent the Cu(I) coordination. Model A structure was used for the 
parameterization of new force fields. The geometric parameters, atomic charges 
(optimized geometries) and force constants (vibrational frequency calculations) 
for Cu(I)-ligand complex were taken from the small model complexes described 
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above, which were optimized using DFT at the B3LYP/6-31G**/LACVP level of 
theory (see QM computational details). The force-constants and ESP charges were 
iteratively adjusted until the normal modes derived from the quantum mechanical 
(QM) and molecular mechanical (MM) calculations were in good agreement. 
Figure 3.8 shows the correlation plot between MM normal modes generated using 
the new force fields and QM normal modes for Cu(I)—His—2Cys complex, which 
is used to validate the developed force fields. The Lennard-Jones potentials for 
Cu(I) non-bonded interactions were taken from corresponding values in 
gromos45a3 force fields. These parameters were then transferred to the topology 
files for each full-length CsoR-Cu(I) complex, replacing the original Gromacs-
generated parameters for the corresponding atoms. The partial charges on the 
neighboring carbon atoms were adjusted such that the overall charge after adding 
the QM-derived charges was the same as in the MM model. The derived force 
constants for bonds, angles and dihedrals are tabulated in Table 3.4. 
 
Figure 3.8. Correlation plot between the normal models obtained from MM and 
QM calculations 
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Table 3.4. The bond lengths, angles, improper dihedrals and the force constants 
developed for Cu(I) complex 
Bonds Bond length, nm Force constant, Kb 
Cu−SGCys36 0.235 48x104 
Cu−SGCys65 0.229 58x104 
Cu−NDHis61 0.212 23 x105 
 
Angles θ Force constant, Kθ 
SGCys65− Cu−SCys36 129.2 536.99 
SGCys65− Cu− NDHis61 117.1 634 
SGCys36− Cu− NDHis61 113.6 634 
Cu−SGCys65−CBCys36 107.0 481 
Cu−SGCys65−CBCys65 104.3 481 
Cu− NDHis61−CEHis61 116.9 574.51 
Cu− NDHis61−CGHis61 136.9 574.51 
 
Out of Plane Bending / Improper Dihedrals Planarity 
NDHis61−SGCys65−SGCys36− Cu Planar 
NDHis61−CEHis61− NEHis61− Cu Planar 
After the derivation of parameters for the Cu(I) coordination, the protein 
was simulated using MD simulations to predict high resolution structures of both 
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the Cu(I)-bound and apo Mtb-CsoR to predict the structural change involved in 
allosteric regulation. Both the dimeric and tetrameric forms of CsoR were 
evaluated and analyzed for the differences in structure and hydrogen bonding 
network. 
MD SIMULATIONS OF CU(I) AND APO CsoR DIMER 
In order to analyze residue interactions between the Cu(I) binding region 
and allosteric networks involved in transmission of conformational change in Mtb-
CsoR protein, equilibrium MD simulations were employed. Molecular dynamics 
methods have been used with a variety of proteins to recognize key residue 
interactions and networks that are involved in conformational changes as 
described in Chapter 2 of this thesis. We performed MD analysis on both the apo 
and Cu(I)-bound states of Mtb-CsoR dimer as an initial step to help identify 
functionally important residue interactions. Earlier experimental studies on Mtb-
CsoR suggest that Mtb-CsoR is present as dimer in solution,104 as opposed to the 
recent experimental work that reveal the evidence for the existence of tetrameric 
form of CsoR in Streptomyces lividans, Thermus thermophillus and other bacteria.106-
109 MD simulations were performed on Cu(I) and Apo CsoR dimer to identify the 
residue interactions in the second coordination sphere of Cu(I) and to analyze the 
communication pathway initiated on binding to the metal. Additionally, MD 
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simulations were also performed on the tetrameric form of CsoR, to understand 
the residue interactions and conformational changes between and within the two 
dimeric units of CsoR that control the overall conformational change in the CsoR 
tetramer. The crystal structure of Cu(I)-bound Mtb-CsoR was published104 and was 
used as a starting structure to optimize the Cu(I) binding geometry and to assign 
bonds between the metal and the coordinating residues. The crystal structure is 
missing a 21 amino acid C-terminal tail and 3 amino acid residues in N-terminal 
and hence our computational model starts with Glu4 and ends with Phe88. An 
attempt was made to build the C-terminal tail using our simulations and 
homology modeling techniques, but due to the unstructured nature of tail and also 
the existence of several orientations of the tail with respect to the CsoR protein, the 
assignment of inter helix-tail interactions was hampered. Additionally, each of 
these orientations will possess a minima and the selection of the relevant 
minimum energy structure would be difficult without any supporting 
experimental data.  
The starting structure for simulation apo CsoR was based on the X-ray 
crystal structure of Cu(I)- bound Mtb-CsoR with missing C-terminal tail and the 
first three N-terminal residues. Equilibration of the Cu(I)-bound Mtb-CsoR protein 
with no Cu(I) ions was performed using MD simulations to obtain a reasonable 
structure of the apo form and to evaluate the changes in quaternary structure of 
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Mtb-CsoR on loosing Cu(I) ions. As the Cu(I) Mtb-CsoR protein structure was 
stabilized by the electrostatic potential created by the two Cu(I) ions, the initial 
simulation of Cu(I)-bound Mtb-CsoR structure with no Cu(I) ions resulted in the 
unfolding of the protein and loss of secondary structure was observed. Several 
minimizations and equilibrations were carried out in order to achieve a stable 
structure during the simulation by gradually decreasing the forces acting on the 
Cu(I) binding residues. Subsequently, gas phase calculations were conducted 
employing the simulated annealing procedures that allow the protein to traverse 
different conformational landscapes and reform the contacts between the helices. 
In the simulated annealing procedure, the temperature of the system was steadily 
increased from 270 K to 320 K in 10 steps and subsequently was cooled down to 
300 K. The most populated structure from the simulated annealing procedure was 
solvated in 20,766 water molecules (solvent). Several cycles of minimizations and 
equilibrations were performed with a constraining force on the protein, allowing 
the water molecules to orient around the protein. The total charge on the apo Mtb-
CsoR protein was zero. Finally the protein was simulated for an additional time 
20 ns of production simulation, with a total of 50 ns simulation including the 
equilibration step. As the crystal structure of apo form of Mtb-CsoR was not solved 
using the X-ray crystallography, the average structure obtained from the 50 ns of 
MD simulation was validated using the X-ray crystal structures of T.thermophillus 
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and S.lividans apo CsoR. In order to understand the conformational space 
traversed by the apo form of T.thermophillus CsoR and S.lividans CsoR, MD 
simulations were also performed on the corresponding apo forms using their 
crystal structures. 
MD SIMULATIONS OF APO Thermus thermophillus (Tt) CsoR 
The thermophilic bacterium T. thermophilus belongs to the phylum 
Deinococcus–Thermus, and thus, is only distantly related to Mtb, Sl etc.106 T. 
thermophilus constitutes of the copZ-csoR-copA operon, which is repressed by CsoR 
under copper-limiting conditions.106 In vitro, T. thermophilus CsoR was shown to be 
promiscuous in binding various metal ions, including Cu(I), Cu(II), Zn(II), Cd(II), 
Ag(I) and Ni(II), all of which release CsoR from the copZ promoter.106 In vivo, it is 
reported that copper and zinc ions significantly increase copZ-csoR-copA 
expression, suggesting that the response of CsoR to various metal ions is also 
physiologically relevant.106 The copper ion binding motifs of most CsoR family 
proteins contain C-H-C,104,105,107,108 whereas the corresponding residues of 
T.thermophilus are C-H-H.106 The 3D crystal structure of Tt-CsoR in its tetrameric 
form was determined at a resolution of 2.1 Å.106 The tetrameric structure is 
composed of two dimers, i.e. chains AB and CD.106 Several disordered main-chain 
regions that were not included in the X-ray crystal structure (M1–L6, V71–G78 and 
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Y93–R94 of chain A; M1–S4, T73–E82 and K92–R94 of chain B; M1–L6, V71–D79 
and Y93–R94 of chain C; and M1–S4, A72–E82 and Y93–R94 of chain D) were 
constructed using protein building and modeling tools. The coordinates of the side 
chains of K11, D79, E85 and E86 of chain A; E37, K38, E85 and E86 of chain B; K11, 
E14, E82, E85, E86 and K92 of chain C; and E37, K38 and E85 of chain D were also 
not determined due to their poor electron densities. Using loop building tool 
PrimeX164 and homology modeling techniques165 the missing residues and loops 
were constructed. The reconstructed crystal structure of Tt-CsoR was simulated 
using MD simulations to understand the residue contacts in apo form of CsoR. 
Though the Cu(I) ion binding motifs and affinity of Tt-CsoR is different from Mtb-
CsoR, the interactions of the conserved residues were assumed to be homologous. 
Simulated annealing was performed to re-establish the α-helix contacts in the 
refined X-ray crystal structure. The most populated structure generated by the 
simulated annealing techniques was solvated in 40,371 water molecules. 
Production run of 20 ns time scale was performed and most populated conformers 
were obtained from cluster analysis of the simulation and is shown in Figure 3.9. 
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Figure 3.9. Average structure of the apo Tt-CsoR protein from 20 ns MD 
simulation 
MD SIMULATION OF APO STREPTOMYCES LIVIDANS (SL) CSOR 
The crystal structure of apo form of Sl-CsoR of 1.7 Å resolution was used as 
a starting structure in our MD simulations. Simulated annealing and production 
MD of 20 ns were performed including 42,645 waters. The most populated 
structure was derived using cluster analysis and is shown in Figure 3.10. 
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Figure 3.10. Average structure of the apo Sl-CsoR protein from 20 ns MD 
simulation 
MD SIMULATIONS OF CU(I)-BOUND MTB-CSOR 
As the founding member of CsoR family, Mtb-CsoR has been characterized 
using biological, biophysical and structural methods in Cu(I)-bound state. The 2.6 
Å crystallographic structure of Cu(I)-bound CsoR was used as a starting structure 
for the QM/MM calculations. The minimum energy structure obtained from the 
QM/MM calculations was used in MD simulations. The developed parameters for 
the Cu(I) coordination geometry were added to gromos 43a2 force fields. The 
extended force field with the electrostatic charges from the DFT calculations was 
used in order to account for the effect of change in electrostatic potential of the 
protein on binding to Cu(I). To validate and test the developed force fields and 
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proposed bonding model from our QM/MM calculations rigid bond model of 
Cu(I) binding geometry was simulated with the inclusion of corrections for the 
electrostatic charges to the force field. 
The Cu(I) Mtb-CsoR structure was initially equilibrated by freezing the 
bonds in the first coordination sphere of the copper at the QM/MM optimized 
geometry. As Cu(I) remained bound to CsoR protein and the bond distance 
between the amino acids and copper remained the same throughout the 
simulation, the constraints were subsequently removed. Charges of the first 
coordination shell were adjusted using the CHELPG charges such that each copper 
coordination site has a charge of -1. Hence the resulting charge on the Cu(I)-bound 
Mtb-CsoR dimer is -2. In the MD simulation, 0.2 M NaCl is added to the solvent to 
neutralize the protein charge and to simulate and mimic the ionic concentration in 
the experiments.  
STRUCTURAL ANALYSIS OF THE DIMER 
In accordance with the initial experiments of Mtb-CsoR,104 the dimers of 
both the Cu(I)-bound and apo Mtb-CsoR were compared structurally to examine 
any changes in the orientation of the helices. The most populated structures were 
obtained from the simulations in dimeric state. Initial benchmarking was 
performed by comparing the X-ray crystal structure of Cu(I)-bound Mtb-CsoR and 
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most populated structure of the protein obtained from the computational 
simulations using the secondary structure alignment methods. The computed 
model exhibited several similarities with that of crystal structure, reproducing the 
experimentally observed hydrogen bonding interaction between the side chains of 
Tyr35, His61 and Glus81. Superposition of the two structures by secondary 
structure matching gave a root mean square deviation of 1.15 Å as shown in Figure 
3.11. Unnatural amino acid substitution studies117 on Mtb-CsoR indicate that this 
H-bond interaction is required to initiate the allosteric switching on binding to 
Cu(I). In the dimeric Cu(I)-bound Mtb-CsoR, the H-bond distance between Nε 
atom of HIS61 and OE1 of Glu81 varied from 1.9 – 2.4 Å and that of OH atom of 
Tyr35 and OE1 of Glu81 was observed to be between 1.7 -2.5 Å. In some 
conformational clusters of Cu(I)-bound Mtb-CsoR, Tyr35 was perceived to act as 
an H-bond bridge between His61 and Glu81 and in other clusters the H-bonding 
triad between Tyr35-His61-Glu81 was observed as shown in Figure 3.12. 
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Figure 3.11. Overlay of X-ray crystal structure (silver) and computed structure of 
Cu(I)-bound Mtb-CsoR (green) 
In the apo form of Mtb-CsoR dimer, the above mentioned H-bonds are not 
detected in the simulations. While, an H-bond interaction (2.6/2.7 Å) involving 
OE1 atom of Glu-122 and the OH atom of Tyr74 and a bridging water molecule 
which further H-bonds (2.7/2.8 Å) with OE1 of Glu122 and Nε atom of His100 
(2.7/2.6 Å) was reported in apo form of Sl-CsoR in its homotetrameric form.107 
Although, these H-bond interactions were not reported in the apo CsoR of Thermus 
thermophilus in its homotetrameric state.106 Instead, in the dimeric apo Mtb-CsoR 
the copper binding amino acid residues were identified to involve in H-bond 
interactions with the amino acid residues present in the N-terminus and in the 
unstructured loop region that connects the α2 and α3 helices. Key H-bond 
interactions observed in the dimeric form of Apo-CsoR were between OH atom of 
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Tyr35 to the N-terminus of Glu4 and between the backbone of Cys36 and OE1 of 
Asp72 shown in Figure 3.12. The interaction with the N-terminus could be an 
artifact of the computational model, due to the lack of first three amino acids that 
constitute the N-terminal of apo CsoR. 
The apo and Cu(I) bound form of Mtb-CsoR obtained from the MD 
simulation were evaluated for the presence of structural changes by implementing 
global alignment of secondary structure of two form and is shown in Figure 3.13. 
The secondary structure alignment of the two structures demonstrates that there 
is significant structural change in the apo form that manifests in α3 and α3’ helices 
and these helices tend to move towards the α2 and α2’ helices. The unstructured 
loop connecting the α2 and α3 helices in the dimeric apo form was perceived to 
interact with copper binding amino acids through the H-bond interactions 
described previously and therefore closing the metal binding site shown in Figure 
3.12. 
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Figure 3.12. (a) Hydrogen bonding network stabilizing the two protomers in Cu(I)-
bound Mtb-CsoR dimer (b) Hydrogen bonding network stabilizing the two 
protomers in apo Mtb-CsoR 
These results predict an overall change in the alignment of the α-helices in 
apo CsoR on binding to Cu(I). Though the simulations of dimeric form of Mtb-
CsoR resulted in key findings which are in agreement with the experiments,104 this 
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model presents certain drawbacks such as the higher flexibility in the truncated α3 
helix (missing C-terminal tail). In the dimer of dimer architecture of Mtb-CsoR, 
this flexibility will be attenuated by the presence of adjacent dimer that restricts 
the motion of α3 helix. Henceforth, particular emphasis was placed on dimer of 
dimers structure of Mtb-CsoR in computational studies which will enable us to 
understand the allostery in CsoR proteins of other bacteria that do not possess the 
C-terminal tail. The computed dimeric forms of apo and Cu(I)-bound Mtb-CsoR 
were also used to develop the homotetrameric structures, using the Sl-CsoR 
tetramer as a template.  
 
Figure 3.13. Overlay of computed structure of Cu(I)-bound (green) and Apo (red) 
Mtb-CsoR. 
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ANALYSIS OF CU(I) AND APO CsoR TETRAMER 
Hydrogen Bonding Network 
 The H-bond interactions reported and analyzed in the earlier sections are 
examined in the simulations of tetrameric form of both apo and Cu(I)-bound Mtb-
CsoR. Plots of H-bond interactions between Tyr35, His61 and Glu81 of the adjacent 
protomer for all the four Cu(I) binding sites were generated for both the apo and 
Cu(I)-bound Mtb-CsoR shown in Figure 3.14. At each copper binding site, three 
H-bonds are possible with a maximum of twelve H-bonds for each tetrameric 
CsoR. In the plots shown in Figure 3.14(b) a maximum of five H-bonds are present 
in the tetramer between OH atom of Tyr35 and OE1 or OE2 of Glu81, suggesting 
that this H-bond interaction is present in all the metal binding sites with an 
exception of five H-bonds when Tyr35 is in H-bonding distance from both OE1 
and OE2 atoms of Glu81. From these plots, it can be established that at least two 
metal binding sites are involved H-bond interactions during the first 0-8 ns time 
frame. Loss of this H-bond interaction was observed after 8 ns and reestablished 
around 9.5 ns. In the subsequent plot, mapping the H-bond interaction between 
Tyr35 – His36 – Glu81 a maximum of six H-bond interactions were observed 
suggesting the prediction that, these interactions can be disrupted by solvent 
water and not all the metal binding sites possess these H-bonds concurrently 
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throughout the 10 ns simulation. Surprisingly, none of these H-bond interactions 
were observed in the apo form of Mtb-CsoR. Instead, new H-bond interactions 
were identified involving OH atom of Tyr35 and Nε-H atom of His61. These 
results substantiate that the conformational switch on binding to copper is 
initiated by this hydrogen bonding network which may be very crucial in 
propagating allostery. As stated in the discussion of Mtb-CsoR dimer, in apo form 
of Sl-CsoR an interaction between Tyr74 (Tyr35 in Mtb-CsoR) and Glu122 (Glu81 
in Mtb-CsoR) with a bridging water molecule was reported.107 In our simulations, 
we did not identify any such bridging water molecule between His61 and Glu 81, 
in both the dimeric and tetrameric forms of Mtb-CsoR. But in the simulations of 
apo form of Sl-CsoR the above described interaction (Figure 3.16) was observed in 
accordance with the experiments. Analysis of H-bond interactions in apo Mtb-
CsoR reveals alternative interactions that are established between the Nε-H atom 
of His61 and OE1 atom of Asp72, backbone C=O of His74 and Gly73 of adjacent 
protomers shown in Figure 3.15(b). The loop regions connecting the α2 and α3 
helices constitutes of Asp72, Gly73, His74 and Gly73 is conserved in the CsoR 
proteins of bacteria.104,111 Additional interactions were observed between OH atom 
of Tyr35 and OE1 of Asp38 and Asp32. Asp 38 is also conserved in the CsoR 
proteins of bacteria, suggesting a key role of these H-bonds in stabilizing the apo 
CsoR conformation and in the transmission of allosteric transitions. 
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Secondary Structure Analysis and Radius of Gyration (Rg) 
 NMR studies conducted on G. thermodenitrificans CsoR in both the apo and 
Cu(I)-bound states revealed that Cu(I) binding results in an discontinuity or kink 
formations in the long α2-helix located between the Cu(I) binding residues His75 
and Cys79.108 Crystal structures of apo CsoR proteins have more recently been 
solved from S. lividans107 and T. thermophilus.106 These structures reveal a similar 
architecture, with the S. lividans structure characterized by a continuous α2 helix 
in the apo form, just as in apo G. thermodenitrificans CsoR in solution.108 
 
Figure 3.14. (a) Number of hydrogen bonds formed between Ty35-Glu81 in Cu(I) 
Mtb-CsoR (b) Number of hydrogen bonds formed between Ty35-Glu81-His61 
during the simulation of Cu(I) Mtb-CsoR 
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Figure 3.15. The hydrogen bonding network reproduced in the average structures 
of the most populated clusters (a) Cu(I)-bound Mtb-CsoR (b) Apo Mtb-CsoR 
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Figure 3.16. Hydrogen bonding network and bridging water molecule stabilizing 
the two protomers in apo Sl-CsoR tetramer 
 To identify the nature of change or disorder in the structure of Mtb-CsoR 
on binding to Cu(I), secondary structure maps were generated from the 
simulations of the apo and Cu(I)-bound Mtb-CsoR. Interestingly, as seen in Figure 
3.17 the α-helical character in the Cu(I) bound Mtb-CsoR was lost and a turn or 
bend-like structure is initiated at His59 and Asn60. This region accommodates 
His61 and Cys65 residues which are involved in copper coordination. These 
results quantify that the α2 helix around the copper coordinating residues starts 
to unfold and transform into a turn. The loss of secondary structure develops into 
a kink in the α2-helix, and the α2-helix bends towards the Cu(I) binding site to 
accommodate the trigonal planar coordination of Cu(I). The secondary structure 
map is projected on to the CsoR structure to show the formation of a kink and loss 
of α-helical character in Figure 3.18. 
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Figure 3.17. Secondary structure map of Apo Mtb-CsoR (top) and Cu(I) Mtb-CsoR 
(bottom) tetramer (constituting of 340 residues each).Turn initiation in Cu(I)-
bound Mtb-CsoR at residue His59 
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Figure 3.18. Secondary structure of the Cu(I)-bound CsoR projected on to Mtb-
CsoR tetramer. The loss of α-helical character is shown in red circles 
This discontinuity in helical geometry of Cu(I)-bound Gt-CsoR was shown 
to be present in solution and was proposed to be contribute to the allosteric 
switching mechanism in Gt-CsoR.108 Although the presence of the kink in the α2 
helix was not reported in Mtb-CsoR in earlier studies,104 this discontinuity in α2 
helical geometry was also recently reported for Cu(I)-bound Mtb-CsoR.108 A 
prominent aspect of structural transition in Gt-CsoR was described to be an 
interruption in the α2 helix in Gt-CsoR; which in turn was proposed to drive a 
global compaction of the tetrameric form. SAXS experiments revealed that CsoR 
is hydrodynamically smaller in the Cu(I)-bound state with radius of gyration Rg 
of 26.9 Å for apo CsoR and 25.1 Å for Cu(I)-bound CsoR of Geobacillus.108 The 
calculated Rg values for apo and Cu(I)-bound Mtb-CsoR are 21.9 Å and 21.7 Å 
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respectively. Though the Rg value for apo CsoR is slightly higher than Cu(I)-
bound Mtb-CsoR, these results were not very conclusive, due to the high flexibility 
of the unstructured loop connecting the α2 and α3 helices that might indeed affect 
calculation of Rg value.  
Principal Component Analysis 
The internal motions in a protein may reveal the transmission of a 
conformational adjustment to affect the binding or reactivity at an active site, as in 
allosteric effects. Such functional internal motions may involve complex 
correlations between atomic motions, and the nature of the motion is inherent in 
the protein structure. We investigated the correlations between atomic positional 
fluctuations in both apo and Cu(I)-bound CsoR protein, as derived from 
(nanosecond) MD simulations in aqueous environment. Applying the essential 
dynamics method, the covariance matrix was calculated and diagonalized for all 
atoms and backbone atoms of the protein to obtain the eigenvectors of the protein 
from these simulations. The RMSF values for the backbone atoms of each amino 
acid residue obtained from the significant eigenvectors of the protein are plotted 
in Figure 3.19. Perturbations were more pronounced near the Cu(I)-binding pocket 
and at the more peripheral loop regions from Ala69 to His74 (Ala66 to His71 in 
Figure 3.19) of the tetramer with relatively smaller changes in the α-helices 
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compared to the apo Mtb-CsoR. Large perturbations occur in the C-terminal α3-
helix from Gly73 through the C-terminus in the apo form. The largest perturbation 
is observed in Asp72, which is perceived to originate from the formation of H-
bond interaction between the OE1 or OE2 atom of Asp72 and the Nε-H atom of 
His61. The other large fluctuations are localized to the amino acids from Ser29 to 
Tyr35 (Ser26 to Tyr32 in Figure 3.20) near Cu(I) binding region. The apo-CsoR 
tetramer is observed to possess greater fluctuations and is globally more dynamic 
across the structured α-helical regions (red line in Figure 3.19). In contrast, Cu(I)-
bound Mtb-CsoR is less globally dynamic, with perturbations observed in residues 
present in the α3 helix through the C-terminus. To further investigate the dynamic 
regions in both apo and Cu(I)-bound Mtb-CsoR, B-factors were calculated from 
the MD simulation data. The B-factors are a measure of fluctuations and quantify 
the degree of flexibility in a protein molecule. The calculated B-factor values were 
projected on to the CsoR structure in apo and Cu(I)-bound states shown in Figure 
3.20. The fluctuations are color coded from red to blue, red depicting high fluxional 
regions and blue depicting the least fluxional regions. Apart from the unstructured 
loop regions which exhibit large fluctuations, Tyr35 was revealed to be highly 
fluxional in apo Mtb-CsoR. The arginine residues are shown to be perturbed to a 
larger extent compared to other amino acid residues in the structured α-helical 
regions of apo Mtb-CsoR. Arg10, Arg15 and Arg52 were identified to be the most 
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fluctuating arginines in the apo form, suggesting a rearrangement of arginine 
residues in the apo form to initiate DNA binding on loosing Cu(I) ions.108 The 
structured α (1, 2 and 3) helices were observed to be rigid (blue in color) in Cu(I)-
bound Mtb-CsoR as opposed to apo CsoR where certain regions of α2 and α3 
helices are shown to possess higher flexibility. Essential dynamics and B-factor 
studies on CsoR reveal that the α-helices of the apo Mtb-CsoR tend to have higher 
flexibility (higher fluctuation) compared to those of Cu(I)-bound Mtb-CsoR, 
indicating that on binding to Cu(I) the α-helices assume a ‘rigid or taut’ structure 
that may affect the affinity to bind DNA promoter region.112 
 
Figure 3.19. RMSF plot of protein backbone derived from the first eigenvector 
from covariance analysis 
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Figure 3.20. Structures of Cu-bound CsoR (top) and Apo-CsoR (bottom) with B-
factors projected on to the structures, least fluctuating (blue) - most fluctuating 
(red) 
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Mechanism of Allosteric Conformational Switch in Mtb-CsoR 
An hypothesis for the mechanism of allosteric Cu(I) regulation in the CsoR 
family has been put forward based on the crystal structure of Cu(I)-bound Mtb-
CsoR104 and was tested experimentally using unnatural amino acid substitutions 
of the Cu(I) coordinating His61 residue.117 The unnatural amino acids substitutions 
were designed to eliminate the H-bond interactions between the Nϵ atom of the 
imidazole ring and the second coordination sphere amino acids Glu81 and 
Tyr35.117 Cu(I) binding to the non-native His61-substituted Mtb-CsoR did not 
significantly affect the Cu(I) binding affinity, but the allosteric coupling free 
energy (ΔGc) was determined to be close to zero.117 This observation lead to the 
proposal that allosteric switching in Mtb-CsoR is initiated upon coordination of 
Cu(I) to the Nδ atom of the His61 ligand, triggering the formation of a H-bond 
network through Nϵ atom that results in dissociation of CsoR from the operator 
region of DNA. 
In our computational models, we were able to reproduce the second 
coordination sphere H-bonding network initiated upon binding to Cu(I). These 
interactions were not detected in the simulations of apo Mtb-CsoR. Similarly, the 
H-bond interactions were not depicted in the apo form of Tt-CsoR as opposed to 
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apo SL-CsoR, in which these second coordination sphere H-bonds were described 
both experimentally and computationally. 
 
Figure 3.21. The vectors representing the direction of motion in (a) apo Mtb-CsoR 
(b) Cu(I)-bound Mtb-CsoR and (c) structural alignment showing different 
conformation of apo(red) and Cu(I)-bound(green) Mtb-CsoR 
Comparison of H-bonding interactions, conformations and fast time scale 
internal dynamic (ps –ns) motions of Cu(I)-bound and apo CsoR was performed 
to demonstrate the allosteric switching in Mtb-CsoR. A global alignment of both 
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Cu(I) and apo forms of Mtb-CsoR in dimeric form (Figure 3.21(c)) reveals that the 
two protomers in the apo CsoR reorient to attain a ‘X-like’ conformation due to the 
absence of an anchor (which is Cu(I)) that holds the protomers in a ‘taut’ 
conformation.112 The loop connecting the α2 and α3 helix interacts with Cu(I) 
coordinating amino acids and closes into the metal binding region in the apo form. 
A RMS value of ~4.42 Å was obtained for the alignment of dimeric form and ~6.20 
Å for tetrameric form of Mtb-CsoR. In the tetrameric architecture, similar 
conformation changes were observed that are consistent with the DNA binding 
studies performed on Sl-CsoR and Gt-CsoR. The vectors of functional models 
derived from the essential dynamics analysis were projected on the most 
populated structure of Cu(I)-bound and apo Mtb-CsoR in tetrameric state in 
Figure 3.21. Comparison of these two structures unveils that the α-helices of apo 
form are highly flexible and this can also be noted from the length of the vectors 
that were scaled based on the degree of displacement from the average structure. 
The direction of the vectors suggest that the, N-terminal region and the loop 
connecting α2 and α3 helices, closes into the Cu(I) binding region in located in the 
periphery of α1, α2 and α3 helices in the apo form. This flexing of the loop in the 
apo form, drags the α3 helix that may translate into the reorganization of the 
dimer-dimer interface. 
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Figure 3.22. The vectors representing the overall motion of helices in Mtb-CsoR on 
loosing Cu(I) ions 
In contrary, the Cu(I)-bound Mtb-CsoR reveals relatively smaller 
displacements in the α-helical structure and the displacement of the loop between 
the α2 and α3 helix was observed to be directed away from the copper binding 
site. The above identified ‘hinge like’ motion directed away from the copper 
binding site indicates the formation of the ‘kink’ in the α2 helix between His59 and 
Asn60 which is due to the enforcement of trigonal coordination geometry to bind 
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Cu(I). Hence, on binding to Cu(I) the Mtb-CsoR attains an open and rigid 
conformation that retains little affinity for DNA binding. This inflexibility of Cu(I)-
bound CsoR may result from the H-bond interactions of Tyr35-His61-Glu81 that 
constrain the movement of the α1 helix of one protomer relative to the α2 and α3 
helices of the adjacent protomer in addition to the inflexibility acquired on binding 
to Cu(I). In the apo form, these inter and intra protomers H-bonds are not present, 
which leads to the increase in the degree of fluctuation and in turn effecting the 
flexibility of apo Mtb-CsoR. A similar model was put forward for the DNA 
promoter binding of apo Sl-CsoR.112 The displacement vectors shown in Figure 
3.22, represents the overall conformational transition of CsoR from the Cu(I) 
bound form to Apo form in Mtb-CsoR. The electrostatic potential maps of the 
Cu(I)-bound Mtb-CsoR shown in Figure 3.23, reveal that the positive potential is 
sparse and is distributed, while in the apo form continuous regions of positive 
potential are concentrated along each face of the tetramer exposing the arginine 
residues (R15 and R52 in Mtb-CsoR)104,111 to initiate DNA binding. 
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Figure 3.23. The electrostatic potential maps of (a) Cu(I)-bound Mtb-CsoR and (b) 
apo Mtb-CsoR 
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CONCLUSIONS 
MD simulations along with essential dynamics analysis enabled us to 
describe the inherent global features of Cu(I)-mediated conformational switch in 
the tetrameric assembly of Mtb-CsoR. In this work, all-atom simulations in explicit 
solvent of the allosteric forms of the paradigm Cu(I) sensing protein of CsoR 
family in Mtb were presented to understand the role of quaternary structural 
change in allosteric communication. In addition, Cu(I) coordination geometry of 
CsoR was also predicted and elaborately explained by considering the effect of 
protonation state of cysteine ligands in allostery. The Cu(I) coordination geometry 
was calculated as a [2+1] binding mode, with the deprotonated cysteines as strong 
ligands and histidine coordination is considered to be very weak. The strength of 
Cu(I)—His61 bonding interaction was anticipated to play a key role in driving 
allosteric conformational switch rather than copper binding affinity of CsoR. Our 
simulations provide some key insights into the mechanism of allosteric regulation 
in Mtb-CsoR and are in close agreement with the extensive experimental findings 
for this system. We find that large quaternary structural conformational 
transitions of CsoR play an essential role in the ability of CsoR to function as an 
allosterically regulated transcriptional repressor. Our simulations of allosteric 
switching in Mtb-CsoR successfully capture this structural transition between 
closed to open conformations upon Cu(I) binding to CsoR. We were able to 
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provide insights on the disordered nature of α helices in the apo Mtb-CsoR that 
transform into more ordered and rigid structures in response to metal ion binding. 
We examined the mobility of residues in the two allosteric forms of the protein 
and observed an increase in the rigidity of the metal binding region and the α-
helices in the Cu(I) bound allosteric form. Our simulations support the existence 
of a functionally important hydrogen-bonding pathway that connects the first 
coordination shell of the Cu(I) complex to the structural change involved in 
allosteric regulation. This pathway was stable only in Cu(I)-bound Mtb-CsoR but 
was destabilized or absent in the apo form. Our data suggest the possibility that 
the allosteric transition occurs by attaining a “rigid” structure when bound to 
Cu(I) and ultimately prevents it from adopting a more flexible high DNA binding 
affinity conformation. 
                 In summary, our simulations provide new perspectives into allosteric 
switching in a metal sensor proteins. These studies take on added significance 
when the crystal structures of both the apo- and Cu(I) bound CsoR protein are 
difficult to crystalize and prevent atomic/molecular level comparison to 
understand the allosteric communication on binding to an effector (Cu(I)). Further 
studies have to be conducted, in order to illustrate the mechanism of allosteric 
regulation with DNA bound to the apo-CsoR. 
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VIRUS-LIKE PARTICLES (VLPS) 
Virus-like particles (VLPs) are assemblies of multiple proteins that mimic 
the organizational features of viruses including repetitive surface particulate 
structures such that they may elicit a pathogen-associated molecular pattern 
recognition response by the innate immune system.1-7 Because they are devoid of 
genetic material VLPs provide a safer and more cost effective alternative to 
traditional vaccine development methods and several high priority viruses1 have 
been targeted, namely the human papillomavirus (HPV)8-10 (Gardasil11,12 and 
Cervarix13,14), Chikungungya,15,16 and hepatitis E17,18 viruses. Despite these 
promising developments, the impact of VLPs on vaccine design at large remains 
limited, in part because many technical and fundamental challenges are currently 
unsolved.1,7,19-25 For example, Gardasil is a very successful VLP-based vaccine that 
comprises of a mixture of VLPs derived from the L1 major capsid proteins of four 
different HPV types, namely 6, 11, 16 and 18. Gardasil induces specific antibody 
responses against these HPV types.26-29 However, with more than 40 oncogenic 
HPV types identified to date,30,31 it is clear that the capabilities of current vaccine 
design technology must be expanded to enable a broader spectrum of protection.  
Traditional vaccine design approaches rely on cost-intensive, repetitive 
laboratory procedures and testing protocols. As a result, vaccine development is a 
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time-consuming and costly undertaking. One possible way of streamlining the 
discovery process is to utilize computer-aided design strategies to narrow the 
search and better understand the properties of various VLPs. By exploring the 
structural and dynamic features of a VLP in silico, and correlating them to 
experimentally observable efficacy data, the most salient molecular features of the 
VLP that may give rise to the immunogenicity can be identified. Exploiting these 
properties will enable a rational design approach that may significantly shorten 
vaccine development time. Due to their enormous size, probing the dynamic 
structure of a VLP under realistic conditions requires computationally intense 
molecular dynamics (MD) simulations. The advent of high-performance 
computing platforms32-34 and sophisticated modeling algorithms,35,36 made these 
daunting simulations within reach.37-39 
Here, we extend the strategy of applying MD simulations for the in silico 
construction and molecular level analysis of candidates for VLP vaccines.36,40 
Specifically, HPV type 16 is examined, as (i) an all-atom X-ray structure with 
known epitope regions is readily available41-43 and (ii) well-defined molecular level 
properties thought to be responsible for the immunogenicity were previously 
identified.44-47 These VLPs can be assembled either from 12 or 72 pentamers of the 
L1 protein arranged in a T=1 or 7 icosahedron structures, respectively.42,43,47 
Whereas Gardasil is based on T=7 L1 icosahedral structure, Cervarix is an 
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alternative HPV vaccine that is based on a T=1 L1 structure. The assemblies are 
stabilized by strong hydrophobic interactions.41,43 The C-terminus of the L1 protein 
consists of four helical regions h2, h3, h4 and h5 that are responsible for intra- and 
inter-molecular stabilization, as illustrated in Figure Error! No text of specified style in 
document..2a. The domains h2, h3 and h5 are responsible for L1 maintaining the 
structural integrity of the pentamer and h4 preserves the inter-pentamer 
connectivity, thereby determining the overall structure. The VLP surface has 
outwardly projecting protein loops containing epitopes that interact with the 
immune system to elicit production of type-specific antibodies.48 Antibodies 
binding to the epitopes often render the associated virus/VLP inactive and 
neutralized. Neutralization assays of HPV-16 VLPs with human sera were used to 
identify five epitope bearing loop regions denoted BC (residue 49 to 70), DE (110 
to 154), EF (170 to 189), FG (262 to 291) and HI (347 to 360).41,43,49 These loops are 
thought to be more flexible than the rest of the L1 monomer and show notable 
conformational differences across HPV types.48 Epitope deletion strongly affects 
the antibody-binding capacity of the VLPs,44 and reduces their immunogenicity by 
a factor of at least 10-20 compared to wild-type VLPs.50 There are several 
characteristics of VLP epitopes that may influence specific immune response; these 
properties include peptide sequence, loop conformation, and 
proximity/orientation relative to neighboring loops.41,43 
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The exact molecular-scale relationship between epitope structure and 
immune response is difficult to establish. For example, if individual epitope 
characteristics such as shape or sequence were the only factors relevant for 
immunogenicity, an L1 protein monomer or L1 pentamer could serve as a vaccine. 
However, the monomer is essentially not at all immunogenic and the pentamer is 
only weakly so,51 in contrast to the highly immunogenic whole VLP. This 
difference in immunogenicity cannot be explained by the assumption that a VLP 
contains more epitopes than a pentamer or a monomer; as the increase in the 
monomer/pentamer dosage (and hence the number of epitopes) does not imply 
any associated increase in the HPV immunogenicity.51 The epitope geometry 
among these structures is also very similar.49 Furthermore, weakly organized VLP 
assemblies are found to be less immunogenic than more tightly packed ones.52 One 
explanation of these observations comes from the fluctuation-immunogenicity 
hypothesis: To illicit proper immune response epitope fluctuations must be 
minimized,40 such that the epitope structures are better defined and rigid over time 
- in tightly packed VLPs the epitope fluctuations are less pronounced than those 
in smaller systems. In other words, simply presenting an epitope to the immune 
system is not enough, as the structural fluctuations may render them 
unrecognizable. This hypothesis emphasizes the importance of understanding the 
dynamics of epitope structure and suggests that the immune response to the 
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smaller, simpler assemblies could be improved if the structural fluctuations can be 
reduced. Allosteric effects are widely recognized as central to controlling structure 
and dynamics of high-order protein assemblies,53-68 and the tightly packed VLP 
constitutes a highly illustrative example of such long-range control. In particular, 
we found that epitope structure and function are strongly affected by allosteric 
interactions with the h4 helix of the L1 protein. We envisioned that this key 
interaction may be reproduced by tethering the L1 protein to a silica surface, thus 
mimicking the structure and conformational dynamics of the epitopes in the much 
more complex VLP assembly using a bioinorganic hybrid construct consisting of 
a silica nanoparticle and a much smaller piece of the virus. In this design the L1 
protein is tethered to silica surfaces covalently. We examined how the epitope 
structure and dynamics are modulated by changing the curvature of the silica 
particle model and surface protein concentration. Interestingly, we found that the 
proposed bioinorganic mimics have epitope properties of the wild type VLP but 
do so in a way that (i) does not require construction of large T-numbered 
assemblies, (ii) facilitates easy synthesis, (iii) are genome-free and more stable than 
a pure macromolecular assembly. A similar construct was previously considered 
experimentally in the context of designing a vaccine against Porcine Circovirus 
Type 2,69 and is already in trials.70 Here, we extend such ideas to HPV 16 VLP 
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vaccines and quantitatively assess the role of the silica nanoparticle on the 
structure and importantly, the dynamics of the epitopes attached to it. 
HYBRID DESIGN PRINCIPLES 
The proposed hybrid designs involve L1 protein or pentamers attached to 
a silica surface using covalent –(CH2)3-NH2- tethers. Using silica in the hybrid 
design has the following advantages. First, surface properties are sufficiently 
adjustable to hold small molecules or larger nanostructures.71 Consequently, silica-
based nanoparticles are very useful in bioanalysis once conjugated with biological 
entities for analyte recognition and/or signal generation. Second, silica 
nanomaterials are effectively “transparent”. They are unlikely to absorb light in 
the near-infrared, visible and ultraviolet regions or to interfere with magnetic 
fields, which allows the functional groups inside silica matrix to keep their original 
optical and magnetic properties; this facilitates use of lighter magnetic fields 
during medical procedures.72-74 Third, silica matrices are highly nontoxic and 
biocompatible. Furthermore, well-established silica surface-chemistry facilitates 
the modification of silica-based nanohybrids.75 Finally, to enable computer-aided 
design, dependable all-atom force fields are available for silica- water, ion and 
biomolecule simulations.76,77 Also, silica surface has a negative potential, and 
therefore electrostatically binds to the inner surface of an L1 protein or pentamer. 
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In a virus, the protein capsid encloses negatively charged DNA or RNA. The latter 
electrostatically stabilize the assembly through interactions with the inner capsid 
surface. As used in applications such as nanotemplating71,78 and in delivery 
agents,79 within hybrid material design, the negatively surface charged silica plays 
the stabilizing role of the viral genome. However, like most other nanomaterials, 
including gold or magnetic nanoparticles, and quantum dots, silica particles are 
difficult to directly and uniformly suspend in aqueous solutions of different 
salinity. One option to overcome these limitations is to coat these materials with a 
more stable and physically adaptive material.75,78 This way, stoichiometrically 
defined nanoparticles with correctly oriented immobilized biological elements are 
obtained.71 For the present simulation, the silica surface is functionalized with 
aliphatic-amino tethers.  
METHODS AND MATERIALS 
MODEL PREPARATION  
The models presented in this work include L1 monomer, pentamer and T=1 
VLP in various arrangements and on different silica surface geometries connected 
via covalent tethers. All-atom, explicit solvent MD simulations were performed 
using NAMD80,81 2.7 for 10 ns on each of these assemblies. Atomic coordinates of 
the L1 monomer are obtained from the crystal structure (PDB code: 1DZL42). To 
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validate the allosteric effect of the h4 helix (residue 414 to 434), test simulations 
were performed on h4 helices that were truncated and artificially rigidified. The 
T=1 VLP is constructed from 60 copies of the monomer using icosahedral 
symmetry transformations (from VIPERDB).82 The pentamer is extracted from this 
VLP to maintain structural continuity with the latter. All systems considered are 
immersed in a box of TIP3P waters,83 extending at least 20 Å from the surface of 
the protein models. A 0.3M NaCl buffer solution was introduced to mimic the 
conditions under which the experiments we conducted, using the VMD84 auto 
ionize feature. The resulting solvated system sizes range from ~105 to ~106 
atoms. The 20 nm x 20 nm silica surface is generated by creating the appropriate 
images of the central unit cell using the IMAGE facility in CHARMM.85,86 The silica 
model has a thickness of 5 nm incorporating 2 core layers of tetrahedral silicate 
moieties, and surface layers including hydrophilic (Si–OH) and hydrophobic (Si–
H) groups on opposite ends. Curvature is introduced in the silica surface via 
steered MD simulations. The silica surface is functionalized with aliphatic-amino 
tethers that can covalently hold the L1 protein to the silica surface, and have simple 
electronic properties. CHARMM2787 force fields are used for protein simulations. 
For simulating the silica surface, force fields developed by MacKerell were used.76 
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FORCE FIELD DEVELOPMENT 
A systematic procedure as demonstrated in recent paper76 was followed to 
develop force fields for the organic tether attached to silica surface. For simulating 
the silica surface, force fields parameters developed by MacKerell’s group were 
used. The parameters of the silicon atom attached to the tether have been modified 
during the optimization of tether parameters. A small model of the tether attached 
to silica, represented in Figure Error! No text of specified style in document..1b was used 
to parameterize the force fields. Initially the structure of the tether is optimized 
using density functional calculations88 at the B3LYP89,90 level. Optimized structure 
of the tether is then used for force field parameterization with CHARMM2787 force 
fields. Available CHARMM27 parameters91,92 for similar organic compounds and 
silica were introduced as the guess parameters for the first optimization step. The 
structure was then calculated with the new MM force fields for validating the 
guess parameters. Charges on the atoms were derived from Merz-Kollman ESP 
charges93 obtained from QM calculations with Gaussian 0394 package. After several 
cycles of optimizing the parameters, reproducibility of target QM bond lengths, 
bond angles and vibrational spectra have been tested. Figure Error! No text of 
specified style in document..1c shows the comparison of structures obtained from QM 
and MM calculations, and Figure Error! No text of specified style in document..1a shows 
the correlation between normal modes for simulations with QM and MM 
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methods. In Table Error! No text of specified style in document..1 bond lengths and 
angles are compared between the QM and MM methods. The new force field 
parameters are tabulated in Table Error! No text of specified style in document..1. 
 
Figure Error! No text of specified style in document..1. (a) Correlation of 
vibrational frequencies obtained from QM and MM normal mode calculations. (b) 
QM Model of the tether bound to silica. (c) Comparison of QM structure (Red) of 
tether to that of MM optimized structure (Green) with the new force fields. 
  
 
 
 
 
(a) 
(b) (c) 
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Table Error! No text of specified style in document..1. Comparison of bond lengths 
(Ǻ) and bond angles (˚) of QM and MM optimized structure using the newly 
developed MM force fields. 
Bond Length MM QM 
Si1-O2 1.67 1.67 
O2-C1 1.43 1.43 
C1-C2 1.51 1.52 
C2-C3 1.51 1.53 
C3-N1 1.44 1.45 
N1-C4 1.37 1.37 
C4-C5 1.50 1.51 
Bond Angle MM QM 
Si1-O2-C1 119.4 121.7 
O2-C1-C2 111.0 111.8 
C1-C2-C3 108.7 111.8 
C2-C3-N1 111.3 112.8 
C3-N1-C4 119.9 120.4 
N1-C4-C5 114.5 115.5 
MOLECULAR DYNAMICS SIMULATION DETAILS AND ASSOCIATED ANALYSIS1  
All MD simulations were run on PowerPC 970MP processors of the 
BigRed supercomputer at Indiana University. To distinguish the behavior of 
the simulated constructs in terms of loop structures and their fluctuations, 
following molecular scale measures were considered. Here, we focus on the 
                                                          
1 The MD simulation and analysis were performed in collaboration with Prof. Ortoleva’s 
group, those include Dr. Abhishek Singharoy and Dr. Harshad Joshi and is part of 
published paper “Epitope Fluctuations in the Human Papillomavirus Are Under 
Dynamic Allosteric Control: A Computational Evaluation of a New Vaccine Design 
Strategy” Singharoy, A.; Polavarapu, A.; Joshi, H.; Baik, M.-H.; Ortoleva, P., J. Am. Chem. 
Soc. 2013, 135, 18458-18468. 
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analysis of the FG loop (Residue 262-291) as it is found to be most relevant for 
eliciting immune response; for certain comparison the EF and HI loops are also 
considered.49 Similar results hold for the other epitopes.  
Dihedral distribution for loops: The distribution of backbone loop dihedral angles 
is a good indicator for the conformational space explored by the epitope 
containing loops and provides a measure of the flexibility of the loop. In each 
case, 10,000 time points were extracted from MD simulations to construct the 
probability distribution of loop conformations. Since distribution from a 
randomly selected half of the ensemble is found to accurately reproduce the other 
half, analyzed structures are representative of the phenomenon of interest. 
Power spectra: The power spectrum provides the distribution of atomic 
vibration intensity across a range of frequencies. Lower frequencies represent 
slower motions, while high frequencies represent faster modes. These 
measures were used to discriminate between the energies of different frequency 
motions of a given loop type as manifested in an assembly of a given size (i.e., 
from L1 monomer to T=1 VLP). Simulations were designed to assess potential 
differences in behavior of loops between the L1 protein assemblies and 
quantify them to serve as a basis of our computer-aided vaccine discovery 
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strategy. This study focused on loops known to contain critical epitopes, 
some of which are neutralizing. 
Positional variance: The overall fluctuations of a particular loop from its average 
configuration were compared. Loop fluctuation is not easily quantified in X-ray or 
cryo-EM data. While a structure provides the most likely or average configuration, 
its fluctuation measures the importance of other configurations away from the 
average, but which may be functionally relevant within the framework of our 
immunogenicity hypothesis. Information about the dynamics obtained from MD 
provides advantages over the inherently averaged experimental data. Positional 
variance of the loop atoms was quantified as another measure of epitope 
fluctuation. Positional variance was computed by summing over the deviation of 
individual backbone atom position and dividing by the number of backbone 
atoms in the loop. This measure is slightly different from the usual root mean 
square fluctuation (RMSF). RMSF measures fluctuation from a fixed reference 
structure by aligning two structures, thus eliminating translational and rotational 
motions. In contrast, average loop positional variance calculated here contains 
contributions from overall displacements of the loops and their motions relative 
to the rotation/translation and internal motions of the assembly. The overall 
motions potentially affect epitope location and orientation within loops; according 
to our hypothesis, these overall fluctuations also affect immunogenicity and 
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binding properties of the monomer or larger assemblies. Thus, including the effect 
of overall and internal assembly motions on loop fluctuations provides a more 
complete measure of their potential relevance to immunogenicity.  
Energy Analysis, Contact maps and Hydrogen Bonds: We also performed 
energy, contact map and hydrogen bond analyses. They were carried out on each 
trajectory using standard tools available in VMD.84 In particular, energies were 
computed using the NAMD Energy plugin. Contact between two residues is 
considered if they were within a cutoff of 10 Å and neglected if the inter-residue 
distance exceeds the cutoff. Finally, hydrogen bonds were defined solely on the 
basis of geometric parameters (bond angle: 20°; bond length: 3.8Å) between 
donors and acceptors. Analysis of interplay between these properties for each of 
the simulated constructs yielded insights into interactions between the pentamer, 
tether and silica surface.  
Correlation analysis: The pairwise correlations measuring the standard inter-
residue three dimensional orientational coupling were computed using the 
covariance between positions of the ith C  atom at time t with respect to its initial 
value along the computed trajectory. A time averaged covariance matrix was built 
as:  
 〈Cij〉 =  
1
T
∫ ∆rî
T
1
(t) ∙ ∆rĵ(t)dt 4.1 
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where ∆rî is the unit vector of the displacement of the the ith C t, and 
T is the length of time over which we calculated the covariations. Positive 
correlations indicate correlated motion between the two residues, whereas 
negative values correspond to anti-correlation. Correlations with magnitude lesser 
than 0.5 were considered statistically insignificant and therefore neglected, where 
∆rî is the unit vector of the displacement of the the ith atom at time t, and T is the 
length of time over which we calculated the covariations. Positive correlations 
indicate correlated motion between the two residues, whereas negative values 
correspond to anti-correlation. Correlations with magnitude lesser than 0.5, were 
considered statistically insignificant and therefore neglected. 
RESULTS AND DISCUSSIONS 
DYNAMIC PROPERTIES AND STRUCTURAL FLUCTUATION 
Figure Error! No text of specified style in document..2a shows a space filling 
model and a cartoon representation of the HPV-L1 protein monomer. The epitope 
bearing loop regions denoted BC (residue 49 to 70), DE (110 to 154), EF (170 to 189), 
FG (262 to 291) and HI (347 to 360)41,43,49 are marked in red, yellow, green, blue and 
cyan, respectively. Five monomers assemble into a HPV-L1 pentamer, as 
illustrated in Figure Error! No text of specified style in document..2b and twelve 
pentamers can finally be arranged in a T=1 icosahedral structure to afford the VLP, 
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shown in Figure Error! No text of specified style in document..2c. Of the five loops the 
FG loop is most important for eliciting immune response, followed by the EF and 
HI.49 The BC and DE loops are thought to be less important. Therefore, we 
concentrate on the FG, EF and HI loops95 in this work.49 To examine the structural 
fluctuations and dynamic properties of the epitopes in this series of increasing 
complexity, we calculated the backbone dihedral angle distributions, positional 
variance and power spectra at each stages of assembly. Not surprisingly, the 
dihedral angles show the narrowest range in the VLP followed by the pentameric 
structure and display the widest range in the monomeric form, which is simply an 
indication of the increasing compactness as we move from the monomer to the 
VLP. Similarly, the positional variance of the loop fluctuations are largest in the 
monomer with amino acid positions showing variances as large as 12 Å2 in EF and 
7 Å2 in FG and HI loops, as shown in Figure Error! No text of specified style in 
document..3a-c. In the pentamer these positional variances decrease significantly 
with the maximum not exceeding 3.5 Å2 in all cases (Figure Error! No text of specified 
style in document..3d-f). Finally, the fluctuations in the amino acid positions become 
negligible in the T=1 VLP, as illustrated in Figure Error! No text of specified style in 
document..3g-i. The high-resolution profiles summarized in Figure Error! No text of 
specified style in document..3 illustrate that the loops are rigidified substantially as the 
monomers are assembled into the pentamer. Although further stiffening occurs 
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when the pentamers are combined to give the final VLP, the change in positional 
variance is much less pronounced, supporting the idea that the full-scale VLP may 
not be necessary to mimic the epitope dynamics sufficiently. As expected, the 
power spectra show a successive decrease in the low-frequency region upon 
forming the pentamer and the VLP. At higher frequency, the power spectra for the 
three constructs are similar because short timescale motions like bond oscillations 
are similar for all three assemblies. These results establish a consistent trend of 
decreasing structural flexibility of the epitopes as the assembly process progresses 
from monomers to the full VLP – the dynamic behavior of an epitope is therefore 
heavily influenced by the neighboring regions of same protein, and the presence 
of other proteins. Interestingly, the mean structure of the epitopes remain 
practically identical in all constructs, as shown in Figure Error! No text of specified 
style in document..3j, where the mean structures of EF, FG and HI loops in the 
monomeric, pentameric and VLP constructs are compared by overlaying them. 
This conclusion is somewhat unexpected, as it is intuitively plausible that the 
organization of the epitope carrying protein into the higher order constructs 
should impact both the structure and dynamics of the protein. The fact that the 
mean structure of the epitope in smaller constructs is identical to that of the whole 
VLP is critically important, however, as this structural fidelity is a necessary, but 
not sufficient, requirement for utilizing smaller virus fragments to elicit the 
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antiviral immune response. This result is particularly interesting within the 
context of the aforementioned experimental observation that the monomeric 
protein and the pentamer are essentially not immunogenic,51 and suggests that this 
failure is due to the dynamic flexibility of the epitope in these constructs. To make 
the simpler constructs immunogenic, we must better understand the origin of the 
structural fluctuations and find means of inhibiting the positional variance in 
them. 
One important factor for decreasing epitope fluctuations is structural 
confinement and inertial effects of the L1 assembly as its size increases.51 A 
monomer has the lowest weight and the epitopes are least confined; therefore, 
associated fluctuations are maximum. In the pentamer and subsequently the VLP, 
both epitope confinement and assembly inertia increase notably, suggesting a 
significant decrease in structural fluctuations. For example, HI from one monomer 
is confined by FG from its counterclockwise neighbor (Figure Error! No text of 
specified style in document..2b). Similarly, FG interacts with loops DE and HI from its 
clockwise neighbor. This structural confinement from inter-epitope interactions is 
particularly effective for loop HI, as shown in the positional variance diagrams 
Figure Error! No text of specified style in document..3g  Figure Error! No text of specified 
style in document..3h  Figure Error! No text of specified style in document..3i. On the 
other hand, loop EF lacks inter-epitope contacts and is more solvent accessible 
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than FG or HI. Thus, it preserves some of its structural fluctuations in the 
pentamer, as illustrated in Figure Error! No text of specified style in document..3a  
Figure Error! No text of specified style in document..3b, and becomes fully confined in 
the VLP (Figure Error! No text of specified style in document..3c). In other words, the 
neighboring proteins inhibit structural fluctuations of the epitope carrying loops 
simply by occupying the space that is needed to execute some of the structural 
fluctuations. Secondly, epitopes are subjected to identical increase in inertia as the 
system size increases, which will dampen structural fluctuations of all epitopes. 
Thus, confinement and increased inertia gives a plausible overall trend, but 
specific inter-epitope interactions are important and must be examined in greater 
detail to understand the non-uniform changes in fluctuations.  
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Figure Error! No text of specified style in document..2. The structures the VLP 
components: (a) the isolated HPV-L1 monomer. The protein is depicted in gray 
with five different epitopes presented in red (BC), yellow (DE), green (EF), blue 
(FG), and cyan (HI). (b) HPV-L1 pentamer (c) HPV particle consisting of 12 
pentamers arranged in T=1 icosahedral structure. 
The tertiary structure of an L1 monomer is composed of β-sheets that carry 
the epitopes and α-helices on either end, as illustrated in Figure Error! No text of 
specified style in document..2a. To better understand how these different components 
interact with each other and modulate the fluctuations, we constructed a 
covariance matrix from a 10 ns trajectory, shown in Figure Error! No text of specified 
style in document..4a. In this diagram, strongly correlated structural distortions can 
be identified by high correlation coefficients that are marked by bright yellow and 
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bright red spots in the diagram. Correlation coefficients smaller than |0.5| can be 
considered statistically independent. 
 
Figure Error! No text of specified style in document..3. Backbone atom positional 
variance for L1 monomer (left), pentamer (middle) and T=1 VLP (center). For each 
loop X-axis denotes the residue number and Y-axis denotes fluctuation in Å2. Like 
the spread of the dihedral distributions, the positional variance decreases as 
assembly size increases. The fourth column shows mean orientation of the 
epitopes suggesting they change minimally between the monomer (blue), 
pentamer (red) and VLP (green). 
Not surprisingly, all epitope carrying loops show significant correlation, as 
they are spatially close and structural distortions of one loop will cause steric 
clashes with another loop. Surprisingly, strong correlations are seen between the 
highly flexible h4 helix and all epitopes with correlation coefficients that are 
consistently larger than |0.6|, marked in green on Figure Error! No text of specified 
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style in document..4a for the three loops of interest in this study. This strong 
communication is unexpected, as h4 is on the opposite side of the protein and the 
distance between the center of the h4 helix and the center of the FG-loop, for 
example, is 55.3 Å. It is not obvious how structural fluctuations in the helix will be 
mediated by the epitope region of the protein over such a long distance. 
Figure Error! No text of specified style in document..4: Covariance matrices from 
10ns trajectory of (a) an isolated L1 protein, (b) an isolated pentamer and (c) T=1 
VLP 
 
Figure Error! No text of specified style in document..5. Positional variance for the 
FG loop the fluctuations of free L1 protein, L1 protein with the h4-helix artificially 
frozen, pentamer and T=1 VLP. 
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To further investigate this unusual coupling, we designed a computational 
experiment by manually changing the force fields associated with the amino acids 
in the h4 helix, as to artificially rigidify the helix and simply freeze the h4 helix 
structurally. If the fluctuations of the h4 helix and those of the epitope loops are 
truly coupled in an allosteric fashion, this artificially induced rigidity on the h4 
helix should be translated to the loops and our simulations should show a reduced 
positional variance for the loops. The positional variance plot for the FG loop is 
given in Figure 4.4 and illustrates that loss of structural fluctuations in the h4 helix 
are indeed reported to the FG-loop. The positional variance of the residues 267-
280 that are part of the FG-loop is greatly reduced from 3-7 Å2 in the original 
protein (black line in Figure 4.4) to 1-3 Å2 (orange line in Figure 4.4) – similar 
observation can also be made for the other loop regions. Thus, allosteric 
interactions between the h4 helix and epitopes play a major role in modulating 
epitope fluctuations. Whereas all epitopes show dynamic allosteric coupling to the 
h4 helix in the monomer, as indicated by the high correlation coefficients shown 
in Figure Error! No text of specified style in document..4,96 the variation of this coupling 
with the assembly into higher order constructs is notably different from each other. 
In the monomer, the differences in fluctuation between epitopes mostly arise from 
intra-molecular confinement. For instance, since FG is more confined than HI its 
fluctuations are dampened: Almost all of the amino acids in the HI-loop can 
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engage in fluctuations giving rise to the positional variances of the backbone atoms 
of these residues to be higher than 4 Å2 consistently, with the maximum variance 
being around 7 Å2 (Figure Error! No text of specified style in document..3g). Amino acids 
in the FG-loop display a distinctively different variance profile. Whereas the 
maximum variance is comparable at ~6 Å2(Figure Error! No text of specified style in 
document..3d), there are many amino acids that show only small positional 
variances affording a profile that covers a range of 0-6 Å2, unlike in the HI loop 
where the range was 3-7 Å2. When multiple L1 proteins are brought together, the 
epitopes arrange on the surface and the h4 helices are either solvent-exposed in 
the pentamer, or they penetrate neighboring pentamers via hydrophobic 
interactions which stabilize the VLP core. In the higher order assemblies, 
additional confinement and strong inter-molecular interactions decrease epitope 
fluctuation compared to the free monomer, simplifying the covariance matrices 
significantly, as shown in Figure Error! No text of specified style in document..4b and 
Figure Error! No text of specified style in document..4c. Most interestingly, the FG and 
EF loops remain correlated to the h4 helix in the pentamer, as highlighted in green 
on Figure Error! No text of specified style in document..3b. The positional variance of the 
amino acids in the pentamer, shown in red in Figure Error! No text of specified style 
in document..4, show a striking similarity to the profile we obtained by simply 
freezing the h4 helix (orange in Figure Error! No text of specified style in document..4). 
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Both the magnitude and shape of the variance profiles are very comparable, 
suggesting that the main reason for diminished fluctuation of the FG-loop in the 
pentamer is the change in chemical environment of the h4 helix, which leads to an 
allosteric stiffening of the epitope containing loops. In the VLP, only the EF loop 
maintains a correlation to the h4 helix (Figure Error! No text of specified style in 
document..4c), but this finding must be interpreted with caution, as the loops in the 
VLP are practically rigid structures showing little to no structural variation. 
Whether or not these small positional variances are correlated to the h4 helix bears 
little chemical meaning. Interestingly, the allostery does not invoke any significant 
changes in the mean structures of the epitopes. Instead, the allosteric connection 
is expressed in variations of structural fluctuations, which in turn impact the 
biochemical behavior of the epitopes. 
This finding is interesting from a general perspective about allosteric 
interactions in proteins. Traditionally,53-55,57,62,97-99 allosteric interactions involve a 
small molecule binding event at one site of a protein that triggers a structural 
change at a different site, which is accompanied by reactivity changes at that site. 
Recently, this classical view of allosteric interactions has been extended and there 
is growing awareness of the fact that the modulation of chemical behavior does 
not have to be related to structural changes necessarily.56,58,59,61-63,100-102 Changes in 
the entropy profile of molecular fragments can be just as powerful in modulating 
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the chemical behavior56,103,104 giving rise to dynamic allosteric effects,105 the most 
prominent manifestation of which is the change in structural fluctuation. Our 
study goes one step further in generalizing the concept of dynamic allostery in that 
we find that the dynamic coupling between two strongly correlated sites is general 
and substrate binding is only one of many possible ways of changing the chemical 
properties of a molecular fragment. In this case, the mean structure of the epitope 
containing loops remains practically invariant across the sequence of L1 constructs 
noted above, but the function and biochemical reactivity of these loops are 
nonetheless altered significantly, as the structural flexibility of the epitopes are 
modified. Our current work constitutes a rare demonstration of a strong dynamic 
allosteric effect across a long distance of 55 Å, where the allosteric signal 
transduction pathway contains standard peptidyl building block – in a previous 
theoretical study,106 long distance dynamic allostery was envisioned to require 
structurally rigid components. Our findings suggest that these long-range 
correlations may be more common than thus far envisioned and that they do not 
require specially constructed, exotic entities to establish the dynamic allostery. 
Rapid and large structural fluctuations of the epitopes are expected to 
reduce the antibody binding affinity,40 and diminish the immune response. 
Depending upon micro-environmental conditions the population of the L1 
assemblies will shift from one form to another; e.g., analytical ultracentrifugation 
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and light scattering analyses show that at a pH of ~6 and salinity >0.5M NaCl a 
T=1 or T=7 VLP structure is stable; at pH 8.2 they dissociate into L1 sub 
assemblies.52 Larger assemblies exhibit lower levels of epitope fluctuation that 
facilitates stronger affinity for antibody binding.40,51 However, some epitope 
fluctuation is required to allow antibody binding due to entropic enhancement of 
the epitope-antibody binding free energy.107 Thus, there is an optimal level of 
epitope fluctuation intensity at which binding is favored, and beyond which the 
entropic barrier to binding becomes significant. Simulations suggest that the 
optimal fluctuation level is at <1Å/residue, which is observed in the VLP 
illustrated in Figures 2c, 2f and 2i. Finally, the allosteric scheme presented here is 
positively co-operative, i.e., the association of the h4 helices within the pentamer 
gives rise to an optimal epitope fluctuation level that, in turn, promotes antibody 
binding and subsequent immune response. A more quantitative and detailed 
study of the energetics involving the allosteric signal transduction pathway and 
epitope-antibody binding is required to decipher the exact mechanism of our 
suggested allostery. This is beyond the scope of the present study, and is partly 
addressed elsewhere.108 In this work, we questioned how the insight discussed 
above can be exploited and we considered a strategy for silica-based hybrid nano-
constructs where HPV substructures are attached to a silica nanoparticle in a way 
that will mimic the epitope properties of an entire T=1 VLP. 
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Figure Error! No text of specified style in document..6. Proof-of-principle models 
of silica-bound L1-proteins where (a) the h4 helix and (b) the β-sheet portions are 
connected to the silica surface. 
HYBRID NANOPARTICLES 
Given the strong allosteric correlation between the epitope containing loops 
and the h4 helix examined above, one potentially effective way of controlling the 
dynamic properties of the loop regions is to modify the chemical environment of 
the h4 helix. To allow fluctuation of L1 epitopes in the sub Å range, which 
corresponds to the fluctuations seen in the T=1 VLP and which we assume to be 
the optimal range of fluctuations for eliciting immune response, we first attached 
the L1 protein to a model silica surface only using the innate electrostatic and 
hydrogen-bond based attraction between the h4 helix and the silica surface. After 
some experimentation, we chose to present the hydrophilic 100-surface of 
crystalline silica, where each terminal surface oxygen of the silicate was 
176 
 
protonated, to the h4 helix of a single L1 protein. The model surface was 20 nm x 
20 nm large and had a thickness of 5 nm incorporating 2 core layers of tetrahedral 
SiO2 moieties. This design is shown in Figure Error! No text of specified style in 
document..6a, where only a small portion of the 400 nm2 silica surface is shown for 
illustration. The surface layers were properly terminated with hydrophilic (Si–
OH) and hydrophobic (Si–H) groups on each side of the silica sheet. Due to the 
finite size of the silica sheet chosen to make the simulations computationally 
feasible, buckling is observed in the silica-water simulations. To avoid such 
buckling of the surface, harmonic restraints are used on the hydrophobic silica 
layer that is furthest from the L1-binding surface. However, the surface in contact 
with the protein is kept unconstrained so that surface fluctuations can affect 
protein dynamics. This is a reasonable approximation that is commonly used in 
studies involving silica sheets.109 The positional variance that results from letting 
the h4 helix interact with the silica surface is shown in Figure Error! No text of 
specified style in document..7 in cyan color. As seen above, all epitope fluctuations 
decrease significantly and the variance of almost all amino acids in the FG-loop 
are <2 Å2. The extent of fluctuation dampening and the shape of the positional 
variance profile is remarkably similar to what we found when we artificially 
inhibited the h4 fluctuations (Figure Error! No text of specified style in document..5, 
orange line), indicating that our basic design idea is plausible and that restriction 
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of fluctuations of the h4 helix is faithfully coupled to the FG loop leading to 
diminished loop fluctuations.  
Whereas the model above is encouraging, it is not probable that the L1 
monomer will self-assemble into the desired structure where only the h4 helix has 
contact to the silica surface, while the rest of the L1 protein maintains its overall 
structure. In fact, we found that a different structure, where the -sheet portion of 
the L1 protein gains contact with the surface, is energetically more preferable in 
good agreement with the notion that β-sheets can bind strongly to silica surfaces.110 
Among the many possible adducts, one is shown in Figure Error! No text of specified 
style in document..6b. The contact between the β-sheet and the silica surface is 
maximized and the h4 helix points away from the surface and, thus, none of the 
conceptual design motif initially envisioned is incorporated in this energetically 
more feasible structure. From a possible vaccine design perspective this protein-
silica association is undesirable, as the structure of the protein as a whole and the 
mean structures of the epitope carrying loops are compromised significantly. As 
these latter structures are energetically favorable and intuitively plausible, it is safe 
to conclude that a self-assembly approach to preparing the desired L1-silica hybrid 
system is not promising to succeed. In addition, all of our monomer simulations 
suggest that the cooperative confinement that is present in the pentamer is needed 
to further reduce the positional variance to the desirable range of < 1 Å2. 
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Figure Error! No text of specified style in document..7. The positional variance 
profiles of the silica-bound protein constructs. The profiles of the monomer and 
T=1 VLP are shown as references. 
A more complex design that may offer a solution to the problems identified 
above and that may provide a more realistic bioinorganic nanoparticle is to place 
the L1 pentamer on the silica surface and control the protein-silica contact points 
by using covalent linkages. Several strategies are readily available for attaching 
proteins to a solid support.111 For example, the silica surface can be treated with 
amino silanes to afford a uniform surface layer of primary amines,112,113 which we 
modeled using terminal –Si–O–(CH2)3–NH2 moieties on the silica surface. The L1-
proteins can be covalently linked to such an activated surface by a peptide 
coupling reaction to afford a permanent amide tether112 containing a Silica–Si–O–
(CH2)3–NH–CO–L1 motif, where the tether is anchored at the h4 helix. This design 
overcomes shortcomings of the monomer-silica structure as (i) interactions 
between epitopes that are located on different L1 proteins in the pentamer are 
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maintained, (ii) the covalent linkage provides control over the silica-protein 
contact point and suppresses structural degradation that may arise from 
undesirable interactions between the 
and (iii) the h4 helix fluctuations will be inhibited both by the covalent linkage and 
non-covalent interactions of the h4 helix with the silica surface, as demonstrated 
in our small model above. Use of silica with aliphatic-amino tethers in the 
construction of hybrid VLPs has several attractive features: Silica (i) has a highly 
tunable surface chemistry which facilitates conjugation with biological entities,114 
(ii) is essentially transparent to light,71 and (iii) is nontoxic and biocompatible.115 
However, like most other nanomaterials, including gold or magnetic nanoparticles 
and quantum dots, silica particles are difficult to directly and uniformly suspend 
in aqueous solutions with different salinities.72,73 Additional details on practical 
advantages of the present design are discussed in section 3.4.2. The proposed 
design provides a simple model that includes fundamental features of a hybrid 
material based vaccine. However, for laboratory preparation of such material 
amorphous silica are preferred.75 Studying amorphous silica computationally is 
difficult due to the large range of surface silicate group densities that can be 
obtained under various conditions, and the associated range of different 
interactions with proteins;77 crystalline silica is more tractable for computer 
simulations. Our focus is on understanding the effects of factors such as atomic 
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forces, interaction energetics, friction imposed by neighboring loops, allostery, and 
inertia on the structure and function of L1 assemblies and, thus, we attached our 
protein models to a 100-surface of crystalline silica.116 With these factors well 
understood, additional complexities in hybrid vaccine design arising from the use 
of amorphous silica can be addressed in future work; for the purpose of this study 
the use of crystalline silica is a reasonable compromise. One additional design 
component that we found to be important is that the silica surface must be curved 
– ideally, resembling the surface curvature found in the VLP. Our final model 
design protocol is illustrated in Figure 4.8: First, the flat silica surface is brought in 
proximity to the VLP. Then the edges of the silica are steered towards atoms on 
the VLP surface. Since overall stability, geometry and nearest neighbor 
interactions within silica is maintained using harmonic restraints, steered motion 
of atoms on the edges of the silica sheet gradually couples to those towards the 
interior. Consequently, the surface buckles forming a hydrophilic convex face with 
radius of curvature similar to that of the T=1 VLP. Next, the pentamer is tethered 
to the alkyl-amino groups across the surface where the silica curvature matches 
the inherent curvature of VLP-confined pentamer. If the silicon surface is left flat, 
the match of structural fluctuations between the silica-tethered pentamer and the 
VLP becomes less ideal, as shown in magenta color in Figure Error! No text of 
specified style in document..7. 
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Figure Error! No text of specified style in document..8. Hybrid design protocol: 
first, a flat sheet of silica generated using CHARMM is curved using the T=1 VLP 
as a template. Then, tethers are planted on the curved hydrophilic silica surface 
forming a -Si-O-(CH2)3-NH2 linkage. Finally an L1 pentamer is attached to the 
surface via the tethers with the connectivity Silica-Si-O-(CH2)3-NH-CO-L1. 
The L1 pentamer with positive potential surface was attached to the silica 
surface possessing negative electrostatic surface potential. The epitope fluctuation 
characteristics of this design are very close to those from the full VLP (Figure Error! 
No text of specified style in document..7) and similarly for helix-epitope correlations. 
However, a closer look into epitope properties reveals that they are different from 
those of the VLP. For example, we observe that the number of inter-epitope 
contacts and hydrogen bonds is lower than those in the T=1 VLP. As the pentamer 
is computationally extracted from a VLP it expands to a new equilibrium 
structure. When the expanded pentamer is attached to a flat silica surface, its 
182 
 
inherent curvature and associated inter-L1 contact (which mediate epitope 
properties) is lost. In particular, a large fraction of the inter-epitope hydrogen 
bonds connecting the FG and HI loops is lost. Thus, the fluctuations are also 
marginally higher in specific regions of the epitope. For example, THR residue 266 
in the FG loops consistently loses hydrogen bonding interactions with the ASN 
residue 357 of the HI loop from its clockwise neighbor, thereby fluctuating more 
than in a complete VLP (Figures 6). Implications of residue-level conformations, 
such as those of THR 266, on the immunogenicity of associated constructs are 
discussed in the main text in the light of experimental findings. In conclusion, 
properties of the pentamer-flat silica design indicate that, in addition to 
confinement, inter-L1 interactions and helix-epitope allostery, one must consider 
surface curvature of the silica nanoparticle, as it plays a crucial role in determining 
epitope dynamics.  
To quantify this finding, the effect of silica surface curvature is investigated. 
Silica surface curvature chosen to be that of the T=1 VLP so that the bound 
pentamer maintains its inherent curvature. This design reproduces all epitope 
properties of the VLP, as is reflected in the positional variance (Figure Error! No 
text of specified style in document..7), dihedral distribution, correlation plot, number of 
hydrogen bonds, contact analysis and epitope energetics. 
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Figure Error! No text of specified style in document..9. Organization of the surface 
epitopes FG and HI using inter- and intra-loop hydrogen-bonds. 
The epitope fluctuation characteristics of the pentamer covalently attached 
to the curved silica surface is remarkably close to that of the full VLP, as shown in 
Figure 4.7 in blue compared to the T=1 VLP fluctuations shown in green. 
Engineering the structural and dynamic properties of the epitope containing loops 
is a necessary condition for eliciting the desired immune response, but there are 
additional conditions that must be met to faithfully reproduce the immunogenic 
properties of the wild type virus and/or the full-scale VLP. Several atomic scale 
features have previously been identified to be important for eliciting a proper 
immune response. For example, mouse monoclonal antibody H16.V5 binds to a 
major part of the FG loop and neutralizes HPV16;117 mutation of ASN-285 leads to 
the failure of this antibody binding, suggesting that ASN-285 is directly involved 
in the H16.V5 binding.117 Similarly, SER-282 appears to be important for the 
epitope to bind another antibody, H16.E70.117 These experimental observations 
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emphasize that immune response to the L1 epitopes strongly depends on the 
details of the epitope structure. Fine scale structural details must therefore be 
carefully accounted for within a design strategy for assembling an artificial hybrid 
vaccine. Hydrogen-bonds play a particularly important role and we have carefully 
monitored the hydrogen-bond network that organizes the orientation of the 
epitopes to each other. Two hydrogen-bonds were especially interesting: The 
THR-266 residue of the FG-loop forms a strong inter-loop hydrogen-bond with an 
ASN-357 residue on a neighboring HI loop in the pentamer, as shown in Figure 
Error! No text of specified style in document..9. This is an important structural feature 
also found in the VLP that must be preserved for proper immune response - it is 
impossible to form this inter-loop hydrogen-bond in a monomer, which is one of 
the reasons why the L1-monomer is unlikely to be useful as a vaccine. A second 
hydrogen-bond of importance involves the residues 280-285, which enforce a 
relatively consistent conformation in that part of the FG-loop by engaging in a 
network of mutually exchangeable hydrogen-bonds with each other. In Figure 4.9 
we depict one such H-bonded snapshot structure, where SER-280 and ASN-285 
formed a hydrogen-bond. As a consequence of these intra-loop hydrogen-bonds, 
the FG-loop adopts a helix-like secondary structure, as illustrated in the detailed 
view of this region in Figure Error! No text of specified style in document..9. As this 
portion of the FG-loop is most solvent accessible, the helix-like folding provides 
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an energetic advantage. This structural detail is present in the VLP and we propose 
that it is an important recognition motif that must be preserved in a vaccine to 
elicit a proper immune response.117 Note that the positional variance profiles 
(Figure Error! No text of specified style in document..7) have consistently indicated a 
very large change in positional variance around residue 280 when moving from a 
monomer to higher order assemblies - this hydrogen-bond network is responsible 
for the significant change in the fluctuation profile, as it is not present in the 
monomer and the residues around 280 have a much higher degree of structural 
freedom. These delicate structural details support and amplify the dynamic 
allosteric effects of the h4 helix discussed above to ultimately generate a structural 
fluctuation profile of the epitopes in the silica-mounted pentamer that is 
essentially identical to what is seen in the much larger T=1 VLP of HPV 16.  
CONCLUSIONS  
The preparation of well-defined small subassemblies, such as the pentamer, 
from monomeric L1-proteins is much easier118 than synthesizing the larger 
assemblies like the T=1 or T=7 icosahedra. Thus, the vaccine development process 
could be expedited significantly if the smaller particles can be used to elicit a 
immune response instead of having to prepare the much more elaborate VLP 
structures.119 The difficulty of assembling the higher order constructs lies in the 
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strong contribution that entropy makes to the energetics of the VLP; enthalpically, 
the interactions between the monomers in the pentamer assembly is much 
stronger than those between pentamers in the VLP. Thus, the translational entropy 
penalty associated with the formation of the pentamer from monomers is partially 
compensated for, allowing the free energy of assembly to be much more favorable 
for the pentamer than for the VLP.120 Therefore, the pentamers are ideal targets in 
a rational vaccine design strategy. Mounting the pentamer on a silica nano-particle 
is enthalpically highly favorable, i.e. the enthalpy of tether mediated pentamer 
binding to silica is much higher than the interaction between pentamers to afford 
the VLP. By providing a minimally invasive chemical modification to install the 
chemical anchor for coupling the pentamer to the surface-modified silica 
nanoparticle, we introduce an additional driving force and engineer precise 
control over the assembly. In comparison, the preparation of the VLP from the 
pentamers is much more demanding, as the entropic penalties originating from 
the required precise relative orientation of the pentamers during the final 
assembly to the VLPs must be overcome.  
Computer simulations have become a standard tool of biomedical research 
over the last few decades, but they are mainly used to rationalize and confirm 
experimental observations.116-120 Given the level of sophistication and degree of 
realism in today’s computer models, truly predictive computer modeling is not 
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only possible, but bears significant advantages over purely experimental 
approaches, as we demonstrate in this work by deriving a logical and rational 
vaccine design strategy. To the best of our knowledge, this is the first 
computational study that used all-atom structures of hybrid silica-protein nano-
constructs to provide a novel nanoscale perspective on a long-standing challenge 
of VLP-based vaccine design. We discovered an intriguing dynamic allosteric 
coupling between the h4 helix and the epitope containing loops and devised an 
effective exploitation strategy for rigidifying the epitopes to reproduce the 
structural and dynamic properties of these epitopes in the VLP using the silica 
surface mounted pentamer. A silica mounted VLP as a basis of a vaccine against 
porcine virus69 was reported previously and served as an inspiration of this work. 
Silica nanoparticles provide a potentially revolutionary opportunity for 
developing vaccines and we demonstrate how they can be utilized rationally. Our 
work highlights an intriguing connection between structure, dynamics and 
function, while explicitly outlining a strategy for exploiting dynamic allostery 
which is a relatively new concept that remains poorly understood. Our design has 
advantages over traditional T=1 VLPs in that they are (a) expected to be thermally 
stable (b) easy to prepare and (c) genome-free. Furthermore, silica nanoparticles 
are already FDA approved,120 but remain an underutilized resource in vaccine 
development. In ongoing work, these theoretically identified vaccine candidates 
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will be prepared and characterized in collaboration with experimentalists to test 
our hypothesis - whereas adjustments and improvements to our initial strategies 
discussed above are expected, the foundation of the control mechanisms that we 
identified and explained above is generally valid. In addition to the obvious 
benefit of having identified a specific vaccine development strategy, the dynamic 
allosteric control mechanism outlined in this work appears to be generally 
applicable and more common than previously thought and deserves further 
investigation.  
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SUMMARY 
Allostery is a commonly used mechanism to regulate the activity of 
proteins, wherein ligand binding to one site of a protein alters the function of 
another site. Thermodynamically, allostery can take place either by a change in 
the mean structure of the protein (enthalpy driven) or by a change in the dynamics 
of the protein (entropy driven) or a combination of both. Structural changes in an 
allosteric protein could be realized by selection of a conformer from a pre-existing 
ensemble of conformers by the allosteric ligand (Monod, Wyman and Changeux 
model),1 or induction of the structural change on binding of the allosteric ligand 
(Koshland, Nemethy and Filmer model).2 The molecular basis of allosteric 
regulation remains a subject of extraordinary interest in biological systems, 
governing processes such as signal transduction, enzymatic activity, metabolite 
flux, and protein degradation. In this dissertation, we investigate the mechanisms 
of coupling between allosteric sites in two different protein systems, which is a 
quantitative measure of the manner in which these sites functionally interact 
(enthalpy or entropy driven). Bacterial metalloregulatory proteins and viral 
capsid proteins were employed as model systems to gain insights into the nature 
of allostery by employing density functional theory and all-atom molecular 
dynamics simulations.  
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In the first case, the effector ligand is a metal ion, namely Cu(I) ion, and 
the protein “active site ligand” is DNA. In CsoR proteins, Cu(I) behaves as an 
allosteric inhibitor of DNA binding. The molecular origins behind Cu(I) mediated 
allosteric transitions were investigated in CsoR proteins of M.tuberculosis, 
T.thermophillus and S.lividans. In Mtb, both the Cu(I) bound and apo forms of CsoR 
were studied to identify key structural features that may determine the affinity to 
bind to Cu(I) or DNA promoter.3-5 All-atom MD simulations and subsequent 
analysis were performed on the apo and Cu(I) bound forms of Mtb-CsoR and apo 
forms of Thermus thermophillus and Streptomyces lividans species. The structural 
comparison of apo- and Cu(I)-bound Mtb-CsoR yielded an RMS value of ~6.20 Å 
in the tetrameric form. A global alignment of both Cu(I) and apo forms of Mtb-
CsoR in dimeric form (Figure 22(c) in Chapter 3) reveals that the two protomers 
in the apo CsoR reorient to attain a ‘X-like’ conformation due to the absence of an 
anchor (which is Cu(I)) that holds the protomers in a ‘taut’ and straight 
conformation. The resulting ‘X-like’ conformation can be more suitable to bind to 
DNA than a rigid and inflexible form that was determined to be characteristic of 
Cu(I)-bound Mtb-CsoR. The essential H-bond interactions between the conserved 
residues in CsoR proteins, that stabilize the apo- and Cu(I)-bound Mtb-CsoR in 
their conformations were identified and a rationale was drawn to explain the 
influence of these H-bond interactions on the flexibility of CsoR protein structure. 
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Differences were also observed in the apo CsoR proteins of different bacterial 
species. In the apo forms of Mtb and Tt CsoR proteins, the H-bond between His61-
Tyr35-Glu81 was not observed, while in apo Sl-CsoR the H-bond interaction 
between Tyr74-Glu122 and a bridging water molecule that interacts with both 
Glu122 and His100 were observed.3 Though the presence of C-terminal tail in 
Mtb-CsoR differentiates it from the CsoR proteins of other bacterial species, our 
simulations were performed on the Mtb-CsoR protein without the C-terminal tail 
in order to compare these structural changes with those of CsoR proteins in other 
bacteria. Further computational studies and analysis should be performed to gain 
insight into specific conformations of apo and Cu(I)-bound CsoR proteins of 
different bacteria. Overall in Mtb-CsoR, our simulations were able to predict 
differences in orientation of α-helices, H-bond interactions and increase in 
flexibility of conserved arginine residues involved in DNA binding, on binding 
to Cu(I).6 The allostery in CsoR proteins can be explained on the basis of 
“population shift model”7 where the equilibrium shifts to the conformation 
ensemble with a rigid and open structure, that possesses least affinity to DNA 
(open or taut) and is stabilized by binding to Cu(I). Future studies focused on 
CsoR bound to DNA should be conducted to understand the DNA bound 
conformation. 
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 In Chapter 4, a computational study that used all-atom structures of hybrid 
silica-protein nano-constructs was performed to provide a novel nanoscale 
perspective on a long-standing challenge of VLP-based HPV vaccine design. 
Interestingly, in L1 capsid proteins of HPV, the allostery between h4 helix and 
epitopes does not invoke any significant changes in the mean structures of the 
epitopes (RMS < 1 Å) unlike that of CsoR proteins in bacteria. Instead, the allosteric 
connection is expressed in variations of structural fluctuations (dynamics or 
entropy driven), which in turn impact the biochemical behavior of the epitopes 
and hence effects the immune response.  
In our simulations, we discovered an intriguing dynamic allosteric 
coupling between the h4 helix and the epitope containing loops of the L1 capsid 
proteins of HPV. Based on the concepts of dynamic allostery in Chapter 4, we 
devised an effective exploitation strategy for rigidifying the epitopes in lower 
assemblies (L1 monomer and pentameric forms) to reproduce the structural and 
dynamic properties of these epitopes in the VLP or higher assemblies (T=1 or T=7 
VLP) using the silica surface mounted pentamer. Silica nanoparticles provide a 
potentially revolutionary opportunity for developing vaccines and we 
demonstrate how they can be utilized in the hybrid vaccine design. This work 
highlights an intriguing connection between structure, dynamics and function of 
proteins, while explicitly outlining a strategy for exploiting dynamic allostery 
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which is a relatively new concept that remains poorly understood.8 The dynamic 
allosteric control mechanism outlined in this work appears to be generally 
applicable and more common than previously thought and deserves further 
investigation in order to develop new rational drug and vaccine design strategies. 
PERSPECTIVES 
 The key implication of understanding allosteric mechanisms in bacterial 
and viral proteins is to design drugs and vaccines that can modulate the 
biochemical behavior by switching on/off signaling pathways while impacting the 
pathogenicity and viability of these microorganisms in human hosts.9-11 
Computational methods such as MD simulations are crucial tools to understand 
the existence of conformational ensembles of different allosteric states and to 
identify key residue-residue networks that propagate within proteins when 
switching from one conformational state to another.7,12-15 Additionally, these 
methods help to detect allosteric sites, analyze them for their potential as drug 
targets and also suggest small molecule drug targets, which can then be tested in 
experimental screening. Hence, understanding the nature and molecular 
mechanisms of allostery is required in pathogenic bacterial proteins. Further 
computational evaluation of CsoR proteins is essential to design allosteric drugs 
that can bind these proteins and modulate the behavior by switching on/off the 
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Cu(I) regulatory mechanisms/networks. For an effective vaccine design, different 
viral capsid proteins should be screened for dynamic allostery and computational 
design targeted towards a single hybrid nanoparticle based VLP vaccine for 
different viruses should be established in future studies. Below, future 
computational studies are proposed to understand these systems and direct the 
allostery towards rational drug and vaccine design.   
Cu(I)-bound forms of Tt-CsoR and Sl-CsoR 
 Both Tt- and Sl-CsoR proteins are the best structural targets to study 
different allosteric states due to the absence of long C-terminal tail (Mtb CsoR), 
like nearly all other CsoRs. Computational models of apo Tt-CsoR and Sl-CsoR 
were described in this thesis, but the conformation of Cu(I)-bound forms should 
be modeled to evaluate the allosteric transition and conformational changes. The 
force fields for the Cu(I) coordination sphere were also obtained for Tt-CsoR in the 
His-Cys-His binding mode (data not shown). Due to the lack of crystal structure 
for Cu(I)-bound forms of Tt-CsoR and Sl-CsoR, it is difficult to build these 
structures using traditional MD programs. Steered MD coupled with QM/MM 
calculations should be performed in order to enforce the Cu(I) coordination 
geometry without disruption of the α-helical character. The force fields developed 
can then be applied and subsequent MD simulation analysis will enable us to 
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determine different allosteric states and conformational changes in CsoR proteins 
can be studied at molecular/atomic level of detail. 
How does CsoR bind to its DNA operator?  
 The Cu(I)-bound structure of Mtb CsoR reveals a novel protein architecture 
with no classical DNA binding motif but the characteristic antiparallel four-helix 
bundles have been suggested to act as a DNA-binding fold.4,16,17 High resolution 
structural studies coupled with a better understanding of the DNA operator will 
provide further insights into the protein-DNA complex formation and how Cu-
binding inhibits the complex. A comparison of all three allosteric states (DNA-
bound, apo and Cu(I)-bound) will provide detailed insights as to how this putative 
hydrogen bonding network drives allosteric communication. A recent report on 
the DNA operator binding S.lividans CsoR predicts that the α-helix RLXR motif 
established contact at the GTA dyad regions of the DNA operator site.17 Using 
docking techniques, the apo Sl-CsoR can be docked onto the DNA operator. 
Steered and directed molecular dynamics simulations can be used to further refine 
the structure of the DNA-CsoR complex of S.lividans. Multiscale and coarse 
grained simulations will be used to simulate the DNA-CsoR protein complex to 
understand the residue interactions and the conformation of CsoR when bound to 
DNA. These studies will enable us to determine the structural allostery in Sl-CsoR 
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proteins. The role of H-bond interactions can then deciphered by comparing all 
the three allosteric states of CsoR.  
Role of the C-terminal tail of Mtb-CsoR  
 As discussed, Mtb CsoR has a unique C-terminal tail consisting of ~30 
amino acids residues, ~18 of which are highly conserved in pathogenic 
mycobacteria. An unexpected finding was that this region plays an important role 
in DNA binding since truncation of the tail before residue 106 significantly 
decreases the DNA binding affinity.4 The conserved residues in the tail are mostly 
neutral and hydrophobic in nature, and are therefore unlikely to interact directly 
with the DNA. One possibility is that the tail influences the oligomerization or the 
conformational state of CsoR in solution when bound to DNA.4 The 
crystallographic structure of Cu(I)-bound CsoR reveals that the tetramer may form 
as a dimer of dimers, with the a3 helices positioned at the dimer-dimer interface.4 
Although the C-terminal tail is not resolved in the X-ray structure, it is very likely 
to be found at this interface where it could potentially stabilize the tetramer or 
alternatively change the distance between positively charged patches on one face 
of the tetramer.4 This may also suggest the possibility that the C-terminal tail can 
wrap around the dimers and might mediate disassembly of the protein-DNA 
complex by interfering with DNA promoter contact sites. In any case, a systematic 
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study on the assembly state of the full-length Mtb-CsoR will likely shed 
considerable light on understanding the fundamental role of the C-terminal tail in 
Mtb CsoR. 
Virtual Screening of Allosteric Drug-like Molecules that Bind CsoR Proteins 
 Target-based ligand screening will enable us to assess many drug-like 
compounds for potential ligands to bind CsoR protein in pathogenic bacteria.18 
Experimental assays are time-consuming, expensive, and not always applicable. 
At the same time, computational approaches using docking and protein pocket 
prediction methods have limited accuracy.19-21 Using MD simulations and 
generating high-resolution structural data of proteins, will not only enable us to 
target various binding pockets in the protein but also allows us to determine the 
conformational ensemble of the allosteric proteins when bound to small ligands. 
This target based drug screening approach combined with the knowledge of 
various residue interactions and H-bonds stabilizing an allosteric state, would 
provide us with a potential strategy to screen for small molecules which can 
modulate the allosteric behavior of CsoR proteins. 
Building a Library of Viral Epitopes to Effectively Design VLP-Nanoparticle Based 
Vaccines 
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 In this dissertation, we described an approach to exploit the dynamic 
allostery present in HPV L1 capsid protein in the design of hybrid nanoparticle-
based vaccines. This method could be applied in screening various epitopes in 
viral capsids to identify the presence of dynamic allostery and its impact on the 
immunogenicity of the VLP.8 Detailed analysis of epitopes is important both for 
the understanding of immunological events and for the development of more 
effective vaccine and diagnostic tools for various diseases. Identification and 
characterization of epitopes is a complex process. Although various methods have 
been developed in this area, there still lacks a simple common approach which can 
be applied to all epitopes. X-ray crystallography remains the only suitable method 
to accurately perform structural analysis of any epitope, understand allostery and 
the immunogenic influence. However, there have been a large number of 
computational methods developed for mapping allostery of different proteins 
which are discussed in this theses. The proposed strategy involves constructing 
putative hybrid vaccine computationally, simulating these epitope constructs to 
arrive at quantitative metrics that influence the immunogenic properties, and then 
using the latter to construct a model of a vaccine with high immunogenicity. The 
designs scored to be highly immunogenic can then be synthesized and tested using 
experimental assays. This vaccine discovery workflow integrating computation 
schemes and laboratory techniques could considerably reduce time and costs 
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associated with experimental screening assays.22 A database of all the viral 
epitopes which are tested to be immunogenic can then be established using 
bioinformatics approaches that will facilitate us to rationally select viral epitopes 
with high immunogenicity while constructing a hybrid VLP.23-25 Different viral 
epitopes determined using the vaccine discovery workflow suggested above, can 
be assembled and presented using a nanoparticle (silica nanoparticles) to achieve 
immunity to several diseases caused by viruses. Though immense amount of 
computational work is required to accomplish this goal, a streamlined process in 
epitope identification and discovery to develop vaccines and diagnostics will be 
beneficial during a pandemic with the available knowledge database of 
immunogenicity of epitopes and biocompatible nanoparticles.  
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